



UNIVERSIDADE FEDERAL DE PERNAMBUCO
CENTRO DE CIÊNCIAS BIOLÓGICAS-CCB
PROGRAMA DE PÓS-GRADUAÇÃO EM BIOQUÍMICA E FISIOLOGIA

RICARDO ABADIE GUEDES

**Efeitos do consumo de etanol e da sua abstinência sobre o
cérebro: ação protetora de antioxidantes**

RECIFE
2012

RICARDO ABADIE GUEDES

**Efeitos do consumo de etanol e da sua abstinência sobre o
cérebro: ação protetora de antioxidantes**

Tese apresentada para o
cumprimento parcial das exigências
para obtenção do título de Doutor
em Bioquímica e Fisiologia pela
Universidade Federal de
Pernambuco, sob orientação do
Prof.Dr Ranilson de Souza Bezerra
e co-orientação do Prof. Dr Rubem
Carlos Araújo Guedes

Data: 22 / 10 / 2012

Catálogo na Fonte:
Bibliotecário Bruno Márcio Gouveia, CRB-4/1788

G924e Guedes, Ricardo Abadie

Efeitos do consumo de etanol e da sua abstinência sobre o cérebro: ação protetora de antioxidantes / Ricardo Abadie Guedes. – Recife: O Autor, 2012.

125 f.. : il., fig., tab.

Orientador: Ranilson de Souza Bezerra

Coorientadora: Rubem Carlos Guedes

Tese (doutorado) – Universidade Federal de Pernambuco. Centro de Ciências Biológicas. Pós-graduação em Bioquímica e Fisiologia, 2012.

Inclui bibliografia e anexos

1. Álcool – Efeito fisiológico 2. Depressão alastrante cortical I. Bezerra, Ranilson de Souza II. Guedes, Rubem Carlos Araújo III. Título.

616.861

CDD (22.ed.)

UFPE/CCB-2013-150

RICARDO ABADIE GUEDES

**Efeitos do consumo de etanol e da sua abstinência sobre o
cérebro: ação protetora de antioxidantes**

Tese apresentada para o
cumprimento parcial das exigências
para obtenção do título de Doutor
em Bioquímica e Fisiologia pela
Universidade Federal de
Pernambuco

Aprovado por:

Prof. Dr. Ranilson de Souza Bezerra - Presidente

Prof. Dr. Luiz Bezerra de Carvalho Júnior – Titular Interno I

Prof. Dr. Ian Porto Gurgel do Amaral – Titular Externo I

Profa. Dr. Suzan Diniz dos Santos – Titular Externo II

Prof. Dr. Antônio Pereira Júnior – Titular Externo III

Data: 22 / 10 / 2012

À minha família

AGRADECIMENTOS

Agradeço primeiramente aos meus orientadores, Prof. Ranilson e Prof. Rubem, por todo incentivo e apoio. A todos os meus amigos e colegas de laboratório, que participaram direta ou indiretamente dos bons (muitos) e maus (poucos) momentos, nesses quatro anos de aprendizado. Agradeço ao médico veterinário, Dr. Edeones França, pela boa vontade e colaboração no fornecimento e manutenção dos animais utilizados nos experimentos. A toda a equipe de professores do Departamento de Bioquímica, cujos ensinamentos foram essenciais para esta continuidade do meu amadurecimento científico. Finalmente à minha família, por todo apoio e interesse dispensados, sem os quais, talvez minha passagem por esta especialização doutoral não houvesse sido possível.

RESUMO

O abuso do consumo do etanol e a ingestão insuficiente de antioxidantes são fatores externos que podem alterar a eletrofisiologia do cérebro. Estudos prévios demonstraram que a excitabilidade cerebral, relacionada com o fenômeno conhecido como depressão alastrante cortical (DAC), foi facilitada pelo consumo crônico de etanol, e o tratamento crônico com carotenóides atenuou esse efeito. Numa primeira etapa, investigou-se o efeito agudo da administração única de etanol (EtOH) sobre a DAC em ratos adultos e jovens previamente tratados (1 hora antes) com 10 µg/kg de astaxantina. Ratos Wistar machos (cinco grupos jovens e cinco adultos, 60 a 80 dias e 150 a 180 dias de idade respectivamente) receberam em duas gavagens com uma hora de intervalo, os seguintes tratamentos: grupos 1 e 2 receberam astaxantina na gavagem I combinada com EtOH (grupo 1) ou água (grupo 2) na gavagem II; os grupos 3 e 4 receberam óleo de oliva (o veículo no qual astaxantina foi dissolvido) na gavagem I combinado com EtOH (grupo 3) ou água (grupo 4) na gavagem II; grupo 5 recebeu água na gavagem I combinada com EtOH na gavagem II. A DAC foi registrada na superfície cortical por 4 horas. Comparado com os respectivos grupos controle água e óleo (grupos 2 e 4), o etanol em dose única (grupos 3 e 5) reduziu as velocidades de propagação da DAC e a astaxantina antagonizou esse efeito. Na segunda etapa, foi avaliado se outro antioxidante, não carotenoide (tocoferol), promoveria efeito similar à astaxantina. Os resultados comprovaram essa hipótese, indicando que a ação antagonista sobre o efeito do etanol na DAC não seria uma propriedade particular da astaxantina, mas provavelmente uma característica geral de moléculas antioxidantes. Em uma etapa final, o tema, no contexto da DAC, foi discutido em um artigo de revisão, que também faz parte do corpo desta tese.

Palavras-chave: Etanol, Astaxantina, Tocoferol, Antioxidantes, Depressão alastrante.

ABSTRACT

Ethanol consumption abuse and the insufficient intake of antioxidants are external factors that may alter the brain electrophysiology. Previous studies demonstrate that brain excitability, related with the phenomenon known as cortical spreading depression (CSD), was facilitated by chronic consumption of ethanol, and that chronic treatment with carotenoids attenuated these effect. On a first stage, it was investigated the acute effect of a single ethanol (Etoh) dose on the CSD in young and adults rats previously treated (1 hour before) with 10 µg/kg of astaxanthin. Male Wistar rats (five young and five adult groups, 60 to 80 and 150 to 180 days of age respectively) received in two gavages with one hour interval, the following treatments: groups 1 and 2 received astaxanthin on gavage I combined with Etoh (group 1) or water (group 2) on gavage II; groups 3 and 4 received olive oil (the vehicle in wich astaxanthin was dissolved) on gavage I combined with with Etoh (group 3) or water (group 4) on gavage II; group 5 received water on gavage I combined with Etoh on gavage II. CSD was recorded on the cortical surface for 4 hours. Compared with the respective control groups water and oil (groups 2 and 4), ethanol in a single dosis (groups 3 and 5) reduced the CSD propagation velocities and astaxanthin antagonized this effect. On a second stage, it was evaluated if a different non-carotenoid antioxidant, (tocopherol), would promote an effect similar to astaxanthin. The results confirmed this hypothesis, indicating that the antagonic action of ethanol on CSD would not be a particular property of astaxanthin, but probably a general feature of antioxidants molecules. In a final stage, the theme, on the CSD context, was discussed in a review article, wich is also part of this thesis.

Key words: Ethanol, Astaxanthin, Tocopherol, Antioxidants, Spreading Depression.

LISTA DE FIGURAS

Figura 1. Distribuição <i>per capita</i> do consumo mundial de bebidas alcoólicas	21
Figura 2. Padrão de distribuição de renda mundial e as respectivas expectativas de vida.	22
Figura 3. Dados sobre morte, em relação a 19 fatores de risco e nível de renda.	23
Figura 4. Dados sobre anos de vida ajustados por invalidez (AVAI), em relação a 19 fatores de risco e nível de renda.	23
Figura 5. Resumo sobre os dados de consumo de etanol para o Brasil, 1990-2006.	24
Figura 6. Classificação de dez fatores de risco para <i>causa mortis</i> por nível de renda.	25
Figura 7. Classificação de dez fatores de risco para anos de vida ajustados por invalidez (AVAI) por nível de renda.	26

LISTA DE ABREVIATURAS

AVAI – Anos de vida ajustados por incapacidade

CAT - Catalase

CSD – Cortical Spreading Depression

DAC – Depressão Alastrante Cortical

ERO – Espécies reativas de oxigênio

ERN – Espécies reativas de nitrogênio

EtOH – Etanol

GPx – Glutathione peroxidase

GSH - Glutathione

OMS – Organização Mundial de Saúde

OPS - Organización Panamericana de la Salud

PAHO – Pan American Health Organization

SOD – Superóxido dismutase

U.S. DOT – United States Department of Transportation

WHO – World Health Organization

SUMÁRIO

RESUMO	
ABSTRACT	
LISTA DE FIGURAS	
LISTA DE ABREVIATURAS	
SUMÁRIO	
1. INTRODUÇÃO	11
2. REVISÃO DE LITERATURA	12
2.1 Uma breve história do consumo do álcool	12
2.2 Álcool: consumo, comportamento e consequências	15
2.3 Álcool e neuropatogênese	27
2.4 Álcool e espécies químicas reativas	28
2.5 Sistema nervoso, espécies reativas de oxigênio e antioxidantes	31
2.6 Depressão alastrante cortical e espécies químicas reativas	40
3. OBJETIVOS	45
3.1 Objetivo geral	45
3.1 Objetivos específicos	45
4. Referências bibliográficas	46
CAPÍTULO I	69
Artigo científico intitulado “The Impairing Effect of Acute Ethanol on Spreading Depression is Antagonized by Astaxanthin in Rats of Two Young-Adult Ages” (Publicado em: Alcoholism: Clinical and Experimental Research, V. 36, N. 9, p. 1563 – 1567, 2012).	70
CAPÍTULO II:	75
Artigo científico intitulado “The use of cortical spreading depression for studying the brain actions of antioxidants” (Publicado em: Nutritional Neuroscience, V. 15, N. 3, p. 111 – 119, 2012).	76

CAPÍTULO III	85
Manuscrito do artigo científico intitulado “Antagonizing effect of α -tocopherol on the ethanol action in spreading depression in the rat cortex” (a ser brevemente submetido.à revista Alcoholism: Clinical and Experimental Research).	86
5. CONCLUSÕES	103
ANEXO I	104
Normas da revista à qual o segundo artigo da tese será submetido, capítulo III.	105
ANEXO II	114
Artigo científico intitulado “Shrimp carotenoids protect the developing rat cerebral cortex against the effects of ethanol on cortical spreading depression”. (Publicado em: Neuroscience Letters, V. 391, p. 51 – 55, 2005). Artigo que fez parte da monografia de graduação requerida como parte das exigências para a obtenção do título de Bacharel em Ciências Biológicas do presente doutorando.	115
ANEXO III	120
Artigo científico intitulado “Dose-Dependent Effects of Astaxanthin on Cortical Spreading Depression in Chronically Ethanol-Treated Adult Rats” (Publicado em: Alcoholism: Clinical and Experimental Research, V. 32, N. 8, p. 1417 – 1421, 2008). Artigo que fez parte da dissertação de mestrado requerida como parte das exigências para a obtenção do título de Mestre em Bioquímica e Fisiologia do presente doutorando.	121

1 – INTRODUÇÃO

O alcoolismo, considerado um grave problema social, está associado a diferentes doenças, como o câncer (BOFFETTA et al., 2006; PARKIN, 2011), acidente vascular cerebral (PATRA et al., 2010), e lesão hepática (LU et al., 2010). Os danos causados à saúde pelo consumo do etanol podem estar ligados à produção de radicais livres e seus efeitos deletérios em diversos órgãos. Entre os órgãos afetados, o cérebro é um dos principais alvos do etanol. Nos estágios iniciais, o uso do álcool provoca sensações de prazer e bem estar e seu uso continuado pode criar uma relação de dependência, e estabelecer um padrão crônico de ingestão. Os efeitos danosos no organismo podem ser exacerbados, pois a adaptação do corpo à substância provoca, frequentemente, um aumento das dosagens requeridas para se atingir as sensações desejadas e, assim, ser satisfeita a demanda fisiológica.

O abuso do consumo do etanol e a ingestão insuficiente de antioxidantes são fatores externos que podem alterar a eletrofisiologia cerebral. Sobre esse tema, nossos estudos prévios durante o mestrado demonstraram que a excitabilidade cerebral, relacionada com o fenômeno conhecido como depressão alastrante cortical (DAC), foi facilitada pelo consumo crônico de etanol, e o tratamento crônico com carotenóides atenuou esses efeitos (ABADIE-GUEDES et al., 2008), indicando papel protetor desse antioxidante contra os efeitos do etanol no sistema nervoso.

As recentes descobertas sobre os efeitos dos radicais livres nos organismos vivos, em geral, e no organismo humano em particular, geraram o crescente interesse no estudo de substâncias antioxidantes. As espécies reativas de oxigênio (ERO) e de nitrogênio (ERN) são produzidas naturalmente

como consequência do metabolismo aeróbico e são integrantes da homeostase do oxigênio nos tecidos. A homeostase do oxigênio consiste na manutenção do balanço entre agentes oxidantes e antioxidantes, balanço este que pode ser modificado por disfunções biológicas, como, por exemplo, nos processos inflamatórios. Quando a homeostase não é mantida, o ambiente pode tornar-se propício ao estresse oxidativo.

Este trabalho propôs estudar o tema com uma abordagem baseada no modelo eletrofisiológico da DAC, que é influenciável pelo álcool e pelos efeitos da sua abstinência. A DAC parece também estar associada a doenças neurológicas como a epilepsia, a isquemia cerebral e a enxaqueca clássica. Os dados deste trabalho pretenderam fornecer informações de relevância para o melhor entendimento do papel fisiológico de substâncias antioxidantes, sobre a atividade elétrica cerebral, e as consequências da modificação de seus padrões. Numa visão de médio prazo, pode-se prever que programas de saúde pública poderão ser beneficiados, direta ou indiretamente, com as informações obtidas neste estudo.

2 – REVISÃO DA LITERATURA

2.1 Uma breve história do consumo do álcool

O álcool é uma das substâncias com ação neural cujo consumo é mais difundido no mundo, sendo amplamente usada na maioria das culturas e grupos sociais humanos. Existem evidências da produção de bebidas intencionalmente fermentadas ainda no final da idade da pedra lascada, em

torno de dez mil anos antes de Cristo. O vinho aparece em pictogramas egípcios de 4000 anos a.C, e é possível que o consumo de cerveja tenha precedido o de pão (MODY, 2008). Por milhares de anos, na história da sociedade ocidental, a cerveja e o vinho foram utilizados como principais líquidos para debelar a sede, devido aos sérios problemas de saúde oriundos do consumo de água, uma vez que esta, naquela época, não passava por qualquer processo de purificação. Fontes de água pura, como nascentes de montanhas, não eram disponíveis para a maioria das populações. A cerveja e o vinho de então continham também, além do álcool, quantidades consideráveis de ácido acético e outros ácidos orgânicos. Esta acidez certamente contribuía, junto com o álcool, para o efeito de esterilização da água utilizada para diluir a cerveja e o vinho, normalmente numa proporção de 2:1. Por conta da diluição, a concentração de álcool nessas bebidas, utilizadas para matar a sede e como fonte de calorias, era geralmente baixa e assim causava poucas consequências adversas. Apesar do conhecimento dos efeitos do consumo de grandes quantidades das preparações alcóolicas, cuidados com os efeitos do álcool contido nas bebidas tornou-se centro de preocupação apenas muito tempo depois (VALLE, 1994).

O desenvolvimento da destilação foi responsável pela primeira grande mudança no modo e na extensão do consumo humano de álcool, desde o advento da fermentação da cerveja e da vinicultura. Mais importante, este desenvolvimento talvez tenha marcado a transição do consumo do vinho e da cerveja como fonte de hidratação e nutrientes, para o consumo de álcool em quantidades suficientes para serem perigosas, chamando atenção para o lado negativo do uso e do abuso do consumo do etanol. A destilação passou a

permitir a concentração e o isolamento do álcool em menores volumes, proporcionando bebidas com conteúdo e “potência” padronizados. O álcool foi comemorado como o melhor meio para o preparo de destilados farmacêuticos e considerado, durante parte da Idade Média, uma panacéia por si só (VALLE, 1994). Durante o período da ocorrência da peste negra na Europa, quando a população naquele continente foi reduzida em dois terços em uma geração, e medicações eficazes não eram conhecidas, bebidas destiladas eram prescritas pelos médicos aos enfermos por causa dos efeitos temporários de sensação de aquecimento e bem estar. O álcool destilado, nesse curto período, foi conhecido inclusive como “aqua vitae” (água da vida) e acreditava-se até que possuísse poderes mágicos (CLAUDIAN, 1970; FORBES, 1970; WILSON, 1973).

Apenas a partir do século 17, com o aumento do consumo do chá e do café, a realização de fervura da água foi amplamente difundida e o consumo de bebidas alcoólicas, como forma de manter o balanço hídrico, diminuiu drasticamente. O processo de fervura da água já era realizado, em grande parte da cultura oriental, há pelo menos 5000 anos, enquanto na sociedade ocidental não era apreciado, nem associado com a eliminação dos patógenos causadores de doenças. A grande diferença no consumo de líquidos entre orientais e ocidentais no passado, tendo os primeiros o costume de consumir chá feito com água fervida, e os últimos a cerveja e o vinho, levantam algumas questões a respeito do metabolismo humano do álcool. Em aproximadamente metade da população chinesa e japonesa, o metabolismo do álcool difere significativamente dos ocidentais devido a diferenças genéticas. Essas diferenças resultam de uma enzima, relacionada ao metabolismo do etanol, a

aldeído desidrogenase, que se apresenta pouco ou não funcional em parte da população oriental. A falta de função dessa enzima, por sua vez, provoca uma síndrome de sensibilidade ao álcool que torna os indivíduos portadores dessa condição pouco tolerantes a essa substância (VALLE, 1994).

Ao longo da história, de forma geral, o consumo de álcool tem um conteúdo ritualístico no seu uso em diversas culturas. Entretanto, com a modernização e mudança na organização econômica e social em muitas dessas culturas, seu uso passou a ser associado principalmente ao contexto recreativo ou à busca imediata do prazer, originando padrões de consumo de grandes quantidades de uma vez ou ao longo do tempo (RONZANI e FURTADO, 2010).

2.2 Álcool: consumo, comportamento e consequências

Os efeitos de relaxamento e desinibição de traços de personalidade proporcionados pela ingestão do etanol passam a ter um papel estimulante e desejado sobre o comportamento social. Entre tais efeitos desejados estão incluídos a “sensação de busca”, descrita como a evitação da monotonia, e definida como o desvio da rotina e a necessidade de mudança e ação, bem como a impulsividade, definida como agir no estímulo do momento, de modo não planejado (GRAU e ORTET, 1999). É criada assim uma expectativa, por meio da qual, se o álcool é consumido, então certas consequências comportamentais e afetivas, importantes no contexto social, se seguem. Trabalhos de investigação psicológica sugerem que essa expectativa sobre o resultado do consumo do etanol pode ser um importante mediador das

variáveis biológicas e ambientais prévias que influenciam o risco do abuso do álcool (como o alcoolismo). Seria uma associação causal, de substancial contribuição, para o álcool posteriormente consumido (YOUNG e OEI, 1993; JONES et al., 2001; GOLDMAN, 2002; CONNOR et al., 2011).

Alguns pesquisadores consideram hoje em dia o álcool etílico como uma “entidade” multifacetada que, dependendo de sua dosagem, pode ser utilizado como “lubrificante social”, uma companhia sofisticada para um jantar, um benfeitor da saúde cardiovascular ou um agente de destruição (VALLE, 1998). O consumo abusivo de álcool é um problema mundial de saúde, que resulta em, aproximadamente, 2,5 milhões de mortes por ano (OMS, 2010), inclusive na perda da vida de centenas de milhares de jovens. Em 1990, 5% das mortes de pessoas entre 5 e 29 anos foram atribuídas às consequências desse consumo (MURRAY e LOPEZ 1997). A idade de início do consumo é um fator importante, pois quanto mais cedo o indivíduo começa a beber, parece ser mais provável tornar-se dependente posteriormente. GRANT e DAWSON (1997) verificaram o aparecimento de dependência de álcool em algum estágio da vida para mais de 40% de grupos de indivíduos, nos quais o início do consumo de bebidas alcoólicas antecedeu os 15 anos de idade, com uma média de redução entre 8 e 10% desse risco para cada ano extra de adiamento do início do consumo. Comparado com o contato mais tardio com a bebida, indivíduos acometidos de alcoolismo, que iniciam um consumo mais precoce parecem apresentar maior gravidade de dependência e problemas relacionados ao álcool (DOM et al., 2006). É sabido que o acesso ao álcool é um forte determinante do consumo (BABOR e CAETANO, 2005). Um estudo recente no Brasil, envolvendo 1900 estudantes com idades entre 11 e 21 anos,

indicou ser muito fácil adquirir álcool em lojas, e beber em um contexto social com amigos e parentes. Apenas 1% dos adolescentes relatou ter tentado comprar bebidas alcoólicas e não ter conseguido (VIEIRA et al., 2007).

Os jovens que começam a beber cedo, durante os anos da adolescência, aparentemente também experimentam maior risco de sofrer acidentes relacionados ao álcool, como aqueles com veículos automotores, quedas, queimaduras e afogamentos, do que usuários de iniciação em idades mais avançadas (HINGSON et al., 2000). O consumo abusivo é, dessa maneira, não apenas o fator causal de diversas doenças, mas também precursor de injúria e violência. Estudos verificaram relação próxima entre o consumo de álcool e aumento da agressividade (DUKE et al., 2011; LEJUEZ et al., 2010; DOM 2006). Nos Estados Unidos, 39% das fatalidades em acidentes automotivos envolveram o consumo de álcool em 2005 (U.S. DOT, 2005). Nas Américas, entre 20% e 50% das fatalidades em acidentes de trânsito estão relacionadas com o álcool (PAHO, 2007).

A maioria dos países reconhece os sérios problemas de saúde pública causados pelo consumo prejudicial de etanol e tem procurado adotar programas e políticas preventivas eficazes para mitigar as consequências negativas do exagero na ingestão dessa substância. Estima-se que em torno de dois bilhões de pessoas consumam bebidas alcóolicas no mundo e 76,3 milhões sejam diagnosticadas com algum distúrbio de uso de álcool (WHO, 2004). Os riscos do etanol para a saúde são muitos, e variam em tipo e intensidade. Alguns, mas não todos, são relacionados à dose e podem resultar diretamente ou dos efeitos do álcool, ou por sua interação com outros fatores. A intoxicação é frequentemente um importante mediador de injúria e a

dependência pode exacerbar significativamente seus riscos e causar exposição prolongada a seus perigos (BABOR e CAETANO, 2005).

O custo total causado pelo consumo excessivo de álcool nos Estados Unidos em 2006 foi estimado em 223,5 bilhões de dólares. Deste total, 161,3 bilhões (72,2%) devidos à perda de produtividade; 24,6 bilhões (11,0%) relativos ao aumento dos custos com saúde; 21,0 bilhões (9,4%) de custos com justiça criminal e 16,7 bilhões (7,5%) por outras causas (BOUCHERY et al., 2011).

Nas Américas, por exemplo, foi estimado que, em 2002, o álcool levou a 5,4% do total de mortes, uma proporção 68% maior, se comparado aos 3,7% da média global. Dessa totalidade 50,5% foram devidos a ferimentos, intencionais ou acidentais (REHM et al., 2006). O consumo *per capita* nas Américas foi aproximadamente 40% maior do que a média global em 2002, 8,7 litros comparados a 6,2 da média mundial (REHM et al., 2006). Quando analisado entre 26 fatores de risco e seu impacto sobre a carga de doenças que geram alguma incapacidade, o álcool é o principal fator nas Américas, enquanto é o quarto no mundo (REHM e MONTEIRO, 2005).

No caso de economias de mercado de pobreza intermediárias, como o Brasil, seu impacto percentual está estimado entre 8% a 14,9%. No Brasil, portanto, mais de 10% dos problemas de saúde são causados pelo consumo de etanol (MELONI e LARANJEIRA, 2004). A alta mortalidade entre os consumidores crônicos de bebidas alcoólicas, que fazem uso de doses consideradas elevadas, deve-se principalmente a suicídio, homicídio, ferimentos acidentais e doenças como cirrose hepática, derrame hemorrágico,

cânceres gástricos e da região superior do sistema respiratório (KLATSKY e ARMSTRONG, 1993; FARCHI et al., 1992).


O abuso do consumo é uma ameaça particularmente grave para o homem, principalmente por ferimentos, violência e doenças cardiovasculares. Globalmente uma porcentagem de 6,2% de mortes masculinas é atribuída ao álcool, comparado com 1,1% de morte de mulheres. Os homens superam em 4 vezes as mulheres em episódios de consumo excessivo, muito provavelmente, a razão pelas maiores taxas de mortalidade e invalidez. Posição socioeconômica e nível educacional mais baixo estão associados a risco aumentado de morte, doença ou ferimento relacionado ao álcool, determinantes que são maiores para o homem do que para a mulher (WHO, 2011). Ao redor do mundo, ocorre uma ampla variação no padrão de consumo, com os maiores níveis encontrados nos países desenvolvidos, principalmente no hemisfério norte; mas também na Argentina e Austrália. Baixas taxas de consumo podem ser encontradas, por exemplo, em países do norte da África e leste do Mediterrâneo, cujas regiões possuem uma grande representação de populações de fé islâmica, as quais apresentam altos níveis de abstenção (WHO, 2011).

A **Figura 1** mostra a distribuição *per capita* do consumo mundial de bebidas alcoólicas, em litros de etanol puro, segundo o último relatório da OMS (WHO, 2011). A **Figura 2** apresenta o padrão de distribuição de renda mundial e as respectivas expectativas de vida. As **Figuras 3 e 4** apresentam respectivamente os dados sobre morte e anos de vida ajustados por invalidez (AVAI), em relação a 19 fatores de risco e nível de renda. O índice conhecido pela sigla AVAI (anos de vida ajustados por invalidez) é um indicador calculado

utilizando-se os dados de morte prematura, anos vividos com incapacidade e expectativa de vida; e definido como uma medida "do tempo vivido com incapacidade e do tempo perdido devido à mortalidade prematura" (MURRAY, 1994). A **Figura 5** apresenta um resumo sobre os dados de consumo para o Brasil. As **Figuras 6 e 7** apresentam uma classificação de dez fatores de risco para, respectivamente, *causa mortis* e AVAI parametrizados por nível de renda.

O consumo individual de álcool pode ser descrito em termos de gramas de álcool consumido, ou por conteúdo alcóolico distinto de cada bebida. Uma dose padronizada, por exemplo, contém 10 gramas na Europa e entre 12 e 14 nos Estados Unidos e Canadá. O consumo de risco é um padrão que aumenta os perigos para a saúde, se duradouro. A OMS define esse nível de risco como uso de 20 a 40 gramas diários para mulheres e 40 a 60 gramas para os homens. O consumo prejudicial se refere ao que leva a consequências tanto para a saúde física quanto mental, e está definida pela OMS como mais de 40 gramas de álcool ao dia para mulheres e mais de 60 gramas por dia para os homens (OPS, 2008).

Consumo adulto (15+) total per capita, em litros de álcool puro



Fonte: Relatório da OMS Sobre o Status do Alcool e Saúde, 2011

Figura 1: fonte WHO 2011

Países de média e baixa renda agrupados por região da OMS, 2004




Figura 2: fonte WHO 2009



Figura 3: fonte WHO 2009




Figura 4: fonte WHO 2009


Brasil

Contexto socioeconômico

População: 189 323 000 ➤ População 15+ anos: 72% ➤ População em área urbana: 85% ➤ Grupo de renda (Banco Mundial): Extrato superior da renda média

Fonte: Nações Unidas, dados de 1990-2006


Registro do consumo adulto (15+) de álcool por tipo de bebida alcóolica (em litros de álcool puro), 2005




Consumo de álcool

Dados populacionais (referentes à população de 15 anos ou mais em litros de álcool puro).

Consumo adulto (15+) per capita, 1961 - 2005



Aumento do consumo per capita, adulto (15+), 2000 - 2005



Estimativa de mudança em cinco anos no consumo per capita (15+) 2001-2005

Aumento
➤ Estável
Redução
Inconclusivo

Consumo adulto (15+) per capita, média de 2003 - 2005 (em litros de álcool puro)

Registrado	6.2
Não-registrado	3.0
Total	9.2
Região Americana-OMS	8.7

Figura 5: fonte WHO 2011

Classificação dos 10 principais fatores de risco causadores de morte por grupo de renda, 2004

Fatores de risco		Mortes (milhões)	Porcentagem do total	Fatores de risco		Mortes (milhões)	Porcentagem do total
Mundo				Países de baixa renda			
1	Hipertensão	7.5	12.8	1	Baixo peso na infância	2.0	7.8
2	Tabagismo	5.1	8.7	2	Hipertensão	2.0	7.5
3	Hiperglicemia	3.4	5.8	3	Sexo sem proteção	1.7	6.6
4	Sedentarismo	3.2	5.5	4	Água, higiene e saneamento precários	1.6	6.1
5	Sobrepeso e obesidade	2.8	4.8	5	Hiperglicemia	1.3	4.9
6	Colesterol alto	2.6	4.5	6	Fumaça de sólidos em ambiente fechado	1.3	4.8
7	Sexo sem proteção	2.4	4.0	7	Tabagismo	1.0	3.9
8	Uso de álcool	2.3	3.8	8	Sedentarismo	1.0	3.8
9	Baixo peso na infância	2.2	3.8	9	Amamentação deficiente	1.0	3.7
10	Fumaça de sólidos em ambiente fechado	2.0	3.3	10	Colesterol alto	0.9	3.4
Países de média renda				Países de alta renda			
1	Hipertensão	4.2	17.2	1	Tabagismo	1.5	17.9
2	Tabagismo	2.6	10.8	2	Hipertensão	1.4	16.8
3	Sobrepeso e obesidade	1.6	6.7	3	Sobrepeso e obesidade	0.7	8.4
4	Sedentarismo	1.6	6.6	4	Sedentarismo	0.6	7.7
5	Uso de álcool	1.6	6.4	5	Hiperglicemia	0.6	7.0
6	Hiperglicemia	1.5	6.3	6	Colesterol alto	0.5	5.8
7	Colesterol alto	1.3	5.2	7	Baixo consumo de frutas e vegetais	0.2	2.5
8	Baixo consumo de frutas e vegetais	0.9	3.9	8	Polição atmosférica urbana	0.2	2.5
9	Fumaça de sólidos em ambiente fechado	0.7	2.8	9	Uso de álcool	0.1	1.6
10	Polição atmosférica urbana	0.7	2.8	10	Riscos ocupacionais	0.1	1.1

Países agrupados por renda bruta per capita - baixa renda (US\$ 825 ou menos), alta renda (US\$ 10 066 ou mais)

Figura 6: fonte WHO 2009

Classificação dos fatores de risco selecionados: 10 principais fatores de risco causais de AVAL por grupo de renda, 2004

Fatores de risco		AVAL (milhões)	Porcentagem do total	Fatores de risco		AVAL (milhões)	Porcentagem do total
Mundo				Países de baixa renda			
1	Baixo peso na infância	91	5.9	1	Baixo peso na infância	82	9.9
2	Sexo sem proteção	70	4.6	2	Água, higiene e saneamento precários	53	6.3
3	Uso de álcool	69	4.5	3	Sexo sem proteção	52	6.2
4	Água, higiene e saneamento precários	64	4.2	4	Amamentação deficiente	34	4.1
5	Hipertensão	57	3.7	5	Fumaça de sólidos em ambiente fechado	33	4.0
6	Tabagismo	57	3.7	6	Deficiência de vitamina A	20	2.4
7	Amamentação deficiente	44	2.9	7	Hipertensão	18	2.2
8	Hiperglicemia	41	2.7	8	Uso de álcool	18	2.1
9	Fumaça de sólidos em ambiente fechado	41	2.7	9	Hiperglicemia	16	1.9
10	Sobrepeso e obesidade	36	2.3	10	Deficiência de zinco	14	1.7
Países de média renda				Países de alta renda			
1	Uso de álcool	44	7.6	1	Tabagismo	13	10.7
2	Hipertensão	31	5.4	2	Uso de álcool	8	6.7
3	Tabagismo	31	5.4	3	Sobrepeso e obesidade	8	6.5
4	Sobrepeso e obesidade	21	3.6	4	Hipertensão	7	6.1
5	Hiperglicemia	20	3.4	5	Hiperglicemia	6	4.9
6	Sexo sem proteção	17	3.0	6	Sedentarismo	5	4.1
7	Sedentarismo	16	2.7	7	Colesterol alto	4	3.4
8	Colesterol alto	14	2.5	8	Drogas ilícitas	3	2.1
9	Riscos ocupacionais	14	2.3	9	Riscos ocupacionais	2	1.5
10	Água, higiene e saneamento precários	11	2.0	10	Baixo consumo de frutas e vegetais	2	1.3

Países agrupados por renda bruta per capita - baixa renda (US\$ 825 ou menos), alta renda (US\$ 10 066 ou mais)

Figura 7: fonte WHO 2009

2.3 Álcool e neuropatogênese

A ingestão de álcool pode produzir, no organismo, uma grande variedade de distúrbios patológicos. O consumo excessivo e prolongado dessa substância caracteriza uma situação que pode levar à degeneração tóxica e disfunção em diversos órgãos. Por ser uma molécula pequena e solúvel tanto em água como em lipídeos, o etanol difunde-se, com facilidade, através das membranas mucosas esofágicas e estomacais. Após a absorção, termina por ser completamente oxidado, nunca ficando armazenado no corpo (DAS e VASUDEVAN, 2007). A relação entre o consumo de etanol e as consequências para a saúde é complexa e multidimensional. As condições patológicas decorrentes do consumo podem ser consideradas completamente atribuíveis ao etanol, o que identifica o consumo como causa necessária para o desenvolvimento da condição patológica, e na falta do qual tal condição não ocorreria. Além disso, têm-se as doenças infecciosas ou crônicas, nas quais o álcool é uma causa componente associada, ou seja, facilita a instalação do quadro e pode agravar suas consequências (REHM et al., 2010). Entre as patologias derivadas 100% do consumo de álcool podem ser citadas: intoxicação aguda, síndrome de dependência, estado de abstinência com ou sem delírio, desordem psicótica, degeneração do sistema nervoso devido ao álcool, polineuropatia alcoólica, cardiomiopatia alcoólica, fibrose e esclerose hepática, falência hepática, cirrose hepática, pancreatite aguda e crônica, dentre outras (EHLERS e CRIADO, 2010; REHM et al., 2010). Entre as patologias não completamente atribuíveis ao etanol, mas nas quais ele tem participação provável, podemos citar a epilepsia, Doença de Alzheimer, câncer de boca, de faringe, de esôfago, de estômago, de fígado, de reto, diabetes

mellitus, pneumonia, desordem depressiva unipolar e tuberculose, (PARKIN, 2011; REHM et al., 2010).

Estudos atuais discutem resultados que apontam para um aumento da expectativa de vida de consumidores moderados, em comparação a consumidores “pesados” (mais de três doses/dia) e a não-consumidores de bebida alcoólica, aqueles que nunca consomem mais de uma dose/mês (RIMM et al., 1996, RUITENBERG et al., 2002). Embora a toxicidade do etanol possa estar associada ao aparecimento de demência em bebedores abusivos, a ingestão moderada parece reduzir, em longo prazo, o risco de demência. Essa relação, entre o consumo e benefícios ou malefícios sofridos, foi verificada em estudos com indivíduos idosos, em que os hábitos de consumo de etanol foram determinados e acompanhados, desde anos antes de começarem a aparecer os casos de demência associados à idade (RUITENBERG et al., 2002).

2.4 Álcool e espécies químicas reativas

Os efeitos deletérios provocados pelo álcool podem ser consequentes à sua toxicidade direta, ou indireta, através de seus metabólitos secundários e/ou a formação de espécies reativas de oxigênio. A oxidação do etanol está associada com uma mudança na homeostase da oxi-redução nos hepatócitos, que levam a certas desordens metabólicas. O etanol por si, a hiperlactacidemia e níveis elevados de NADH aumentam a atividade da enzima xantina oxidase, que por sua vez resulta na produção do ânion superóxido. O álcool pode induzir a formação de espécies reativas ainda pela reação da enzima aldeído oxidase, que gera oxi-radicais e pelo aumento da disponibilização de NADH

para as mitocôndrias que, com o metabolismo oxidativo alterado, respondem com o aumento do efluxo de radicais livres (DAS e VASUDEVAN, 2007). É possível que, desta maneira, dano oxidativo possa acumular-se como uma consequência secundária do consumo e metabolização do etanol.

De fato, uma das maiores ameaças à homeostasia celular dos organismos aeróbicos é a formação dos intermediários reativos e os subprodutos do metabolismo do oxigênio (FRIDOVICH, 1978; HALLIWELL e CROSS, 1994). Essas espécies reativas são, ironicamente, derivadas de processos metabólicos e fisiológicos normais que são essenciais para a célula (YU, 1994). O processo evolutivo dotou os organismos aeróbicos com mecanismos bem balanceados para neutralizar os efeitos oxidativos maléficos do oxigênio e seus metabólitos reativos. Esses componentes protetores são denominados sistemas de defesa antioxidantes (DAVIES, 1986; HARRIS, 1992). Sua função é proteger a homeostase celular da ruptura por radicais livres e outras moléculas reativas criadas durante a redução do oxigênio (BENDICH et al., 1984; LUNEC et al., 1985). O desbalanceamento em favor dos radicais oxidativos gerados no metabolismo, sobre o seu efetivo controle pelos mecanismos antioxidantes, caracteriza a situação de estresse oxidativo. Nessa condição, a intrincada rede de defesa de enzimas e moléculas antioxidantes, integrada com outros componentes celulares dedicados ao reparo das moléculas danificadas ou alteradas, tornam-se insuficientes para a integridade da homeostase celular (RIVETT, 1985; SALO et al., 1998). Os dados experimentais disponíveis mostram que a remoção de peróxido de hidrogênio e oxigênio singleto, pelo sistema de defesa antioxidante, é essencial para a possibilidade de vida aeróbica saudável. A exposição ao oxigênio puro a

1 atm, por exemplo, por um período curto como 6 horas, causa inflamação do peito, rouquidão e tosse. Exposição por período mais prolongado leva a danos pulmonares (HALLIWELL e CROSS, 1994).

Mecanismos de defesa contra o estresse oxidativo induzido por radicais livres envolvem: (i) mecanismos preventivos, (ii) mecanismos de reparo, (iii) defesas físicas e (iv) defesas antioxidantes. As defesas antioxidantes enzimáticas incluem a superóxido dismutase (SOD), glutathione peroxidase (GPx) e catalase (CAT). Antioxidantes não-enzimáticos estão representados pelo ácido ascórbico (vitamina C), α -tocoferol (vitamina E), glutathione (GSH), carotenóides, flavonóides e outros antioxidantes. Sob condições normais, existe um balanço entre a produção de espécies reativas, as atividades e os níveis intracelulares desses antioxidantes. Esse balanço é essencial para a saúde e a sobrevivência dos organismos (VALKO et al., 2007).

Embora as espécies reativas sejam formadas normalmente no metabolismo para cumprir uma série de ações fisiológicas, ao reagir com uma grande variedade de componentes celulares, sua produção excessiva pode causar alterações morfológicas e funcionais nas células, inclusive o desbalanceamento da homeostase do cálcio intracelular, considerada a base dos mecanismos de injúrias por excitotoxicidade (TURRENS, 2003).

Outros estudos têm relatado que o dano oxidativo de biomoléculas parece estar envolvido com o aparecimento e o desenvolvimento de diversas doenças sistêmicas crônicas, como o câncer, além de doenças cardiovasculares, sendo essas duas as maiores causas de morbidade e mortalidade no mundo ocidental (TAPIERO et al., 2004). Humanos adultos jovens que consomem etanol de forma crônica têm uma maior probabilidade de

serem patologicamente afetados em diversos órgãos, como fígado, rins, coração pâncreas e cérebro (LIEBER, 1995). O estresse oxidativo, induzido pelo álcool, está relacionado com os sistemas mitocondriais e microssomais, envolvendo o metabolismo do etanol e a formação de espécies reativas de oxigênio e nitrogênio. Estas, quando produzidas em grande quantidade, podem provocar a depleção dos mecanismos antioxidantes endógenos e, assim, estabelecer um ambiente propício ao estresse oxidativo, pela atuação dos radicais livres (RASHBA-STEP et al., 1993; DAS e VASUDEVAN, 2007).

2.5 Sistema nervoso, espécies reativas de oxigênio e antioxidantes

Com relação à ação das espécies reativas de oxigênio **no sistema nervoso central**, é importante mencionar que essa ação, juntamente com outros fatores, tem sido associada, em países desenvolvidos, com a incidência aumentada de doenças neurodegenerativas, incluindo danos relacionados a estresse oxidativo (CHEN et al., 2009). Isso pode ser intensamente produzido em condições de sobrecarga de oxidantes no organismo, como em alimentação parenteral (CHEN et al., 2007), em casos de hipo-funcionamento dos mecanismos antioxidantes neurais, ou pelo consumo excessivo de etanol. Nessas condições, a suplementação dietética de antioxidantes pode ser benéfica (CODONER-FRANCH et al., 2010). Taxas aumentadas de peroxidação no cérebro, por exemplo, pode levar à produção excessiva de espécies reativas de oxigênio, as quais, se não forem neutralizadas por mecanismos antioxidantes, são altamente deletérias ao tecido cerebral. Essa neutralização fisiológica das espécies reativas pode falhar na presença de um

número de fatores, como deficiência nutricional (RAMESH et al., 2010), processo de envelhecimento (GEMMA et al., 2007) e o consumo de etanol (LOUREIRO et al., 2011). Esses fatores podem romper o cenário óxido-redutor normal do cérebro, levando a uma situação de aumento do estresse oxidativo no qual o cérebro torna-se susceptível ao desenvolvimento de certas disfunções neurológicas, como as que ocorrem na Doença de Alzheimer (AXELSEN et al., 2011), diabetes (SEIFRIED et al., 2007) e epilepsia (GROSSO et al., 2011). Propriedades antioxidantes têm se mostrado importantes na proteção do cérebro contra os efeitos deletérios dos radicais livres, particularmente em doenças neurodegenerativas (OCHIAI et al., 2007).

O etanol pode permear praticamente todo o tecido cerebral, exercendo a maior parte dos seus efeitos tóxicos através da produção de espécies reativas de oxigênio (TAPIERO et al., 2004). O tecido cerebral é particularmente vulnerável ao dano oxidativo, possivelmente por causa do seu alto consumo de oxigênio, baixo nível de enzimas antioxidantes, altos níveis de ferro livre e consequente produção de grandes quantidades de espécies reativas (LAMARCHE et al., 2004). A isquemia cerebral, por exemplo, leva a danos no cérebro, causados por diversos mecanismos patogênicos, que também são deflagrados por neurotrauma. Estes mecanismos incluem, entre outros, a excitotoxicidade, a produção excessiva de radicais livres, a inflamação e a apoptose. Além do mais, tanto a isquemia quanto o trauma cerebral deflagram mecanismos autoprotetores similares, nos quais se incluem a produção de proteínas de choque térmico, citocinas anti-inflamatórias e antioxidantes endógenos. A terapia neuroprotetora, utilizando antioxidantes, procura minimizar a ativação de vias tóxicas, aumentando a atividade dos mecanismos

neuroprotetores endógenos (LEKER e SHOHAMI, 2002). O acúmulo de danos oxidativos em neurônios pode ser, primária ou secundariamente, a causa para o aumento da incidência de doenças neurodegenerativas como neoplasias, doença de Parkinson, de Alzheimer e esclerose lateral amiotrófica, em populações idosas (HALLIWELL 2001; RAO e BALACHANDRAN; 2002).

O etanol perturba processos relevantes na formação do cérebro, podendo resultar em migração celular tardia e anômala, depressão da neurogênese e desenvolvimento estrutural e funcional aberrante (GONZÁLEZ et al., 2007). Na “síndrome do alcoolismo fetal”, uma série de disfunções comportamentais, intelectuais e neurológicas pode se desenvolver, como consequência da exposição do embrião, em formação, ao etanol, comprometendo o desenvolvimento normal do sistema nervoso central (COSTA et al., 2000; LIPINSKI et al., 2012; MATTSON et al., 2012). O hipocampo é um dos principais alvos da injúria nessa síndrome, podendo originar déficits em aprendizado e memória, os quais são encontrados em crianças acometidas de tal quadro. Moléculas com ação antioxidante como a vitamina E (α -tocoferol) e o β -caroteno protegem células nervosas, cultivadas a partir do hipocampo de ratos, contra os efeitos do etanol, em um modelo *in vitro* de síndrome do alcoolismo fetal associado com isquemia (MITCHELL et al., 1999). Uma das desordens neurológicas mais comumente identificada como sendo associada ao alcoolismo é a síndrome de Wernicke-Korsakoff. Esta síndrome é causada por deficiência de tiamina, que pode ser consequência de sua insuficiência na dieta ou por redução da absorção, provocada pelo consumo de álcool, que leva à lesão bilateral no diencéfalo (notadamente no tálamo e corpos mamilares). A sua característica mais marcante é a

deterioração da memória (FADDA e ROSSETTI, 1998; KESSELS e KOPELMAN, 2012; SUBRAMANYA et al., 2010). Nessa condição patológica pode ocorrer tanto amnésia anterógrada quanto retrógrada. Além da perda de memórias formadas anteriormente ao estabelecimento da síndrome, nos estágios avançados dessa neuropatologia, a dificuldade persistente na formação de novas memórias compromete a capacidade de aprendizado de novas informações, um estado frequentemente persistente e irreversível (FADDA e ROSSETTI, 1998; KESSELS e KOPELMAN, 2012; LOUGH, 2012).

Estudos recentes demonstraram que, na Doença de Alzheimer, a deposição de peptídeos β -amilóides e a morte neuronal estão relacionadas a uma crescente disfunção neural cognitiva. O estresse oxidativo observado na doença, provocado provavelmente por níveis aumentados de ferro e cobre na neurópila (regiões do sistema nervoso central com predominância de terminações axonais e dendríticas, mas com poucos corpos celulares), causa alteração no metabolismo de esfingolipídios e do colesterol, e proporciona o acúmulo celular de ceramidas de cadeia longa e colesterol (SMITH et al. 2000; CUTLER et al., 2004). Esse acúmulo de colesterol livre é tóxico para a célula, o que por sua vez pode levar a uma cascata neurodegenerativa que é evidenciada pelo aparecimento dos sintomas clínicos da doença. Foi verificado que o tratamento com α -tocoferol mostrou-se eficaz em reduzir a formação de ceramidas, e proteger neurônios contra a morte induzida pelo acúmulo de peptídeo β -amilóide (CUTLER et al., 2004).

O consumo de etanol provoca o acúmulo de lipídios no fígado (esteatose hepática), que em princípio não caracteriza uma condição patológica. A persistência de consumo abusivo, entretanto, pode favorecer o

desenvolvimento de esteatohepatite, com produção e acúmulo de lipídios tóxicos (como as ceramidas), ativação de citocinas pró-inflamatórias e desenvolvimento de resistência à insulina (DE LA MONTE et al., 2009; SETSHEDI et al., 2011). O aumento intracelular de ceramidas, bem como de diacilglicerol e acil-coenzima A de cadeia longa, tem sido demonstrado como sendo uma condição promotora da resistência à insulina. Isso ocorre por interferência na fosforilação de proteínas da via da insulina, incluindo o substrato do receptor de insulina (IRS 1 e 2), fosfatidil-inositol-3-quinase (PI3 quinase) e Proteína Quinase C (SILVEIRA et al. 2008). A Insulina, através de vias intracelulares complexas, que começam com a sua ligação ao seu receptor na superfície das células, transmite sinais pró-crescimento, pró-sobrevivência e de ativação do metabolismo energético (DE LA MONTE E WANDS, 2005).

No sistema nervoso central, as cascatas de sinalização da insulina e do fator de crescimento semelhante à insulina tipo 1 (IGF-1) têm funções críticas na regulação e manutenção de funções cognitivas e motoras. Essas moléculas sinalizadoras possuem seus receptores abundantemente expressos em vários tipos celulares por todo o cérebro, incluindo neurônios e oligodendroglia (BROUGHTON et al., 2007; D'ERCOLE e YE, 2008; FREUDE et al., 2008). Uma vez que a insulina e os fatores de crescimento semelhantes à insulina (IGF 1 e 2) mediam a sobrevivência, plasticidade, metabolismo energético e funções neuroglicais, a debilitação prolongada nas respectivas cascatas de sinalização pode ter sérias consequências sobre a cognição e o comportamento (CHESIK et al., 2008; SCHUBERT et al., 2003). O etanol causa resistência à insulina por perturbar a composição de lipídeos de membrana causando assim alterações

significativas que prejudicam a ligação da insulina com o seu receptor, e subsequentemente toda a sequência de sinalização (COHEN et al., 2007; DE LA MONTE et al., 2008; HALLAK et al., 2001). A lipólise induzida pela resistência à insulina leva à geração de lipídios como as ceramidas, que podem aumentar ainda mais a resistência à insulina, a função mitocondrial e assim, a sobrevivência da célula (HOLLAND e SUMMERS, 2009; LANGEVELD e AERTS, 2009). Ceramidas são moléculas lipídicas sinalizadoras que modulam respostas celulares positivas ou negativas tais como proliferação, motilidade, plasticidade, inflamação e apoptose (SUMMERS, 2006). Em estados de lipólise associada à resistência à insulina, as ceramidas acentuam o desenvolvimento dessa resistência através da ativação de citocinas inflamatórias e inibição da sinalização estimulada pela insulina (BOURBON et al., 2002; HAJDUCH et al., 2001). Em humanos alcoólatras, a atrofia e degeneração da substância branca com expressão reduzida de gens relacionados à mielina, e grau aumentado de estresse oxidativo, foram associados com o aumento da expressão de gens para ceramidas (DE LA MONTE et al., 2008). As ceramidas produzidas em regiões externas ao sistema nervoso, como por exemplo, no fígado sob influência do álcool, ultrapassam a barreira hematoencefálica e podem disparar mecanismos apoptóticos no cérebro, numa condição de proteção reduzida das vias pró-sobrevivência e crescimento, proporcionadas pela insulina, formando um eixo hepato-cerebral de neurodegeneração (DE LA MONTE et al., 2009; SETSHEDI et al., 2011).

Em diversas células, o álcool prejudica a diferenciação e o crescimento celulares, interfere nos efeitos estimulantes de fatores tróficos e é capaz de alterar a expressão de proteínas do citoesqueleto (GUERRI et al., 2001).

Quando tais alterações causadas pelo etanol afetam as células gliais, podem levar à perturbação nas interações glia-neurônio e produzir defeitos no funcionamento do cérebro (GONZÁLES et al., 2007; GUERRI et al., 2001). Os astrócitos, que formam o maior grupo de células não excitáveis no sistema nervoso central de mamíferos, são células capazes de regular a atividade neuronal e a neurotransmissão sináptica. Apropriadamente estimulados por uma série de neuromoduladores, hormônios e neurotransmissores, os astrócitos respondem com um aumento na concentração intracelular de cálcio livre. Este aumento, por sua vez, regula eventos intracelulares como expressão gênica, diferenciação, respostas metabólicas, sistemas de transportes de íons e secreção de substâncias neuroativas (GONZÁLEZ et al., 2007). Entretanto, o aumento nos níveis de cálcio no citoplasma, como ocorre nos astrócitos durante a metabolização do etanol ingerido, pode levar a uma maior captação deste íon pelas mitocôndrias. O aumento da captação de cálcio pela mitocôndria leva essa organela à produção excessiva de espécies reativas de oxigênio; o aumento da produção das espécies reativas, por sua vez, leva à uma sobrecarga da concentração de cálcio citoplasmático, num jogo de puxa-empurra “de auto-alimentação” (GONZÁLEZ et al., 2007). Dessa maneira, pode-se visualizar que a manutenção de níveis elevados de cálcio intracelular é uma das formas pelas quais o álcool pode provocar, por estresse oxidativo, a morte dos astrócitos, tão importantes na manutenção da homeostase no sistema nervoso central. As espécies reativas produzidas pelas mitocôndrias são mediadores da sinalização molecular relacionada à via apoptótica mitocôndria-dependente, que envolve a ligação com proteínas anti e pró-

apoptóticas, liberação de citocromo c e a sinalização via p53 que levam à morte celular (NIIZUMA et al., 2009).

Estudos *in vitro* demonstraram que o aumento dos níveis de peróxido de hidrogênio e a redução da glutathiona mitocondrial são os agentes causadores mais prováveis da apoptose induzida pelo etanol (TAPIERO et al., 2004). Estudos já demonstraram o efeito benéfico do α -tocoferol, em aumentar a sobrevivência de células cerebelares de rato frente à neurotoxicidade induzida pelo etanol, tanto *in vitro* como *in vivo*, sendo essa resistência associada ainda a uma elevação nos níveis de proteínas anti-apoptóticas (HEATON et al, 2004).

FISCHER e KITTNER (1998) descreveram uma redução dose-dependente da severidade de ataques epiléticos no modelo de abrasamento por pentilenotetrazol em ratos, para doses moderadas de etanol (0,5 – 1,5 g/kg, por 28 dias). Por outro lado, o tratamento subcrônico, com altas doses, seguido por longos períodos de abstinência, levaram a efeitos pró-convulsivos. SCORZA e colaboradores (2003) verificaram que a administração de etanol, seguida pela sua abstinência, provoca alterações neuropatológicas e aumento de crises epiléticas no modelo de epilepsia produzida pela pilocarpina. Eles concluíram que a síndrome da abstinência do álcool é um evento crucial no desenvolvimento de alterações funcionais e neuropatológicas associadas à epilepsia. Interações medicamentosas entre o etanol e drogas antiepiléticas têm sido também descritas (FISCHER, 2005). KOZAN e colaboradores (2007) verificaram que administração de α -tocoferol reduziu a frequência média da atividade epileptiforme, principalmente associada com etanol, no modelo de epilepsia induzida por penicilina. Esta, quando injetada intracorticalmente, age bloqueando especificamente a transmissão sináptica de neurotransmissores

inibitórios (McDONALD e BARKER, 1977), facilitando assim a atividade epileptiforme. Por outro lado, o etanol parece estimular a inibição mediada pelos receptores inibitórios do GABA (gama-aminobutíric acid; em português, ácido gama-aminobutírico). Os receptores de glutamato do tipo NMDA, por sua vez, são inibidos pela exposição ao etanol, elevando o nível do limiar para a atividade epileptiforme, o que, associado à estimulação dos mecanismos GABAérgicos, aparentemente contribui para a redução encontrada na frequência de espículas epileptiformes no eletroencefalograma. Durante os períodos de abstinência ao etanol, sugere-se que a falta da inibição elevada do sistema GABA mais a quantidade excessiva dos receptores excitatórios NMDA participem do efeito pró-convulsivante da abstinência do álcool (KOZAN et al., 2007). Uma possibilidade é que isto represente a base de um mecanismo de plasticidade.

As distintas populações celulares do cérebro normal geram atividade elétrica continuamente, durante todo o período de vida do organismo. Todas as funções regulatórias dependentes do cérebro no organismo dependem direta ou indiretamente dessa atividade elétrica. Em humanos, bem como em animais de laboratório, uma interessante maneira de adquirir informação importante sobre o funcionamento cerebral consiste em registrar a atividade elétrica produzida espontaneamente pelo cérebro. Esta técnica, denominada eletroencefalograma (EEG), pode ser definida como a medida das oscilações temporais do potencial elétrico entre dois pontos do cérebro. Por ser uma técnica não invasiva (um certo número de eletrodos é fixado sobre a pele do crânio e as oscilações de potencial elétrico são registradas de maneira pareada), é amplamente utilizada em humanos, auxiliando no diagnóstico de

diversas desordens neurológicas (GUEDES, 2005). Em animais experimentais, os registros podem ser realizados de maneira invasiva, sob anestesia, na qual o crânio é aberto cirurgicamente e os eletrodos de registro são posicionados sobre a superfície ou mesmo dentro do córtex; neste caso, é denominado eletrocorticograma (ECoG). Sob estresse oxidativo, como por exemplo, na injúria por isquemia/reperfusão, a atividade elétrica cerebral pode ser afetada em diferentes intensidades (KARA et al., 2011). Em animais sob estresse oxidativo, diversos relatos descrevem susceptibilidades alteradas para desordens relacionadas à excitabilidade do cérebro, tais como epilepsia e doenças degenerativas (GROSSO et al., 2011; AYYLDIZ et al., 2007; WALDBAUM e PATEL, 2010). A implicação fisiopatológica de tal conjunto de evidências, para a saúde humana, levou-nos a querer investigar em que extensão o desarranjo no estado redox poderia alterar a atividade elétrica do córtex cerebral. Para este propósito, temos usado como modelo experimental o fenômeno da depressão alastrante da atividade elétrica cortical (DAC).

2.6 Depressão alastrante cortical e espécies químicas reativas

A DAC é um fenômeno eletrofisiológico que foi primeiramente descrito por Aristides Leão (LEÃO, 1944; 1947). É definida como uma redução da atividade elétrica do córtex cerebral, em resposta à estimulação de um ponto cortical. Essa estimulação pode ser de natureza química, elétrica ou mecânica. A redução observada no registro eletrocorticográfico propaga-se concentricamente (com velocidade na ordem de 2 a 5 mm/min) por toda a superfície do córtex, a partir do ponto inicialmente estimulado. Após alguns

minutos, a atividade elétrica retorna completamente ao normal, o que caracteriza o fenômeno como completamente reversível (LEÃO, 1944). Esse fenômeno já foi registrado em inúmeros vertebrados, como aves, mamíferos e mesmo em anfíbios (LEÃO, 1972; BURES et al., 1974; DO CARMO e MARTINS FERREIRA, 1984; GORJI, 2001), já tendo sido registrado em humanos (MAYEVSKY et al., 1996; DOHMEN et al, 2008; FABRICIUS et al, 2008).

A modulação imposta por diferentes tratamentos experimentais, sobre a velocidade com que a DAC se propaga, proporciona um indício sobre o estado geral do tecido nervoso quanto à facilidade ou dificuldade de transmissão dos sinais elétricos cerebrais. Esta informação, por sua vez, nos permite comparar as modificações do perfil de atividade elétrica no cérebro, resultantes de tratamentos ou condições impostas, para buscar um melhor entendimento dos eventos envolvidos na modificação da excitabilidade cerebral. Mudanças nas características da DAC relacionam o fenômeno a doenças neurológicas de interesse clínico, como a epilepsia, enxaqueca com aura, isquemia cerebral (LEHMENKÜHLER et al., 1993; LEÃO, 1944; GUEDES e CAVALHEIRO, 1997).

Durante a DAC, enquanto a atividade elétrica espontânea é reduzida, ondas “epileptiformes”, semelhantes àquelas descritas em pacientes epiléticos, usualmente aparecem e se propagam (LEÃO, 1944; GUEDES e DO CARMO, 1980). Essa e outras evidências experimentais sugerem que a DAC pode ter seus mecanismos relacionados aos de doenças humanas, como a epilepsia (LEÃO, 1944; 1972; GUEDES et al., 2009), a migrânea com aura, outrora denominada “enxaqueca clássica” (HADJIKHANI et al., 2001), e

também à isquemia cerebral (DOHMEN et al., 2008). Dentre outros possíveis fatores, os radicais livres produzidos no tecido nervoso são freqüentemente apontados como envolvidos na DAC (NETTO e MARTINS-FERREIRA, 1989; EI-BACHÁ et al., 1998). Pelo exposto, a DAC foi utilizada neste estudo como modelo experimental, em prosseguimento à linha de pesquisa desenvolvida na UFPE/Departamento de Nutrição, onde a parte experimental deste trabalho foi realizada.

Evidências experimentais indicam que o tecido neural, em condições fisiológicas, oferece certo grau de resistência à propagação da DAC (GUEDES e DO CARMO, 1980). Quando essa resistência diminui, em função de algum tratamento experimental, a DAC passa a se propagar com velocidades mais altas do que as observadas em condições controle; o contrário ocorre, se a resistência cortical à DAC for experimentalmente aumentada. Assim, procedimentos experimentais, que enfraqueçam ou reforcem a capacidade cerebral de se contrapor à DAC, podem fornecer informações valiosas para a compreensão desse fenômeno e para as doenças a ele relacionadas. Na UFPE (no Departamento de Nutrição), a DAC vem sendo estudada em ratos submetidos a manipulações ambientais (SANTOS-MONTEIRO et al., 2000), farmacológicas (AMÂNCIO-DOS-SANTOS et al., 2006), nutricionais (ROCHA-DE-MELO et al., 2006) e hormonais (ACCIOLY et al, 2012). Dentre as diversas condições, que influenciam a DAC, está o consumo de etanol: o tecido nervoso torna-se mais susceptível à DAC, sob o efeito prolongado do etanol, em comparação com grupos tratados com água destilada (GUEDES e FRADE, 1993; SONN e MAYEVSKY, 2001).

Para testar a hipótese de que a ação facilitadora do etanol sobre a DAC está associada ao estresse oxidativo induzido pelo álcool, BEZERRA e colaboradores (2005) registraram a DAC em ratos tratados cronicamente (por 18 dias) com um extrato alcoólico de carotenóides do camarão (*Litopenaeus vannamei*). Eles verificaram uma redução da velocidade de propagação da DAC, em comparação com ratos tratados apenas com o etanol. Esse estudo, do qual resultou a publicação do artigo (BEZERRA et al, 2005), sugere a aceitação da hipótese acima e fez parte do trabalho de conclusão do curso de graduação do doutorando que ora apresenta esta tese.

O extrato de carotenóides do camarão, acima descrito, possui na sua composição vários carotenóides, sendo a astaxantina o mais abundante. Assim, em prosseguimento ao trabalho acima, no seu mestrado, o presente doutorando investigou a possibilidade de que os efeitos desse extrato de carotenóides fossem devidos, senão exclusivamente, ao menos principalmente à astaxantina. Os resultados confirmaram essa hipótese: o tratamento com astaxantina pura (comercial) neutralizou os efeitos do tratamento crônico com etanol sobre a DAC, de forma semelhante ao observado com o extrato de carotenóides do camarão; o trabalho resultou na publicação de mais um artigo (ABADIE-GUEDES et al., 2008).

Duas perguntas se seguiram a esse trabalho e foram sequencialmente investigadas durante o doutorado: a primeira pergunta objetivou verificar se, em comparação com o tratamento crônico, o tratamento agudo com etanol (apenas um dia) teria efeito sobre a DAC e se a astaxantina, também ministrada por um dia, neutralizaria tal efeito.

A segunda pergunta procurou investigar se a ação protetora dos carotenóides sobre o efeito do etanol na DAC seria restrita apenas a essa classe de antioxidantes (carotenóides) ou se outras moléculas com ação antioxidante, mas que não sejam carotenóides, também a exerceriam. Para responder a essa pergunta, decidiu-se investigar uma molécula que tivesse, ao lado da ação antioxidante, um importante papel metabólico e fisiológico. A vitamina E (α -tocoferol) atende a esses critérios, sendo que alguns dos seus efeitos sobre o sistema nervoso já têm sido estudados (CHERUBINI et al., 2008; CUDDIHY et al., 2008; MARINO et al., 2004; SHICHIRI et al., 2007). Assim, analisou-se a ação da vitamina E sobre a DAC, na presença do etanol, e essa ação foi comparada com aquela previamente descrita para a astaxantina. Os resultados desses experimentos revelaram que o tocoferol antagoniza os efeitos do etanol sobre a DAC, de forma semelhante ao carotenóide astaxantina.

3.0 OBJETIVOS

3.1 Objetivo geral

Estudar os efeitos de diferentes regimes de consumo de álcool sobre a atividade elétrica no córtex de ratos Wistar, e comparar a ação de dois diferentes tipos de moléculas antioxidantes em modificar o efeito do etanol sobre a eletrofisiologia nesses animais.

3.2 Objetivos específicos

1) Caracterizar o efeito agudo da administração de etanol sobre a DAC, em animais adultos jovens de duas faixas distintas de idade; e avaliar se o tratamento agudo com astaxantina se oporia a tal efeito;

2) investigar se o α -tocoferol modificaria as alterações na propagação da DAC causadas pelo etanol, bem como pela sua abstinência;

(3) comparar eventuais modificações com aquelas previamente observadas com a astaxantina.

4. Referências bibliográficas

ABADIE-GUEDES, R., GUEDES, R.C.A., BEZERRA, R.S. The Impairing Effect of Acute Ethanol on Spreading Depression is Antagonized by Astaxanthin in Rats of 2 Young-Adult Ages. **Alcoholism: Clinical and Experimental Research**, v. 36, n. 9, p.1563-1567, 2012.

ABADIE-GUEDES, R., SANTOS, S.D., CAHÚ, T.B., GUEDES, R.C.A., BEZERRA, R.S. Dose-dependent effects of astaxanthin on cortical spreading depression in chronically ethanol-treated adult rats. **Alcoholism: Clinical and Experimental Research**, v. 32, p. 1-5, 2008.

ACCIOLY, N.E, BENEVIDES R.D.L., Costa B.L.S.A, Guedes R.C.A. Ovariectomy in the developing rat decelerates cortical spreading depression in adult brain. **International Journal of Developmental Neuroscience**, v. 30, p. 405–410, 2012.

AMÂNCIO-DOS-SANTOS A., PINHEIRO, P.C.F., LIMA, D.S.C., OZIAS, M.G., OLIVEIRA, M.B., GUIMARÃES, N.X., GUEDES, R.C.A. Fluoxetine inhibits cortical spreading depression in weaned and adult rats suckled under favorable and unfavorable lactation conditions. **Experimental Neurology**, v. 200, p. 275-282, 2006.

AXELSEN, P.H., KOMATSU, H., MURRAY, I.V. Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease. **Physiology**, v. 26, p. 54–69, 2011.

- AYYILDIZ, M., COSKUN, S., YILDIRIM, M., AGAR, E. The effects of ascorbic acid on penicillin-induced epileptiform activity in rats. **Epilepsia**, v. 48, p. 1388–1395, 2007.
- BABOR, T.F., CAETANO, R. Evidence-based alcohol policy in the Americas: strengths, weaknesses, and future challenges. **Pan American Journal Public Health**, v. 18, p. 4-5, 2005.
- BENDICH, A., D'APOLITO, P., GABRIEL, E., MACHLIN, L.J. Interaction of dietary vitamin C and vitamin E on guinea pig immune responses to mitogens. **The Journal of Nutrition**, v. 114, p. 1588-1593, 1984.
- BEZERRA, R.S., ABADIE-GUEDES, R., MELO, F.R.M., PAIVA, A.M.A., AMÂNCIO-DOS-SANTOS, A., GUEDES, R.C.A. Shrimp carotenoids protect the developing rat cerebral cortex against the effects of ethanol on cortical spreading depression. **Neuroscience Letters**, v. 391, p. 51–55, 2005.
- BOFFETTA, P., HASHIBE, M., LA VECCHIA, C., ZATONSKI, W., REHM, J. The burden of cancer attributable to alcohol drinking. **International journal of cancer**, v. 119, p. 884 – 887, 2006.
- BOUCHERY, E.E., HARWOOD, H.J., SACKS, J.J., SIMON, C.J., BREWER, R.D. Economic Costs of Excessive Alcohol Consumption in the U.S., 2006. **American Journal of Preventive Medicine**, v. 41, p. 516–524, 2011.
- BOURBON, N.A., SANDIRASEGARANE, L., KESTER, M. Ceramide-induced inhibition of Akt is mediated through protein kinase Czeta: implications for growth arrest. **Journal of Biological Chemistry**, v. 277, p. 3286-3292, 2002.

BROUGHTON, S.K., CHEN, H., RIDDLE, A., KUHN, S.E., NAGALLA, S., ROBERTS, C.T. JR., BACK, S.A. Large-scale generation of highly enriched neural stem-cell-derived oligodendroglial cultures: maturation-dependent differences in insulin-like growth factor-mediated signal transduction. **Journal of Neurochemistry**, v. 100, p. 628-638, 2007.

BURES, J., BURESOVA, O., KRIVANEK, I. The mechanisms and applications of Leão's spreading depression of eletroencephalografic activity. **Praga: Academia**, 1974.

CHEN, Q., ESPEY, M.G., SUN, A.Y., LEE, J.H., KRISHNA, M.C., SHACTER, E., CHOYKE, P.L., POOPUT, C., KIRK, K.L., BUETTNER, G.R., LEVINE, M. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. **Proceedings of the National Academy of Sciences**, v. 104, p. 8749–54, 2007.

CHEN, K., ZHANG, X., WEI, X-P., QU, P., LIU, Y-X., LI, T-Y. Antioxidant vitamin status during pregnancy in relation to cognitive development in the first two years of life. **Early Human Development**, v. 85, p. 421–7, 2009.

CHERUBINI, A., RUGGIERO, C., MORAND, C., LATTANZIO, F., DELL'AQUILA, G., ZULIANI, G., DI IORIO, A., ANDRES-LACUEVA, C. Dietary antioxidants as potential pharmacological agents for ischemic stroke. **Current Medicinal Chemistry**, v. 15, p. 1236-48, 2008.

CHESIK, D., DE KEYSER, J., WILCZAK, N. Insulin-like growth factor system regulates oligodendroglial cell behavior: therapeutic potential in CNS. **Journal of Molecular Neuroscience**, v. 35, p. 81-90, 2008.

CLAUDIAN, J. History of the usage of Alcohol. In: Tremoiliers, J. (ed.): International Encyclopedia of Pharmacology and Therapeutics, **Pergamon**, Oxford, v. 1, p. 3-26. 1970.

CODOÑER-FRANCH, P., LÓPEZ-JAÉN, A.B., DE LA MANO-HERNÁNDEZ, A., SENTANDREU, E., SIMÓ-JORDÁ, R., VALLS-BELLÉS, V. Oxidative markers in children with severe obesity following low-calorie diets supplemented with mandarin juice. **Acta Paediatrica**, v. 99, p.1841–1846, 2010.

COHEN, A.C., TONG, M., WANDS, J.R., DE LA MONTE, S.M. Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. **Alcoholism: Clinical and Experimental Research**, v. 31, p. 1558-1573, 2007.

CONNOR, J.P., GEORGE, S.M., GULLO, M.J., KELLY, A.B., YOUNG, R.McD., A Prospective Study of Alcohol Expectancies and Self-Efficacy as Predictors of Young Adolescent Alcohol Misuse. **Alcohol and Alcoholism**, v. 46, n. 2, p. 161–169, 2011.

COSTA, E.T., OLIVERA, D.S., MEYER, D.A. FERREIRA, V.M.M., SOTO, E.E., FRAUSTO, S., SAVAGE, D. D., BROWNING, M.D., VALENZUELA, C.F. Fetal Alcohol Exposure Alters Neurosteroid Modulation of Hippocampal N-Methyl-D-aspartate Receptors. **The Journal of Biological Chemistry**, v. 275, p. 38268 – 38274, 2000.

CUDDIHY, S.L., ALI, S.S., MUSIEK, E.S., LUCERO, J., KOPP, S.J., MORROW, J.D., DUGAN, L.L. Prolonged alpha-tocopherol deficiency

decreases oxidative stress and unmasks alpha-tocopherol-dependent regulation of mitochondrial function in the brain. **Journal of Biological Chemistry**, v. 283, p. 6915-24, 2008.

CUTLER, R.G., KELLYT, J., STORIET, K., PEDERSEN, W.A., TAMMARA, A., HATANPAA, K., TRONCOSO, J.C., MATTSON, M.P. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. **Proceedings of The National Academy of Sciences of the U S A**, v. 101, p. 2070-2075, 2004.

DAS, K.S., VASUDEVAN, D.M. Alcohol-induced oxidative stress. **Life Sciences**. v. 81, p. 177–187, 2007.

DAVIES, K.J.A. Intracellular proteolytic systems may function as a secondary antioxidant defenses: a hypothesis. **Free Radical Biology and Medicine**, v. 2, p. 155-173, 1986.

DE LA MONTE, S.M., WANDS, J.R. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. **Journal of Alzheimers Disease**, v. 7, p. 45-61, 2005.

DE LA MONTE, S.M., TONG, M., COHEN, A.C., SHEEDY, D., HARPER, C., WANDS, J.R. Insulin and insulin-like growth factor resistance in alcoholic neurodegeneration. **Alcoholism Clinical and Experimental Research**, v. 32, p. 1630-1644, 2008.

DE LA MONTE, S.M., LONGATO, L. TONG, M., DENUCCI, S., WANDS, J.R.

The Liver-Brain Axis of Alcohol-Mediated Neurodegeneration: Role of Toxic Lipids. **International Journal of Environmental Research and Public Health**, v. 6, p. 2055-2075, 2009.

D'ERCOLE J.A., YE, P. Expanding the mind: insulin-like growth factor I and brain development. **Endocrinology**, v. 149, p. 5958-5962, 2008.

DO CARMO, R.J., MARTINS-FERREIRA, H. Spreading depression of Leão probed with ion-selective microelectrodes in isolated chick retina. **Anais da Academia Brasileira de Ciências**, v. 56, n. 4, p. 401-421, 1984.

DOHMEN, C., SAKOWITZ, O.W., FABRICIUS, M., BOSCHE, B., REITHMEIER, T., ERNESTUS, R.I., BRINKER, G., DREIER, J.P., WOITZIK, J., STRONG, A.J., GRAF, I.R. Spreading depolarizations occur in human ischemic stroke with high incidence. **Annals of Neurology**, v. 63, p. 720-728, 2008.

DOM, G., HULSTIJN, W., SABBE, B. Differences in impulsivity and sensation seeking between early- and late-onset alcoholics. **Addictive Behaviors**, v. 31, p. 298–308, 2006.

DUKE, A.A., GIANCOLA, P.R., MORRIS, D.H., HOLT, J.C.D., GUNN, R.L. Alcohol Dose and Aggression: Another Reason Why Drinking More Is a Bad Idea. **Journal of Studies on alcohol and Drugs**, v. 72, p. 34-43, 2011.

EHLERS, C.L., CRIADO, J.R. Adolescent ethanol exposure: does it produce long-lasting electrophysiological effects? **Alcohol**, v. 44, p. 27-37, 2010.

EL-BACHÁ, R.S., LIMA-FILHO, J.L., GUEDES, R.C.A. Dietary antioxidant deficiency facilitates cortical spreading depression induced by photoactivated riboflavin, **Nutritional Neuroscience**, v. 1, p. 205–212, 1998.

FABRICIUS, M., FUHR, S., WILLUMSEN, L., DREIER, J.P., BHATIA, R., BOUTELLE, M.G., HARTINGS, J.A., BULLOCK, R., STRONG, A.J., LAURITZEN, M. Association of seizures with cortical spreading depression and peri-infarct depolarisations in the acutely injured human brain. **Clinical Neurophysiology**, v. 119, p. 1973–1984, 2008.

FADDA, F., ROSSETTI, Z.L. Chronic ethanol consumption: from neuroadaptation to neurodegeneration. **Progress in Neurobiology**, v. 56, p. 385 - 431, 1998.

FARCHI, G., FIDANZA, F., MARIOTTI, S., MENOTTI, A. Alcohol and mortality in the Italian rural cohorts of the Seven Countries Study. **International Journal of Epidemiology**, v. 21, p. 78–82, 1992.

FISCHER, W., KITTNER, H. Influence of ethanol on the pentylenetetrazol-induced kindling in rats. **Journal of Neural Transmission**, v. 105, p. 1129–42, 1998.

FISCHER, W. Influence of ethanol on the threshold for electroshock-induced seizures and electrically evoked hippocampal afterdischarges. **Journal of Neural Transmission**, v. 112, p. 1149-63, 2005.

FORBES, R.J. A Short History of the Art of Distillation. E.J. Brill, Leiden, 1970.

FREUDE, S., LEESER, U., MULLER, M., HETTICH, M.M., UDELHOVEN, M., SCHILBACH, K., TOBE, K., KADOWAKI, T., KOHLER, C., SCHRODER, H., KRONE, W., BRUNING, J.C., SCHUBERT, M. IRS-2 branch of IGF-1 receptor signaling is essential for appropriate timing of myelination. **Journal of Neurochemistry**, v. 107, p. 907-917, 2008.

FRIDOVICH, I. The biology of oxygen radicals. **Science**, v. 201, p. 275-880, 1978.

GEMMA, C., VILA, J., BACHSTETTER, A., BICKFORD, P.C. Oxidative stress and the aging brain: from theory to prevention. In: Riddle DR (ed.) Brain aging: models, methods, and mechanisms. Boca Raton: **CRC Press**, p. 1–15. 2007.

GOLDMAN, M.S. Expectancy and risk for alcoholism: the unfortunate exploitation of a fundamental characteristic of neurobehavioral adaptation. **Alcoholism: Clinical and Experimental Research**, v. 26, p. 737–746, 2002.

GONZÁLEZ, A., PARIENTE, J.A., SALIDO, G.M. Ethanol stimulates ROS generation by mitochondria through Ca^{2+} mobilization and increase GFAP content in rat hippocampal astrocytes, **Brain Research**, v. 1178, p. 28–37, 2007.

GORJI, A. Spreading depression: a review of the clinical relevance. **Brain Research Reviews**, v. 38, p. 33-60, 2001.

GRANT, B.F., DAWSON, D.A. Age at onset of alcohol use and its association with DSM-IV alcohol abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey. **Journal of Substance Abuse**, v. 9, p. 103-110, 1997.

GRAU, E., ORTET, G. Personality traits and alcohol consumption in a sample of non-alcoholic women. **Personality and Individual Differences**, v. 27, p. 1057–1066, 1999.

GROSSO, S., LONGINI, M., RODRIGUEZ, A., PROIETTI, F., PICCINI, B., BALESTRI, P., et al. Oxidative stress in children affected by epileptic encephalopathies. **Journal of Neurological Sciences**, v. 300, p. 103–6, 2011.

GUEDES, R.C.A. Electrophysiological methods: application in nutritional neuroscience. In: Liebermann H, Kanarek R, Prasad C (eds.) Nutritional neurosciences: overview of an emerging field. **New York: CRC Press**, p. 39–54, 2005.

GUEDES, R.C.A., ABADIE-GUEDES.R., BEZERRA, R.S. The use of cortical spreading depression for studying the brain action of antioxidants. **Nutritional Neuroscience**, v. 15, p. 111-119, 2012.

GUEDES, R.C.A., CAVALHEIRO, E.A. Blockade of spreading depression in chronic epileptic rats: reversion by diazepam. **Epilepsy Research**, v. 27, n. 1, p. 33-40, 1997.

GUEDES, R.C.A., DO CARMO, R.J. Influence of ionic disturbances produced by gastric washing on cortical spreading depression. **Experimental Brain Research**, v. 39, p. 341-349, 1980.

GUEDES, R.C.A., FRADE, S.F. Effect of ethanol on cortical spreading depression. **Brazilian Journal of Medical and Biological Research**, v. 26, p. 1241-1244, 1993.

GUEDES, R.C.A., OLIVEIRA, J.A.C., AMÂNCIO-DOS-SANTOS, A., GARCÍA-CAIRASCO, N. Sexual Differentiation of Cortical Spreading Depression propagation after Acute and Kindled Audiogenic Seizures in the Wistar Audiogenic Rat (WAR). **Epilepsy Research**, v. 83, p. 207-214, 2009.

GUERRI, C., PASCUAL, M., REANAU-PIQUERAS, J. Glial and fetal alcohol syndrome. **Neurotoxicology**, v. 22, p. 593-599, 2001.

HADJIKHANI, N., SANCHEZ DEL RIO, M., WU, O., SCHWARTZ, D., BAKKER, D., FISCHL, B., KWONG, K.K., CUTRER, F.M., ROSEN, B.R., TOOTELL, R.B.H., SORENSEN, A.G., MOSKOWITZ, M.A. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. **Proceedings of the National Academy of Sciences U S A**, v. 98, p. 4687-92, 2001.

HAJDUCH, E., BALENDRAN, A., BATTY, I.H., LITHERLAND, G.J., BLAIR, A.S., DOWNES, C.P., HUNDAL, H.S. Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells. **Diabetologia**, v. 44, p. 173-183, 2001.

HALLAK, H., SEILER, A.E., GREEN, J.S., HENDERSON, A., ROSS, B.N., RUBIN, R. Inhibition of insulin-like growth factor-I signaling by ethanol in neuronal cells. **Alcoholism Clinical and Experimental Research**, v. 25, p. 1058-1064, 2001.

HALLIWELL, B. Role of free radicals in the neurodegenerative diseases – Therapeutic implications for antioxidant treatment. **Drugs & Aging**, v. 18, p. 685–716, 2001.

HALLIWELL, B., CROSS, C.E. Oxygen-derived species: Their relation to human disease and environmental stress. **Environmental health perspectives**, v. 102, p. 5–12, 1994.

HARRIS, E.D. Regulation of antioxidant enzymes. **FASEB Journal**, v. 6, p. 2675-2683, 1992.

HEATON, M.B., MADORSKY, I., PAIVA, M., SILER-MARSIGLIO, K. I. Vitamin E amelioration of ethanol neurotoxicity involves modulation of apoptotic-related protein levels in neonatal rat cerebellar granule cells. **Developmental Brain Research**, v. 150, p. 117–124, 2004.

HINGSON, R.W., HEEREN, T., JAMANKA, A., HOWLAND, J. Age of drinking onset and unintentional injury involvement after drinking. **Journal of the American Medical Association**, v. 284, n. 12, p. 1527-1533, 2000.

HOLLAND, W.L., SUMMERS, S.A. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. **Endocrine Reviews**, v. 29, p. 381-402, 2008.

HUGHES, D.A. Dietary Carotenoids and Human Immune Function. **Nutrition**, v. 17, p. 823-827, 2001.

JONES, B.T., CORBIN, W., FROMME, K. A review of expectancy theory and alcohol consumption. **Addiction**, v. 96, p. 57–72, 2001.

KAMIMURA, S., GAAL, K., BRITTON, R.S., BACON, B. R., TRIADAFILOPOULOS, G., TSUKAMOTO, H. Increased 4-hidroxy-nonenal levels in experimental alcoholic liver disease: association of lipid peroxidation with liver fibrogenesis. **Hepatology**, v. 16, p. 448-453 1992.

KARA, I., NURTEN, A., AYDIN, M., ÖZKÖK, E., ÖZEN, I., ÖZERMAN, B., TUNA, S., KARAMÜRSEL, S. Ischemia/reperfusion in rat: antioxidative effects of enoant on EEG, oxidative stress and inflammation. **Brain Injuri**, v. 25, p. 113–26. 2011.

KESSELS, R.P.C., KOPELMAN, M.D. Context Memory in Korsakoff's Syndrome. **Neuropsychology Review**, v. 22, p. 117 – 131, 2012.

KLATSKY, A.L., ARMSTRONG, M.A. Alcohol use, other traits, and risk of unnatural death: a prospective study. **Alcohol Clinical and Experimental Research**, v. 17, p. 1156–1162, 1993.

KOZAN, R., AYYILDIZ, M., YILDIRIM, M., AGAR, E. The influence of ethanol intake and its withdrawal on the anticonvulsant effect of α -tocopherol in the penicillin-induced epileptiform activity in rats. **NeuroToxicology**, v. 28, p. 468–470, 2007.

LANGEVELD, M.; AERTS, J.M. Glycosphingolipids and insulin resistance.

Progress in Lipid Research, v. 48, p. 196-205, 2009.

LAMARCHE, F., GONTHIER, B., SIGNORINI, N. EYSSERIC, H., BARRET, L.

Impact of ethanol and acetaldehyde on DNA and cell viability of cultured neurons. **Cell Biology and Toxicology**, v. 20, p. 361-374, 2004.

LEÃO, A.A.P. Spreading depression of activity in the cerebral cortex, **Journal of Neurophysiology**, v. 7, p. 359-390, 1944.

LEÃO, A.A.P. Spreading depression. In Purpura DP, Penry K, Tower DB, Woodbury DM, Walter RD. Experimental Models of Epilepsy. **Raven Press**, New York, p. 173-195, 1972.

LEJUEZ C.W., MAGIDSON, J.F., MITCHELL, S.H., SINHA, R., STEVENS, M.C., DE WIT, H. Behavioral and Biological Indicators of Impulsivity in the Development of Alcohol Use, Problems, and Disorders. **Alcoholism: Clinical and Experimental Research**, v. 34, n. 8, p. 1334-1345, 2010.

LEKER, R.R., SHOHAMI, E. Cerebral Ischemia and trauma – different etiologies yet similar mechanisms: neuroprotective opportunities. **Brain Research Reviews**, v. 39, p. 55–73, 2002.

LEHMENKÜHLER, A.; GROTEMEYER, K. H.; TEGTMEIER, F. Migraine: Basic Mechanisms and Treatment. Urban and Schwarzenberg, Munich, 1993.

LIEBER, C.S. Medical disorders of alcoholism. **The New England Journal of Medicine**, v. 333, p. 1058–1065, 1995.

LIPINSKI, R.J., HAMMOND, P., O'LEARY-MOORE, S.K., AMENT, J.J., PECEVICH, S.J., JIANG, Y., BUDIN, F., PARNELL, S.E., SUTTIE, M., GODIN, E.A., EVERSON, J.L., DEHART, D.B., OGUZ, I., HOLLOWAY, H.T., STYNER, M.A., JOHNSON, G.A., SULIK K.K. Ethanol-Induced Face-Brain Dysmorphology Patterns Are Correlative and Exposure-Stage Dependent. **Public Library of Science One**, v. 7, n. 8, e43067. doi:10.1371/journal.pone.0043067, 2012.

LOUGH, M.E. Wernicke's Encephalopathy: Expanding the Diagnostic Toolbox. **Neuropsychology Review**, v. 22, p. 181 – 194, 2012.

LOUREIRO, S.O., HEIMFARTH, L., REIS, K., WILD, L., ANDRADE, C., GUMA, F.T., GONÇALVES, C.A., PESSOA-PUREUR, R. Acute ethanol exposure disrupts actin cytoskeleton and generates reactive oxygen species in c6 cells. **Toxicology in Vitro**, v. 25, p. 28–36, 2011.

LU, Y., WU, D., WANG, X., WARD, S.C., CEDERBAUM, A.I. Chronic alcohol-induced liver injury and oxidant stress are decreased in cytochrome P4502E1 knockout mice and restored in humanized cytochrome P4502E1 knock-in mice. **Free Radical Biology & Medicine**, v. 49, p. 1406 – 1416, 2010.

LUNEC, J., BLAKE, D.R., McCLEARY, S.J., BRAIDSFORD, S., BACON, P.A. Self-perpetuating mechanisms of immunoglobulin G aggregation in rheumatoid inflammation. **The Journal of Clinical Investigation**, v. 76, p. 2084-2090, 1985.

MANTLE, D., PREEDY, V.R. Free radicals as mediators of alcohol toxicity.

Adverse Drug Reactions and Toxicological Reviews, v. 18, p. 235–252, 1999.

MARINO, M.D., AKSENOV, M.Y., KELLY, S.J. Vitamin E protects against alcohol-induced cell loss and oxidative stress in the neonatal rat hippocampus. **International Journal of Developmental Neuroscience**, v. 22, p. 363–377, 2004.

MATTSON, S.N., ROESCH, S.C., GLASS, L., DEWEESE, B.N., COLES, C.D., KABLE, J.A., MAY, P.A. KALBERG, W.O., SOWELL, E.R., ADNAMS C.M., JONES, K.L., RILEY, E.P. Further Development of a Neurobehavioral Profile of Fetal Alcohol Spectrum Disorders. **Alcoholism, Clinical and Experimental Research**, Article first published online: 13 September 2012, DOI: 10.1111/j.1530-0277.2012.01952.x.

MAYEVSKY, A., DORON, A., MANOR, T., MEILIN, S., ZARCHIN, N., OUAKNINE, G.E. Cortical spreading depression recorded from the human brain using a multiparametric monitoring system. **Brain Research**, v. 740, p. 268-274, 1996.

MCDONALD, R.L., BARKER, J.L. Pentylenetetrazol and penicilin are selective antagonists of GABA-mediated post-synaptic inhibition in cultured mamalian neurones. **Nature**, v. 267, p. 720–1, 1977.

MELONI, J.N., LARANJEIRA, R. The social and health burden of alcohol abuse. **Revista Brasileira Psiquiatria**, n. 26, p. 7–10, 2004.

- MITCHELL, J.J., PAIVA, M., HEATON, M.B. Vitamin E and β -carotene protect against ethanol combined with ischemia in an embryonic rat hippocampal culture model of fetal alcohol syndrome. **Neuroscience Letters**, v. 263, p. 189–192, 1999.
- MODY, I. Extrasynaptic GABAA receptors in the crosshairs of hormones and ethanol. **Neurochemistry International**, v. 52, p. 60-64, 2008.
- MURRAY, C., LOPEZ, A.D. The global burden of disease. **Cambridge, Harvard University Press**, 1997.
- MURRAY, C.J.L. Quantifying the burden of disease: the technical basis for disability-adjusted life years. **Bulletin of the World Health Organization**, v. 72, p. 429-445, 1994.
- NETTO, M., MARTINS-FERREIRA, H. Elicitation of spreading depression by rose bengal photodynamic action. **Photochemistry and Photobiology**, v. 50, p. 229-234, 1989.
- NIIZUMA, K., ENDO, H., CHAN, P.H. Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. **Journal of Neurochemistry**, v. 109 p.133–138, 2009.
- OCHIAI, T., SHIMENO, H., MISHIMA, K., IWASAKI, K., FUJIWARA, M., TANAKA, H., SHOYAMA, Y., TODA, A., EYANAGI, R., SOEDA, S. Protective effects of carotenoids from saffron on neuronal injury in vitro and in vivo. **Biochimica et Biophysica acta**, v. 1770, p. 578–584, 2007.

ORGANIZACIÓN MUNDIAL DE LA SALUD. Estrategia mundial para reducir el uso nocivo del alcohol, **OMS**, 2010.

ORGANIZACIÓN PANAMERICANA DE LA SALUD. **Alcohol y atención primaria de la salud**, ISBN 978 92 75 32856 9, 2008.

PAN AMERICAN HEALTH ORGANIZATION. Alcohol and public health in the Americas - a case for action. **PAHO HQ Library Cataloguing-in-Publication**, ISBN 978 92 75 12849 7, 2007.

PARKIN, D.M. Cancers attributable to consumption of alcohol in the UK in 2010. **British Journal of Cancer**, v. 105, p. S14 – S18, 2011.

PATRA, J., TAYLOR, B., IRVING, H., ROERECKE, M., BALIUNAS, D., MOHAPATRA, S., REHM, J. Alcohol consumption and the risk of morbidity and mortality for different stroke types - a systematic review and meta-analysis. **BioMed Central public health**, v. 10, artigo nº 258, disponível em: <http://www.biomedcentral.com/1471-2458/10/258>, 2010.

RAMESH, B.N., SATHYANARAYANA-RAO, T.S., PRAKASAM, A., SAMBAMURTI, K., JAGANNATHA-RAO, K.S. Neuronutrition and Alzheimer's Disease. **Journal of Alzheimer's Disease**, v. 19, p. 1123–39. 2010.

RAO, A. V., BALACHANDRAN, B. Role of antioxidative stress and antioxidants in neurodegenerative diseases. **Nutritional Neuroscience**, v. 5, p. 291–309, 2002.

RASHBA-STEP, J., TURRO, N.J., CEDERBAUM, A.I. Increased NADPH- and NADH-dependent production of superoxide and hydroxyl radical by microsomes after chronic ethanol treatment. **Archives of Biochemistry and Biophysics**, v. 300, p. 401–408, 1993.

REHM, J., MONTEIRO, M. Alcohol consumption and burden of disease in the Americas – implications for alcohol policy. **Pan American Journal of Public Health**, p. 241-248, 2005.

REHM, J., PATRA, J., BALIUNAS, D., POPOVA, S., ROERECKE, M., TAYLOR, B. Alcohol consumption and the global burden of disease 2002. **Geneva: WHO Department of Mental Health and Substance Abuse, Management of Substance Abuse**, 2006.

REHM, J., BALIUNAS, D., BORGES, G.L.G., GRAHAM, K., IRVING, H., KEHOE, T., PARRY, C.D., PATRA, J., POPOVA, S., POZNYAK, V., ROERECKE, M., ROOM, R., SAMOKHVALOV A.V., TAYLOR, B. The relation between different dimensions of alcohol consumption and burden of disease: an overview. **Addiction**, v. 105, p. 817–843, 2010.

RIMM, E.B., KLATSKY, A., GROBBEE, D., STAMPFER, M.J. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits? **British medical journal**, v. 312, p. 731 – 36, 1996.

RIVETT, A.J. Preferential degradation of the oxidatively modified form of glutamine synthetase by intracellular mammalian proteases. **The Journal of Biological Chemistry**, v. 260, p. 300-305, 1985.

ROCHA-DE-MELO, AP., CAVALCANTI, J.B., BARROS, A.S., GUEDES, R.C.A.

Manipulation of rat litter size during suckling influences cortical spreading depression after weaning and at adulthood. **Nutritional Neuroscience**, v. 9, p. 155-160, 2006.

RONZANI, T.M., FURTADO, E.F. Estigma social sobre o uso de álcool. **Jornal Brasileiro de Psiquiatria**, v. 59, p. 326-332, 2010.

RUITENBERG, A., VAN SWIETEN, J.C., WITTEMAN, J.C.M., METHA, K.M., VAN DUIJN, C.M., HOFMAN, A., BRETELER, M.M.B. Alcohol consumption and risk of dementia: the Rotterdam Study. **Lancet**, v. 359, p. 281–286, 2002.

SALO, D.C., LIN, S.W., PACIFICI, R.E., DAVIES, K.J.A. Superoxide dismutase is preferentially degraded by a proteolytic system from red blood cells following oxidative modification by hydrogen peroxide. **Free Radical Biology and Medicine**, v. 5, p. 335-339, 1998.

SANTOS-MONTEIRO, J.S., TEODÓSIO, N.R., GUEDES, R.C.A. Long-lasting effects of early environmental stimulation on cortical spreading depression in normal and early malnourished adult rats. **Nutritional Neuroscience**, v. 3, p. 29-40, 2000.

SCHUBERT, M., BRAZIL, D.P., BURKS, D.J., KUSHNER, J.A., YE, J., FLINT, C.L., FARHANG-FALLAH, J., DIKKES, P., WAROT, X.M., RIO, C., CORFAS, G., WHITE, M.F. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. **The Journal of Neuroscience**, v. 23, p. 7084-7092, 2003.

SCORZA, F.A., ARIDA, R.M., CYSNEIROS, R.M., PRIEL, M.R., DE ALBUQUERQUE, M., CAVALHEIRO, E.A. The effects of alcohol intake and withdrawal on the seizures frequency and hippocampal morphology in rats with epilepsy. **Neuroscience Research**, v. 47, p. 323-8, 2003.

SEIFRIED, H.E., ANDERSON, D.E., FISCHER, E.I., MILNER, J.A. A review of the interaction among dietary antioxidants and reactive oxygen species. **Journal of Nutritional Biochemistry**, v. 18, p. 567-579, 2007.

SETSHEDI, M., LONGATO, L., PETERSEN, D.R., RONIS, M., CHEN, W.C., WANDS, J.R., DE LA MONTE, S.M. Limited Therapeutic Effect of N-Acetylcysteine on Hepatic Insulin Resistance in an Experimental Model of Alcohol-Induced Steatohepatitis. **Alcoholism: Clinical and Experimental Research**, v. 35, n. 12, p. 1 – 13, 2011.

SHICHIRI, M., TAKANEZAWA, Y., UCHIDA, K., TAMAI, H., ARAI, H. Protection of cerebellar granule cells by tocopherols and tocotrienols against methylmercury toxicity. **Brain Research**, v. 1182, p. 106-15, 2007.

SILVEIRA, L.R., FIAMONCINI, J., HIRABARA, S.M., PROCÓPIO, J., CAMBIAGHI, T.D., PINHEIRO, C.H. J., LOPES, L.R., CURI, R. Updating the effects of fatty acids on skeletal muscle. **Journal of Cellular Physiology**, v. 217, n. 1, p. 1–12, 2008.

SMITH, M.A., ROTTKAMP, C.A., NUNOMURA, A., RAINA, A.K., PERRY, G. Oxidative stress in Alzheimer's disease. **Biochimica et Biophysica Acta**, v. 1502, p. 139-144, 2000.

SONN, J., MAYEVSKY, A. The effect of ethanol on metabolic, hemodynamic and electrical responses to cortical spreading depression. **Brain Research**, v. 908, p. 174-186, 2001.

SUBRAMANYA, S.B., SUBRAMANIAN, V.S., SAID, H.M. Chronic alcohol consumption and intestinal thiamin absorption: effects on physiological and molecular parameters of the uptake process. **American journal of physiology. Gastrointestinal and liver physiology**, v. 299, p. G23 – G31, 2010.

SUMMERS, S.A. Ceramides in insulin resistance and lipotoxicity. **Progress in Lipid Research**, v. 45, p. 42-72, 2006.

TAPIERO, H., TOWNSEND, D.M., TEW, K.D. The role of carotenoids in the prevention of human pathologies. **Biomedicine & Pharmacotherapy**, v. 58, p. 100-110, 2004.

TURRENS, J.F. Mitochondrial formation of reactive oxygen species. **Journal of Physiology**, v. 522, p. 335–344, 2003.

UNITED STATES DEPARTMENT OF TRANSPORTATION - NATIONAL HIGHWAY TRAFFIC SAFETY ADMINISTRATION. Traffic Safety Facts. **National Center for Statistics and Analysis**, 2005.

VALKO, M., LEIBFRITZ, D., MONCOLA, J., CRONIN, M.T.D., MAZURA, M., TELSER, J. Free radicals and antioxidants in normal physiological functions and human disease. **The International Journal of Biochemistry & Cell Biology**, v. 39, p. 44–84, 2007.

VALLE, B.L. Alcohol in human history. In: Toward a Molecular Basis of Alcohol Use and Abuse. (ed.) **Birkhäuser Verlag, Basel/Switzerland**, p. 1-8, 1994.

VALLE, B.L. Alcohol in the western world. **Scientific American**, New York, v. 278, n. 6, p. 80-85, 1998.

VIEIRA, D.L., RIBEIRO, M., ROMANO, M. LARANJEIRA, R.R. Alcohol and adolescents: study to implement municipal policies. **Revista de saúde pública**, v. 41, p. 396-403, 2007.

WALDBAUM, S., PATEL, M. Mitochondria, oxidative stress, and temporal lobe epilepsy. **Epilepsy Research**, v. 88, p. 23–45, 2010.

WEITZMAN, E.R., FOLKMAN, A., FOLKMAN, M.P.H.K.L., WECHSLER, H. The relationship of alcohol outlet density to heavy and frequent drinking and drinking-related problems among college students at eight universities. **Health & Place**, v. 9, p. 1–6, 2003.

WILSON, C.A. Food and drink in Britain from the stone age to recent times. **Anchor Press**, London, 1973.

WORLD HEALTH ORGANIZATION. Global Status Report on Alcohol. **WHO**, http://www.who.int/substance_abuse/publications/alcohol/en/, 1999.

WORLD HEALTH ORGANIZATION, Expert Committee on Problems Related to Alcohol Consumption. **WHO**, www.who.int/substance_abuse/expert_committee_alcohol/en/index.html, 2007.

WORLD HEALTH ORGANIZATION^B. Global Status Report: Alcohol Policy, **WHO**, http://www.who.int/substance_abuse/publications/alcohol/en/, 2004.

WORLD HEALTH ORGANIZATION, Expert Committee on Problems Related to Alcohol Consumption. **WHO**, http://www.who.int/substance_abuse/expert_committee_alcohol/en/index.html, 2007.

WORLD HEALTH ORGANIZATION. Global Health Risks Report: Mortality and burden of disease attributable to selected major risks. **WHO**, ISBN 978 92 4 156387 1, 2009.

WORLD HEALTH ORGANIZATION. Global strategy to reduce the harmful use of alcohol, **WHO**, ISBN 978 92 4 159993 1.

WORLD HEALTH ORGANIZATION. Global Status Report on Alcohol and Health, 2011. **WHO**, http://www.who.int/topics/alcohol_drinking/en/.

YOUNG, R.M., OEI, T.P.S. Grape expectations: the role of alcohol expectancies in the understanding and treatment of problem drinking. **International Journal of Psychology**, v. 28, p. 337–64, 1993.

YU, B.P. Cellular defenses against damage from reactive oxygen species. **Physiological Reviews**, v. 74, n. 1, p. 139 – 162, 1994.

CAPÍTULO I

The Impairing Effect of Acute Ethanol on Spreading Depression is Antagonized by Astaxanthin in Rats of 2 Young-Adult Ages

Ricardo Abadie-Guedes, Rubem C. A. Guedes, and Ranilson S. Bezerra

Background: Ethanol (EtOH) abuse and insufficient ingestion of antioxidants are external factors that can alter brain electrophysiology. Our previous studies have demonstrated that the excitability-related brain electrophysiological phenomenon known as cortical spreading depression (CSD) was facilitated by chronic EtOH intake, and chronic treatment with carotenoids attenuated this effect. Here, we investigated the acute effect of a single EtOH administration on CSD in young and adult rats previously (1 hour) treated with 10 $\mu\text{g}/\text{kg}$ of astaxanthin.

Methods: Male Wistar rats (5 young- and 5 adult groups, 60 to 80 and 150 to 180 days of age, respectively) were treated by 2 gavage procedures at 1-hour interval as follows: groups 1 and 2 received astaxanthin in gavage I combined with EtOH (group 1) or water (group 2) in gavage II; groups 3 and 4 received olive oil (the vehicle in which astaxanthin was dissolved) in gavage I combined with EtOH (group 3) or water (group 4) in gavage II; group 5 received water in gavage I combined with EtOH in gavage II. CSD was recorded on the cortical surface for 4 hours.

Results: Compared to the respective water and oil controls (groups 2 and 4; CSD velocities: 3.73 ± 0.09 and 3.78 ± 0.07 mm/min in the young groups; 2.99 ± 0.10 and 3.05 ± 0.19 mm/min in the adult groups), a single dose of EtOH (groups 3 and 5) decreased CSD propagation velocities (3.29 ± 0.23 and 3.16 ± 0.10 mm/min in the young groups; 2.71 ± 0.27 and 2.75 ± 0.31 mm/min in the adult groups). Astaxanthin antagonized the impairing effect of acute EtOH on CSD (group 1; mean velocity: 3.70 ± 0.19 and 3.13 ± 0.16 mm/min for the young and adult groups, respectively).

Conclusions: The results showed an antagonistic effect of acute EtOH treatment on CSD propagation that was reverted by astaxanthin. The EtOH–astaxanthin interaction was not influenced by the age, as it was found in both young and adult animals.

Key Words: Acute Ethanol, Astaxanthin, Antioxidants, Spreading depression.

HUMAN YOUNG ADULTS who consume ethanol (EtOH) chronically have a high probability of being pathologically affected in several organs, like liver, kidney, heart, pancreas, and brain (Lieber, 1995). EtOH can permeate almost all the brain tissue, exerting most of its toxic effects through the production of reactive oxygen species (ROS; Tapiero et al., 2004). Antioxidant molecules like carotenoids have also been shown to be important in protecting the brain against the deleterious effects of free radicals, particularly in neurodegenerative diseases (Mitchell et al., 1999; Tapiero et al., 2004). Among carotenoids, astaxanthin is predominant in marine organisms, like algae, crustaceans,

and fish. It is a powerful biological antioxidant, strongly scavenging free radicals and protecting the living tissue against lipid peroxidation and oxidative damage (Miki, 1991). Recently, it has been pharmacokinetically demonstrated that several rat tissues, including the brain, present high affinity for astaxanthin (Choi et al., 2011). Moreover, besides being a potent antioxidant, astaxanthin has also anticancer and anti-inflammatory activities (Higuera-Ciapara et al., 2006).

Contrasting with the extensive investigation of the brain effects of chronic EtOH, the impact of a single dose of EtOH has not been investigated in detail, although some recent studies suggested important, gene-related (Guo et al., 2011; de Licon et al., 2009), as well as cortical excitability (Conte et al., 2008), effects of this acute condition. Also, no systematic investigation has addressed the role of age in the effects of EtOH on the brain.

The aim of this study was to investigate, in rats of 2 young-adult ages, the effects of a single dose of EtOH on the propagation of cortical spreading depression (CSD), a phenomenon related to brain excitability. CSD has been first described as a cerebral cortex response elicited by electrical, mechanical, or chemical stimulation of 1 point of the tissue. This response is expressed as a reversible and slowly

From the Laboratório de Enzimologia—LABENZ, Departamento de Bioquímica (RA-G, RSB), CCB, Universidade Federal de Pernambuco, Recife, PE, Brazil; and Departamento de Nutrição (RCAG), CCS, Universidade Federal de Pernambuco, Recife, PE, Brazil.

Received for publication August 23, 2011; accepted January 9, 2012.

Reprint requests: Rubem Carlos Araújo Guedes, Departamento de Nutrição Universidade Federal de Pernambuco, Cidade Universitária, Recife, PE50670-901, Brazil; Tel.: +55-81-21268936; Fax: +55-81-21268473; E-mail: guedes.rca@gmail.com or rguedes@ufpe.br

RCAG and RSB contributed equally to this work.

Copyright © 2012 by the Research Society on Alcoholism.

DOI: 10.1111/j.1530-0277.2012.01766.x

propagating “wave” of depolarization causing a depression in spontaneous and evoked cortical electrical activity, with a simultaneous direct current (DC) slow potential change in the tissue (Leão, 1944, 1947). Besides being much studied in several animal species (Gorji, 2001; Guedes, 2005), CSD has also been recorded in the human brain, both in vitro (Gorji and Speckmann, 2004) and in vivo (Fabricius et al., 2008). During CSD, the neurons and probably glial cells suffer depolarization, causing brain electrical silence, which led some researchers to recently start using the term “spreading depolarization” as the causal event of spreading depression (Dreier, 2011). It is largely assumed that CSD is involved in the production of the symptoms of migraine aura (Lauritzen et al., 2011) and would also causally related to other neurological diseases like epilepsy and stroke (Lauritzen et al., 2011; Leão, 1944).

Nutritional, environmental, and pharmacological factors have been shown to influence brain CSD propagation in rats (Amâncio-dos-Santos et al., 2006; Amaral et al., 2009; Guedes, 2005; Tenório et al., 2009). Current discussions on the possible CSD mechanisms often mention the involvement of neurotransmitter activity (Gorelova et al., 1987; Guedes et al., 1987, 1992), and free radicals produced in the brain (El-Bachá et al., 1998; Guedes et al., 1996). Experimental evidence indicates that conditions that either weaken or strengthen the ability of the brain to counteract CSD may shed new light on the phenomenon and the diseases related to it. One of such conditions is EtOH ingestion: acute EtOH ingestion has impaired CSD propagation (Sonn and Mayevsky, 2001), whereas daily ingestion for 7 or more days facilitated it (Abadie-Guedes et al., 2008; Guedes and Frade, 1993). We have previously demonstrated that the antioxidant molecules known as carotenoids exert an antagonistic action against the effect of chronic EtOH on CSD in rats (Abadie-Guedes et al., 2008; Bezerra et al., 2005).

In this study, we hypothesized that CSD propagation would be influenced (i) by the age of animals; (ii) by a single dose of EtOH; and that (iii) the EtOH effect would be counteracted by a single astaxanthin administration.

MATERIALS AND METHODS

Astaxanthin (purchased from Sigma, St. Louis, MO) was dissolved in olive oil, to a final concentration of 10 $\mu\text{g}/\text{ml}$. Then, the astaxanthin solution was kept in the dark and in an N_2 atmosphere.

The animals (male Wistar rats) were handled in accordance with the norms of the Ethics Committee for Animal Research of the Universidade Federal de Pernambuco, Brazil (where the experiments had been conducted), which complies with the “Principles of Laboratory Animal Care” (National Institutes of Health, Bethesda, MD). They were reared in polypropylene cages ($51 \times 35.5 \times 18.5$ cm) in a room maintained at $21 \pm 1^\circ\text{C}$ with a 12 hour light/12 hour dark cycle (lights on at 7:00 AM). Five groups of Wistar young (60 to 80 days of age) and 5 groups of adult rats (150 to 180 days old) were given 2 gavages (a method consisting of administering substances directly into the stomach through a cannula inserted in the mouth) at a 1-hour interval, as follows: groups 1 and 2 received astaxanthin in gavage I combined with 3 g/kg EtOH

(group 1) or water (group 2) in gavage II; groups 3 and 4 received olive oil (the vehicle in which astaxanthin was dissolved) in gavage I, combined with 3 g/kg EtOH (group 3) or water (group 4) in gavage II; finally, group 5 received water in gavage I combined with 3 g/kg EtOH in gavage II. Astaxanthin-treated rats received 10 $\mu\text{g}/\text{kg}$ of this carotenoid per gavage, diluted in 95% EtOH, as previously described (Abadie-Guedes et al., 2008). This EtOH dose (3 g/kg) is within the range usually employed in experiments with rodents (Bonthius et al., 2001; Nash et al., 2007) and has been shown to produce blood alcohol levels effective in experimentally altering the nervous system (Nash et al., 2007).

All groups had free access to water and a commercial laboratory chow diet (containing 23 g protein per 100 g diet; Purina do Brazil Ltd, Paulínia, SP, Brazil).

Immediately after gavage II, the CSD recording session was carried out, as previously described (Bezerra et al., 2005). Briefly, under anesthesia with a mixture of 1 g/kg urethane plus 40 mg/kg chloralose (Sigma; injected intraperitoneally), a tracheal cannula was inserted and 3 trephine holes were made on the right side of the skull, aligned along the anteroposterior direction and parallel to the midline. One hole was positioned on the frontal bone (2 mm in diameter) and was used to apply the stimulus to elicit CSD. The other 2 holes were drilled on the parietal bone (3 to 4 mm in diameter) and were used to record the propagating CSD wave. The distance between the centers of contiguous holes was about 3 to 5 mm. Rectal temperature was continuously monitored and maintained at $37 \pm 1^\circ\text{C}$ by means of a heating blanket. At 20-minute intervals, CSD was elicited by application, for 1 minute, of a cotton ball (1 to 2 mm in diameter) soaked with 2% KCl solution (approximately 270 mM) placed on the frontal cortical surface through the hole drilled on that region. On the 2 parietal holes, both the slow DC-potential change and the reduction in the spontaneous cortical electrical activity accompanying CSD were continuously recorded for 4 hours using a pair of Ag-AgCl agar-Ringer electrodes (1 in each hole), as previously described (Abadie-Guedes et al., 2008). A common reference electrode, of the same type, was placed on the nasal bones (see insert of Fig. 1). The DC-potential changes were recorded by connecting the electrodes to GRASS DC-amplifiers (Astro-Med Industrial Park, West Warwick, RI), and the ECoG was recorded with AC-amplification (band pass filters set at 1 to 35 Hz range). Both DC-recording and ECoG were performed in a model 7-D GRASS chart recorder (Astro-Med Industrial Park). In some experiments, DC-recording was also computer-digitalized and recorded. The CSD velocity of propagation was calculated from the time required for a CSD wave to cover the distance between the 2 cortical electrodes. In the measurement of CSD velocities, the initial point of each DC negative rising phase was used. A repeated measure analysis of variance (ANOVA) followed by a post hoc (Tukey–Kramer) test was used to compare body weights and CSD propagation rates between groups. Differences between groups were accepted as significant when $p \leq 0.05$. All values are presented as means \pm standard deviations.

RESULTS

As previously observed (Bezerra et al., 2005), CSD was consistently elicited by 2% KCl applied for 1 minute on a cortical point in the frontal region. Once elicited, CSD propagated and was recorded by the 2 electrodes placed on the parietal cortex of the stimulated hemisphere. Examples of the electrophysiological recordings (electrocorticogram and slow potential changes) are shown in Fig. 1.

As described in Materials and Methods, in both young and adult ages, 2 groups of animals were treated with EtOH,




Fig. 1. Recordings of spontaneous cortical electrical activity (E; second and fourth traces in each panel) and slow potential change (P; first and third traces) during cortical spreading depression in two 150 to 180 day old and two 60 to 80 day old rats treated with 2 gavages at a 1-hour interval. The 2 animals of the upper row (marked with Ax + Et) were treated with 10 μ g/kg astaxanthin dissolved in olive oil in gavage I and with 3 g/kg ethanol (EtOH) in gavage II. The 2 animals in the lower row (marked with oil + Et) were treated with olive oil in gavage I and with EtOH in gavage II. Spreading depression was elicited by applying a cotton ball (1 to 2 mm diameter) soaked with 2% KCl solution for 1 minute on the frontal cortex. Horizontal bars over P1 indicate the time (1 minute) of KCl stimulation. The right hemisphere inset shows the recording positions 1 and 2 (on the parietal cortex) and the position of the reference electrode (R), on the nasal bone, as well as the place of KCl stimulus (on the frontal cortex). Vertical calibration bars equal 1 mV for the electrocorticogram and 10 mV for the P-recordings (negative upward).

one of which in combination with oil (group 3) and the other with water (group 5). EtOH acute treatment was associated with lower CSD propagation velocities (mean values in mm/min: 3.29 ± 0.23 and 3.16 ± 0.10 in the young groups; 2.71 ± 0.27 and 2.75 ± 0.31 in the adult groups), as compared to the respective water and oil controls (groups 2 and 4; CSD velocities: 3.73 ± 0.09 and 3.78 ± 0.07 in the young groups; 2.99 ± 0.10 and 3.05 ± 0.19 in the adult groups). This impairing effect of EtOH on CSD was counteracted by astaxanthin (group 1 mean velocity: 3.70 ± 0.19 and 3.13 ± 0.16 for the young and adult groups, respectively). Treatment with astaxanthin alone (10 μ g/kg without EtOH; group 2) did not modify the CSD propagation velocity. All data are presented in Fig. 2.

DISCUSSION

Three main findings were demonstrated in this work. First, a single dose of EtOH impairs the propagation of CSD in the rat cortex. Second, a previous single administration of astaxanthin reverses this neurophysiologic effect of acute EtOH. Third, within the age-range of this study (60 to 180 days), the interaction between the EtOH and astaxanthin effects on CSD did not depend on the animal's age. Furthermore, CSD




Fig. 2. Reduction in cortical spreading depression velocity in the cortical surface of young and adult rats treated with 10 μ g/kg astaxanthin in gavage I combined with 3 g/kg ethanol (EtOH) (group A + E) or water (group A + W) in gavage II. These groups were compared with groups treated with olive oil (the vehicle in which astaxanthin was dissolved) in gavage I combined with 3 g/kg EtOH (group O + E) or water (group O + W) in gavage II; finally, group W + E received water in gavage I combined with 3 g/kg EtOH in gavage II. Data are expressed as mean \pm SEM. Asterisk indicates that all young-values are higher than the corresponding adult-values. Different capital and lowercase letters represent significant difference in the means of the different treatments administered per gavage (ANOVA plus Tukey test; $p < 0.05$). CSD, cortical spreading depression.

propagation has previously described as being age-dependent (Guedes et al., 1996); this finding has been presently confirmed. Although a different methodology was employed in this study, our data on CSD deceleration associated to acute EtOH treatment are generally in agreement with those of Sonn and Mayevsky (2001). The major methodological discrepancy between these studies lies in the fact that those authors administered EtOH by intravenous continuous infusion, whereas in our experiments, EtOH was administered by gavage (see Materials and Methods).

It is important to mention the contrasting effects produced by acute as compared to chronic EtOH administration. Guedes and Frade (1993) treated adult rats with EtOH for 7 days and found an increase in CSD propagation velocity. In line with that Bezerra and colleagues (2005) and Abadie-Guedes and colleagues (2008) also found a facilitation of CSD propagation after treating rats with EtOH for 18 days. Taken together, these data suggest an important difference between acute and chronic EtOH actions on CSD.

CSD can be used as a physiological index that is valuable for understanding the relationship between oxidative stress and neural function. The resistance offered by the brain tissue to CSD propagation can be augmented or diminished by experimental conditions, resulting in lower or higher CSD velocities of propagation, respectively (Merkler et al., 2009; Rocha-de-Melo et al., 2006). Experimental increasing or decreasing the brain ability to counteract CSD may help in understanding the phenomenon and the diseases related to it.

Several clinically relevant conditions have been investigated, concerning EtOH effects on CSD. These conditions include nutritional, metabolic, environmental, hormonal, and pharmacological factors. Some of these conditions facilitate CSD, as for example malnutrition (Rocha-de-Melo et al., 2006), hypoglycemia (Costa-Cruz et al., 2006), and γ -aminobutyric acid (GABA)-enhancing drugs (Guedes et al., 1992), while others like serotonergic drugs (Amâncio-dos-Santos et al., 2006), hypernutrition (Rocha-de-Melo

et al., 2006), aging (Guedes et al., 1996), and peripheral afferent stimulation (Monte-Silva et al., 2007) impair CSD.

In humans, alcohol consumption is characterized by single episodes of EtOH intake, in the beginning. Later on, alcohol consumption becomes a habit, with drinking events repeated at short intervals. Most of the clinical and experimental investigations focus on this late chronic phase, and little attention has been given to the acute intake period. In a recent clinical study, Conte and colleagues (2008) described distinct electrophysiological alterations in patients diagnosed as chronic EtOH addicts, as compared with healthy volunteers who drank a single EtOH dose. In line with these findings, our results in rats demonstrate CSD propagation alterations even after a single dose intake, stressing the importance of further investigating this point.

It is known that ROS can be formed as a consequence of EtOH metabolism (Tapiero et al., 2004), and the presence of antioxidants may help in protecting tissues such as gastric mucosa (Kim et al., 2005) and brain (Mitchell et al., 1999) from the deleterious effects of EtOH. The use of the CSD phenomenon as a neurophysiologic model allowed us to demonstrate a consistency between our data and those previously described in the literature, regarding the protective effect of astaxanthin against EtOH action on the brain tissue (Abadie-Guedes et al., 2008; Bezerra et al., 2005). In addition, the data obtained herein raise the issue of the effective impact of a single EtOH dose on brain electrophysiological phenomena. It was also here observed that 1 astaxanthin dose alone was able to counteract EtOH action on CSD.

Although our findings can be explained by different mechanisms, we hypothesize that the most likely mechanism is based on the chemical properties of astaxanthin, which make this molecule a very effective antioxidant. This molecule is composed by 2 carbonyl and 2 hydroxyl groups, and 11 conjugated ethylenic double bonds, forming a polyene system that is probably responsible for its potent antioxidant power, acting by donating the electrons and reacting against free radicals. Generally, the final products will have a more stable structure (Briton, 1995; Tapiero et al., 2004). We suggest that ROS scavenging would be a possible mechanism whereby astaxanthin could antagonize the EtOH effects on CSD. However, the measurement of blood and brain ROS levels, which has not been carried out in the present work, would be required to prove our hypothesis. Notwithstanding that, we think that this hypothesis is very plausible, mainly because ROS production in the nervous tissue has been shown to elicit CSD in the isolated chicken retina (Netto and Martins-Ferreira, 1989) and in the rat cortex (El-Bachá et al., 1998). In addition, CSD susceptibility has been proven to be increased in rats with diets deficient in the antioxidant vitamins C and E (El-Bachá et al., 1998; Guedes et al., 1996). Furthermore, brain structural effects of EtOH in laboratory animals are counteracted by antioxidant molecules like α -tocopherol in rats (Marino et al., 2004) and ascorbic acid in frogs (Peng et al., 2005). Recently, a neuroprotective effect of astaxanthin against oxidative stress by cerebral

ischemia has been reported in rats. The authors have suggested that such effect is also related to the antioxidant activities of astaxanthin (Lee et al., 2010). These pieces of evidence reinforce our hypothesis in favor of an antioxidant-dependent mechanism for the brain protective effect of astaxanthin.

Another possible mechanism of EtOH action on CSD would involve the GABA system. Several actions of EtOH have been attributed to occur via the GABA system (Kozan et al., 2007; Kumar et al., 2003; Sonn and Mayevsky, 2001). Interestingly, administration of GABAergic compounds modulates CSD (Guedes et al., 1992).

In conclusion, the demonstration of EtOH effects on the CSD model, and the interaction of EtOH with antioxidants like astaxanthin resemble findings observed in a number of clinical disorders (Lauritzen et al., 2011). The appropriate extrapolation of our experimental model to the humans certainly requires caution and presents some limitations. However, our previous pieces of evidence (Abadie-Guedes et al., 2008; Bezerra et al., 2005) and the present study highlight the possibility of testing antioxidant molecules like astaxanthin in clinical trials in the development of more effective strategies for treating such human diseases, like alcoholism.

ACKNOWLEDGMENTS

This work was financially supported by FINEP/RECARCINE (1650/10), PETROBRAS, CNPq (558258/2009-3, 475787/2009-9), CAPES (Procad/2007 and Ciências do Mar/2009), CNPq (INCT de Neurociência Translacional–No. 573604/2008-8), Facepe (APQ0975-4.05/08), and IBN-Net/Finep (No. 4191). RCAG and RSB are Research Fellows from CNPq (No. 301190/2010-0 and 303570/2009-1, respectively).

REFERENCES

- Abadie-Guedes R, Santos SD, Cahú TB, Guedes RCA, Bezerra RS (2008) Dose-dependent effects of astaxanthin on cortical spreading depression in chronically ethanol-treated adult rats. *Alcohol Clin Exp Res* 32:1417–1421.
- Amâncio-dos-Santos A, Pinheiro PCF, Lima DSC, Ozias MG, Oliveira MB, Guimarães NX, Guedes RCA (2006) Fluoxetine inhibits cortical spreading depression in weaned and adult rats suckled under favorable and unfavorable lactation conditions. *Exp Neurol* 200:275–282.
- Amaral AP, Barbosa MS, de Souza VC, Ramos IL, Guedes RC (2009) Drug/nutrition interaction in the developing brain: dipyrone enhances spreading depression in rats. *Exp Neurol* 219:492–498.
- Bezerra RS, Abadie-Guedes R, Melo FRM, Paiva AMA, Santos AA, Guedes RCA (2005) Shrimp carotenoids protect the developing rat cerebral cortex against the effects on cortical spreading depression. *Neurosci Lett* 391:51–55.
- Bonthius DJ, Pantazis N, Karacay B, Bonthius NE, Taggard DA, Lothman EW (2001) Alcohol exposure during the brain growth spurt promotes hippocampal seizures, kindling and spreading depression. *Alcohol Clin Exp Res* 25:734–745.
- Briton G (1995) Structure and properties of carotenoids in relation to function. *FASEB J* 9:1551–1558.

- Choi HD, Kang HE, Yang SH, Lee MG, Shin WG (2011) Pharmacokinetics and first-pass metabolism of astaxanthin in rats. *Br J Nutr* 105:220–227.
- Conte A, Attilia ML, Gilio F, Iacovelli E, Frasca V, Marini Bettolo C, Gabrielle M, Giacomelli E, Prencipe M, Berardelli A, Ceccanti M, Inghilleri M (2008) Acute and chronic effects of ethanol on cortical excitability. *Clin Neurophysiol* 119:667–674.
- Costa-Cruz RR, Amâncio-dos-Santos A, Guedes RC (2006) Characterization of cortical spreading depression in adult well-nourished and malnourished rats submitted to the association of pilocarpine-induced epilepsy plus streptozotocin-induced hyperglycemia. *Neurosci Lett* 401:271–275.
- Dreier JP (2011) The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. *Nat Med* 17:439–447.
- El-Bachá RS, Lima-Filho JL, Guedes RCA (1998) Dietary antioxidant deficiency facilitates cortical spreading depression induced by photoactivated riboflavin. *Nutr Neurosci* 1:205–212.
- Fabricsius M, Fuhr S, Willumsen L, Dreier JP, Bhatia R, Boutelle MG, Hartings JA, Bullock R, Strong AJ, Lauritzen M (2008) Association of seizures with cortical spreading depression and peri-infarct depolarisations in the acutely injured human brain. *Clin Neurophysiol* 119:1973–1984.
- Gorelova NA, Koroleva VI, Amemori T, Pavlik V, Bure's J (1987) Ketamine blockade of cortical spreading depression in rats. *Electroencephalogr Clin Neurophysiol* 66:440–447.
- Gorji A (2001) Spreading depression: a review of the clinical relevance. *Brain Res Rev* 38:33–60.
- Gorji A, Speckmann EJ (2004) Spreading depression enhances the spontaneous epileptiform activity in human neocortical tissues. *Eur J Neurosci* 12:3371–3374.
- Guedes RCA (2005) Electrophysiological methods: application in Nutritional Neuroscience, in *Nutritional Neuroscience: Overview of An Emerging Field* (Liebermann H, Kanarek R, Prasad C eds), pp 39–54. CRC Press, New York.
- Guedes RCA, Amorim LF, Teodósio NR (1996) Effect of aging on cortical spreading depression. *Braz J Med Biol Res* 29:1407–1412.
- Guedes RCA, Azeredo FAM, Hicks TP, Clarke RJ, Tashiro T (1987) Opioid mechanisms involved in the slow potential change and neuronal refractoriness during cortical spreading depression. *Exp Brain Res* 69:113–118.
- Guedes RCA, Cabral-Filho JE, Teodósio NR (1992) GABAergic mechanisms involved in cortical spreading depression in normal and malnourished rats, in *Spreading Depression* (Do Carmo RJ ed), pp 17–26. Springer, Berlin.
- Guedes RCA, Frade SF (1993) Effect of ethanol on cortical spreading depression. *Braz J Med Biol Res* 26:1241–1244.
- Guo W, Crossey EL, Zhang L, Zucca S, George OL, Valenzuela CF, Zhao X (2011) Alcohol exposure decreases CREB binding protein expression and histone acetylation in the developing cerebellum. *PLoS One* 6:e19351. doi: 10.1371/journal.pone.0019351
- Higuera-Ciapara I, Félix-Valenzuela L, Goycoolea FM (2006) Astaxanthin: a review of its chemistry and applications. *Crit Rev Food Sci Nutr* 46:185–196.
- Kim JH, Choi SK, Choi SY, Kim HK, Chang HI (2005) Suppressive effect of astaxanthin isolated from *Xanthophyllomyces dendrorhous* mutant on ethanol-induced gastric mucosal injury in rats. *Biosci Biotechnol Biochem* 69:1300–1305.
- Kozan R, Ayyildiz M, Yildirim M, Agar E (2007) The influence of ethanol intake and its withdrawal on the anticonvulsant effect of α -tocopherol in the penicillin-induced epileptiform activity in rats. *Neurotoxicol* 28:463–470.
- Kumar S, Kralic JE, O'Buckley TK, Grobin AC, Morrow AL (2003) Chronic ethanol consumption enhances internalization of $\alpha 1$ subunit-containing GABAA receptors in cerebral cortex. *J Neurochem* 86:700–708.
- Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, Strong AJ (2011) Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. *J Cereb Blood Flow Metab* 31:17–35.
- Leão AAP (1944) Spreading depression of activity in the cerebral cortex. *J Neurophysiol* 7:359–390.
- Leão AAP (1947) Further observations on the spreading depression of activity in the cerebral cortex. *J Neurophysiol* 10:409–414.
- Lee DH, Lee YJ, Kwon KH (2010) Neuroprotective effects of astaxanthin in oxygen-glucose deprivation in SH-SY5Y cells and global cerebral ischemia in rat. *J Clin Biochem Nutr* 47:121–129.
- de Licona HK, Karacay B, Mahoney J, McDonald E, Luang T, Bonthius DJ (2009) A single exposure to alcohol during brain development induces microencephaly and neuronal losses in genetically susceptible mice, but not in wild type mice. *Neurotoxicol* 30:459–470.
- Lieber CS (1995) Medical disorders of alcoholism. *New Engl J Med* 333:1058–1065.
- Marino MD, Aksenov MY, Kelly SJ (2004) Vitamin E protects against alcohol-induced cell loss and oxidative stress in the neonatal rat hippocampus. *Int J Dev Neurosci* 22:363–377.
- Merkler D, Klinker F, Jürgens T, Glaser R, Paulus W, Brinkmann BG, Sereida M, Guedes RCA, Brück W, Liebetanz D (2009) Propagation of spreading depression inversely correlates with cortical myelin content. *Ann Neurol* 66:355–365.
- Miki W (1991) Biological functions and activities of animal carotenoids. *Pure Appl Chem* 63:141–146.
- Mitchell JJ, Paiva M, Heaton MB (1999) Vitamin E and β -carotene protect against ethanol combined with ischemia in an embryonic rat hippocampal culture model of fetal alcohol syndrome. *Neurosci Lett* 263:189–192.
- Monte-Silva KK, Assis FL, Leal GM, Guedes RC (2007) Nutrition-dependent influence of peripheral electrical stimulation during brain development on cortical spreading depression in weaned rats. *Nutr Neurosci* 10:187–194.
- Nash CM, Ibram F, Dringenber HC, Reynolds JN, Brien JF (2007) Effects of maternal administration of vitamins C and E on ethanol neurobehavioral teratogenicity in the guinea pig. *Alcohol* 41:577–586.
- Netto M, Martins-Ferreira H (1989) Elicitation of spreading depression by rose Bengal photodynamic action. *Photochem Photobiol* 50:229–234.
- Peng Y, Kwok KH, Yang PH, Ng SS, Liu J, Wong OG, He ML, Kung HF, Lin MC (2005) Ascorbic acid inhibits ROS production, NF-kappa B activation and prevents ethanol-induced growth retardation and microencephaly. *Neuropharmacology* 48:426–434.
- Rocha-de-Melo AP, Cavalcanti JB, Barros AS, Guedes RCA (2006) Manipulation of rat litter size during suckling influences cortical spreading depression after weaning and at adulthood. *Nutr Neurosci* 9:155–160.
- Sonn J, Mayevsky A (2001) The effect of ethanol on metabolic, hemodynamic and electrical responses to cortical spreading depression. *Brain Res* 908:174–186.
- Tapiero H, Townsend DM, Tew KD (2004) The role of carotenoids in the prevention of human pathologies. *Biomed Pharmacother* 58:100–110.
- Tenório AS, Moura FR, Silva LP, Guedes RC (2009) Lasting facilitatory effects of neonatal vibrissae removal on the propagation of cortical spreading depression: an electrophysiological study in well-nourished and early-malnourished adult rats. *Nutr Neurosci* 12:281–288.

CAPÍTULO II

The use of cortical spreading depression for studying the brain actions of antioxidants

R C A Guedes¹, Ricardo Abadie-Guedes², Ranilson de Souza Bezerra²

¹Departamento de Nutrição, Universidade Federal de Pernambuco, 50670901, Recife, PE, Brazil

²Departamento de Bioquímica, Universidade Federal de Pernambuco, 50670901, Recife, PE, Brazil

Objectives: We review the main adverse effects of reactive oxygen species (ROS) in the mammalian organism, introducing the reader on the worldwide problem of the ROS neurophysiological impact on the developing and the adult brain, and discussing the neuroprotective action of antioxidant molecules.

Methods: We briefly present the electrophysiological phenomenon designated as 'cortical spreading depression' (CSD), as a parameter of normal brain functioning. We highlight recent electrophysiological advances obtained in experimental studies from our laboratory and from others, showing how to investigate the ROS effects on the brain by using the CSD phenomenon.

Results: Under conditions such as aging, ROS production by photo-activation of dye molecules and ethanol consumption, we describe the effects, on CSD, of treating animals with (1) antioxidants and (2) with antioxidant-deficient diets.

Discussion: The current understanding of how ROS affect brain electrophysiological activity and the possible interaction between these ROS effects and those effects of altered nutritional status of the organism are discussed.

Keywords: EEG, Cortical spreading depression, Carotenoids, Reactive oxygen species, Brain development, Malnutrition

Introduction: the redox scenario in the central nervous system

In the mammalian organism, the production of free radicals such as the reactive oxygen species (ROS) is considered an important event occurring with variable intensity at distinct phases of life, from the intrauterine period until late aging. The excessive production of ROS is certainly deleterious for the organism, but under physiological conditions this event can efficiently be maintained under control by mechanisms involving antioxidant molecules. However, several external factors can modify this physiological control, either increasing or decreasing the efficiency of the mechanisms that protects the organism against the harmful effects of ROS.¹

Concerning the ROS action on the central nervous system, the increased incidence of neurodegenerative diseases in developing countries has been associated to several factors, including neural damage due to oxidative stress.² This can be intensely produced in conditions of oxidant load of the organism, as in perinatal nutrition,³ or in cases of hypo-functioning of

neural antioxidant mechanisms, when dietary antioxidant supplementation can be beneficial.⁴ For example, increased rates of cerebral lipid peroxidation can lead to the excessive production of ROS which, if not neutralized by antioxidant mechanisms, are highly deleterious to the brain tissue. This physiological ROS neutralization can fail in the presence of a number of factors, like nutritional imbalance,⁵ aging process,⁶ and the consumption of ethanol.⁷ These factors can disrupt the normal brain redox scenario, leading to a situation of increased oxidative stress in which the brain becomes susceptible to the development of certain neurological dysfunctions, like those occurring in Alzheimer's disease,⁸ diabetes,¹ and epilepsy.⁹

In the last two decades, a considerable scientific effort has been produced to clarify whether antioxidant supplementation can help in preventing these various dysfunctions. The implication is that understanding the specific molecular effects of ROS on brain functioning is of great importance in determining the role of antioxidants on these diseases and may certainly help in shedding light on the epidemiological findings, which sometimes point to opposite neuropsychological effects of antioxidants.

Correspondence to: R C A Guedes, Departamento de Nutrição, Universidade Federal de Pernambuco, 50670901 Recife, PE, Brazil. Email: rc.guedes@terra.com.br; guedes.rca@gmail.com

The action of ROS in the developing brain

As in other organs, the biochemical and morphological organization of the brain can be disrupted by the oxidative stress subsequent to the imbalance between the increase in the ROS production and the decreased effectiveness of antioxidant systems. When this occurs early in life, during the so-called 'brain growth spurt' period,¹⁰ the deleterious consequences for the brain functioning can be particularly severe,¹ as compared with the adult brain. The brain growth spurt period corresponds to the highest speed of developmental processes like neurogenesis, gliogenesis, and cell migration, in the neural tissue.¹¹ Under such conditions, dietary antioxidants can avoid the increase of intracellular ROS concentration, thus preventing cell damage.¹² Basic processes such as neuronal excitability and learning- and memory-dependent functions may be affected to some extent by oxidative stress, and this can contribute to the appearance of important disabling neuropathological disorders. These in many cases are permanent, and can affect an impressive number of children in several parts of the world.^{1,8,9} This certainly has prompted several research groups to investigate the neural protective effects of antioxidant molecules, mainly those from nutraceutical- and dietary sources, both in laboratory animals and in humans, using *in vivo* and *in vitro* models.

We will next present data from our laboratory documenting the effects of ROS on the brain electrophysiological activity in both developing and adult animals.

Antioxidants and brain electrophysiology

The distinct cell populations of the normal brain continuously generate electrical activity, as long as the organism is alive. All brain-dependent regulatory functions in the organism depend directly or indirectly on this electrical activity. In humans, as well as in laboratory animals, an interesting way of getting important information on brain functioning consists in recording the electrical activity produced spontaneously by the brain. This technique is denominated electroencephalogram (EEG), and can be defined as the measurement of the temporal oscillations of electrical potential between two points of the brain. Because EEG is a non-invasive technique (a number of electrodes are fixed on the scalp and the potential oscillations are recorded pair wise), it is widely used in humans, aiding in the diagnosis of several neurological disorders.¹³ In experimental animals, the recording can be performed in an invasive manner, under anesthesia, in which the skull is surgically opened and the recording electrodes are placed on the cortical surface and even inside the cortex; in this case, it is denominated 'electrocorticogram' (ECoG).

Under oxidative stress, as for example in ischemia/reperfusion injury, the brain electrical activity may be more or less affected.¹⁴ In animals under oxidative stress, several reports document altered susceptibility to disorders related to brain excitability, such as epilepsy,^{9,15,16} and neurodegenerative diseases.^{12,17} Collectively, the physiopathological implications of such pieces of evidence for the human health led us to investigate to what extent the redox disorders could alter the electrical activity of the brain. For that purpose we have used, as an experimental model, the cortical spreading depression (CSD) phenomenon (see^{13,18} for a review).

CSD as a tool for studying brain antioxidant effects

CSD was originally described in the 1940s by the Brazilian scientist Aristides Leão, at that time a young PhD student working at Harvard University, USA. The phenomenon was then described as being a reversible and propagated 'wave-like' electrophysiological response of the cerebral cortex subsequent to its punctual stimulation. The response consists of a reduction (depression) of the spontaneous and evoked electrical activity of the cerebral cortex.¹⁹ During CSD there is a depolarization of neurons and probably also of glial cells, and this led some researchers recently to start using the term 'spreading depolarization' as a synonym for spreading depression.²⁰ Simultaneously to the neuronal depolarization, a reversible dilation of the pial blood vessels,²¹ and a slow potential change (also called DC potential change) of the tissue have been also described by Leão.²² In contrast to what some may think, the term 'depression', in this context, is not directly related with the psychiatric disease, named also by that term. Rather, it has an electrophysiological meaning, signifying that the amplitude of the ECoG activity at the depressed region tends to zero. Once elicited, CSD concentrically propagates to remote cortical regions, while the initially depressed point starts to recover. The complete recovery of the tissue usually requires about 5–10 minutes, as evaluated by the restoration of the pre-depression ECoG pattern and DC level of the slow potential change. Because this DC variation has an 'all-or-none' feature, it is very suitable for estimating the CSD velocity of propagation. This velocity usually ranges from 2 to 5 mm/minute in all vertebrate species so far studied, from fishes to mammals including the human species, and is considered very low when compared with the much higher conduction velocity of neuronal action potentials, which in mammals is in the order of m/second. The very low CSD velocity is compatible with a mechanism of propagation of humoral nature, in which the release of one or more chemical compounds from

the depolarized neural cells would diffuse through the extra-cellular space, and would 'contaminate' the neighbor cells, which then become electrophysiologically depressed.²³ Once depressed, these neighbor cells would release the CSD-eliciting chemical factors; the neurotransmitter glutamate and the ion potassium, among others, are the most frequently postulated candidates.²⁰ The released chemical factors would then contaminate other cells, and so on, giving rise to a positive feedback loop that is very effective in maintaining the auto-regenerative propagation of CSD.

We believe that the CSD phenomenon is an interesting electrophysiological model that is valuable for understanding the relationship between oxidative stress, nutrition, and neural development and function. Experimental evidence indicates that the resistance offered by the brain tissue to CSD propagation can be increased or decreased by experimental manipulations, resulting in lower or higher CSD velocities of propagation, respectively.^{24,25} Experimental procedures that either augment or diminish the brain ability to counteract CSD may help in understanding the phenomenon and the diseases related to it. Therefore, CSD can be considered as a real electrophysiological tool, which can aid in understanding the normal and pathologic brain.²⁶

In previous studies, we have characterized alterations in brain CSD susceptibility in animals submitted to environmental, pharmacological, and nutritional manipulations.^{27–32} One of the conditions studied was the manipulation of antioxidants, which will be reviewed and discussed in the following sections.

CSD, aging, and dietary antioxidants

During the mammalian aging process, the production of ROS is an important event, and the oxidation of DNA, proteins, and lipids by ROS, when accumulated in the aged brain, can functionally affect it.³³ This includes functions that are dependent on the brain excitability.³⁴ With that in mind, we investigated in rodents (albino rats and gerbils) the influence of aging on brain susceptibility to CSD (for details, see³⁵).

In albino rats and Mongolian gerbils (*Meriones unguiculatus*) with ages ranging from 2.5 to 24 months (rats) and from 1.5 to 58 months (gerbils), under anesthesia with urethane + cloralose mixture (1000 + 40 mg/kg, respectively, intraperitoneally), CSD was recorded during 2 hours on two points of the parietal cortex. For each animal, the mean CSD velocity of propagation was calculated based on the time spent for the CSD-wave to cross the inter-electrode distance. We plotted the CSD velocities as a function of ages and the correlation coefficients between the two variables, as well as the equations

for the computed regression lines were calculated. In both rodent species, we found a significant ($P < 0.05$) negative correlation between CSD velocities and ages (Fig. 1). The lower CSD velocity found in aged animals is apparently contrasting with the tendency of the aged brain in presenting higher levels of lipid peroxidation, which lead to the formation of ROS³⁶ and would accelerate CSD. However, in the rat brain the levels of the antioxidant molecule ascorbic acid (AA) are preserved in the aged cerebral cortex,³⁷ and this could help explaining the lower CSD velocity in the aged rat. Other brain changes related to aging such as alteration of the intra- and extracellular brain volumes³⁸ may also help in explaining this effect.

In view of the above-commented evidence of increased ROS production during aging, and also because ROS can elicit retinal spreading depression,³⁹ we decided to investigate the CSD propagation in




Figure 1 Mean CSD velocities of propagation as a function of the age of rats (Wistar and Sprague-Dawley strains) and gerbils (*Meriones unguiculatus*). Each point in the graphics corresponds to the mean velocity for one animal. The equations for the computed regression lines, as well as the corresponding correlation coefficients are given in each graph. In all cases there is a significant negative correlation between CSD velocities and age. Adapted from published data of our lab.³⁵




Figure 2 CSD velocities of propagation in rats and gerbils of different ages, as described in Fig. 1, showing absence of significant correlation between the two variables, after the animals had been submitted to dietary deficiency of the antioxidant vitamins C and E for 4–6 weeks. Adapted from published data of our lab.³⁵

animals deprived of antioxidant vitamins in their diet. Under this condition, the significant negative correlation between CSD velocity and animal's age disappeared (Fig. 2), suggesting the involvement of brain ROS in the aging effect on CSD.

CSD, photo-activation-induced ROS, and dietary antioxidants

It has been demonstrated in the isolated retina that CSD can be elicited when a *bolus* of the photo-sensible dye Rose Bengal, which had previously been applied to the preparation in darkness, is illuminated.³⁹ The photo-activation of this dye is known to produce ROS (singlet oxygen⁴⁰). Thus, we decided to test if illumination of another light-sensible molecule, the yellow-colored neutral dye riboflavin, which has biological importance as vitamin B2, could elicit CSD in the rat cortex *in vivo*. Riboflavin is capable of reducing oxygen to the ROS superoxide when activated by photons.⁴¹

We studied two groups of adult Wistar rats: one control ($n = 9$), fed a normal chow diet, and one deficient group ($n = 15$), which received during 4–6 weeks previously to the experiment a diet free from the antioxidant vitamins C and E.⁴² In urethane + cloralose anesthetized rats, a 1–2 hours 'baseline' CSD recording was performed, when CSD was elicited at 20-minute intervals by conventional stimulation with 2% KCl applied for 1 minute to a point of the frontal cortical surface. After this baseline period, tests were performed with 1.0 mM riboflavin applied to the same frontal region and illuminated for 1–3 minutes by a 40 W white light bulb, placed 10–15 cm over the cortical surface. As can be seen in Table 1,

in the control group, this procedure elicited CSD in 29.7% of the cases (11 out of 37 applications, with CSD appearing in 7 out of the 9 rats of this group). In the antioxidant-deficient animals, the effectiveness of photo-activated riboflavin to elicit SD increased significantly to 62.8% (44 out of 70 riboflavin applications; 15 out of 15 rats; $P < 0.05$). Neither illumination of an equivalent volume of Ringer solution applied to the same region nor the application of riboflavin without illumination did elicit CSD (Fig. 3).

The results demonstrate⁴² that photo-activated riboflavin is capable of eliciting CSD in the rat cerebral cortex and that dietary deficiency of the antioxidant vitamins C and E can enhance brain susceptibility to this process, suggesting that the increased levels of free radicals in the brain, which probably occur under dietary antioxidant deficiency, might be involved in this effect.

CSD, ethanol-induced ROS, and shrimp antioxidants

The enhanced formation of ROS in the brain can occur because of excessive alcohol ingestion, which produces lipid peroxidation. This increased ROS production is potentially injurious to the brain tissue³⁶ and the ROS effects are usually counteracted by mechanisms involving antioxidant substances, like carotenoids, which can be found in several foods from vegetal and animal origin. An interesting animal source of carotenoids is represented by the crustaceans like shrimps, where carotenoids are present as a carotenoprotein in some associations in legs parts, blood, eyes, eggs, hepatopancreas, ovary, and the carapace.⁴³

Table 1 Number of applications of riboflavin and percentage of SD elicitation in control and vitamin-deficient rats

Rat no.	Control group			Deficient group		
	A = applications	B = elicitations	B = (as % of A)	A = applications	B = elicitations	B = (as % of A)
1	3	0	0.0	6	1	16.7
2	5	0	0.0	3	1	33.3
3	6	1	16.7	5	2	40.0
4	7	2	28.6	6	3	50.0
5	3	1	33.3	4	2	50.0
6	3	1	33.3	5	3	60.0
7	4	2	50.0	5	3	60.0
8	3	2	66.7	6	4	66.7
9	3	2	66.7	3	2	66.7
10				3	2	66.7
11				6	4	66.7
12				6	5	83.3
13				3	3	100.0
14				4	4	100.0
15				5	5	100.0
Total	37	11		70	44	
Average	4.1	1.2		4.7	2.9	
Mean			32.8			64.0
±SD			±25.1			±24.6

The groups are significantly different, either by using the Rank sum test ($P < 0.05$) or Student's *t*-test ($P < 0.01$). Data from our previous paper.⁴²




Figure 3 ECoG and DC recordings in the parietal cortex of a rat, showing CSD elicitation by the classical KCl stimulation (A), and also by photo-activation of riboflavin (Rb), seen in (B). Illumination of an equivalent volume of Ringer solution did not elicit CSD (C and E). The same negative result was observed when riboflavin was applied without illumination (first arrow in D and F). CSD appeared 3–4 minutes later when riboflavin was illuminated (second arrow in D and F). Vertical bars at P1 and P2 in A correspond to -10 mV. Modified from a figure of our previous publication.⁴²

We had initially treated adult rats, with one daily ethanol application per gavage during 7 days,⁴⁴ and demonstrated a facilitating effect on CSD propagation, as compared with water-treated controls (Fig. 4). More recently, we tested whether a shrimp carotenoid extract (obtained from shrimp heads) could have a protecting effect on the CSD actions of ethanol. A carotenoid ethanolic extract (30 μ g/kg/day) prepared from shrimp heads was given per gavage to pregnant or lactating rat dams, and we analyzed CSD in their pups, which were compared with age-mated ones from mothers treated either with the vehicle (ethanol) or with distilled water. In line with the initial experiments,⁴⁴ ethanol treatment was associated with higher ($P < 0.05$) CSD velocities as compared with the distilled water group. Carotenoid




Figure 4 Effect of ethanol treatment on CSD propagation velocities in 80–100-day-old adult rats ($n = 10$). Ethanol was administered daily per gavage during 7 days. For comparison, a control group ($n = 8$) received distilled water by the same gavage procedure. One hour after the last gavage, a 4-hour-CSD recording session was initiated. Data are expressed as mean \pm standard deviation. Asterisks indicate that the ethanol-treated group presented significantly higher CSD propagation velocities, as compared with the control group ($P < 0.05$; t -test). (Data from our previous publication.⁴⁴)




Figure 5 Mean CSD velocities in the cerebral cortex of just-weaned rat pups (36–40 days of life) whose mothers had been treated with 30 μ g/kg/day of an ethanolic extract of shrimp carotenoids (E + C), either during the gestation or during the lactation period, as compared to corresponding controls treated with vehicle – ethanol (E; 3 g/kg) or distilled water (DW). Data are expressed as mean \pm standard deviation. Asterisks represents higher values ($P < 0.05$) comparing groups treated during gestation and lactation. Different capital and lowercase letters represent significant difference ($P < 0.05$) in the means of the different treatments administered per gavage (analysis of variance (ANOVA) plus Tukey's test; $P < 0.05$). Modified from a figure of our previous publication.⁴⁵

treatment resulted in lower CSD velocities ($P < 0.05$), when compared to the vehicle (ethanol) group, and this effect was more intense in the groups treated during lactation, as compared with the groups treated in the gestation period.⁴⁵ The results are shown in Fig. 5, and suggest a protective action of shrimp carotenoids against the ethanol effects on spreading depression.

Because astaxanthin is the most abundant carotenoid present in the shrimp, we proposed that the CSD effects of the shrimp extract were caused by astaxanthin. To test this proposition, we analyzed CSD in adult rats (60–70 days of life) treated per gavage for 18 days with pure astaxanthin (from Sigma Co., St Louis, MO, USA) in doses of 2.5, 10, or 90 μ g/kg/day, diluted in 95% ethanol (corresponding to a dose of 3 g/kg/day of ethanol), which is within the range of ethanol dose usually employed in rodents.^{46,47} Three control groups were treated, respectively, with the vehicle (ethanol group), or with distilled water, or with soybean oil (used as alternative vehicle to dissolve astaxanthin, which is not hydrosoluble). In an additional group, the influence of astaxanthin without ethanol was evaluated by treating the animals with 10 μ g/kg/day astaxanthin dissolved in soybean oil instead of ethanol. From the weaning until the day of the electrophysiological recording (79–89 days), all animals had free access to water and a commercial lab chow diet (Purina do Brazil Ltd, São Lourenço da Mata, PE, Brazil containing 23 g protein/100 g diet). Fig. 6 represents the average CSD velocities calculated for the whole 4-hour period. Compared with the ethanol group, the CSD




Figure 6 Dose–response relationship of the antagonizing astaxanthin effect on CSD propagation in adult rats (90 days of life) treated per gavage with astaxanthin at doses of 2.5, 10, and 90 µg/kg/day compared to rats treated with vehicle- (ethanol, E; 3 g/kg) and controls treated with distilled water (DW). Data are expressed as means \pm standard deviation, calculated in each hour of recording. Different lowercase letters represent significant difference ($P < 0.05$) in the means of the different treatments administered per gavage (ANOVA plus Tukey's test; $P < 0.05$). Modified from a figure of our previous publication.⁴⁸

velocities in the astaxanthin groups decreased as a function of astaxanthin dose, following an exponential decay model, which is represented by the equation $y = 2.9048 + 1.1988e^{(-x/9.0217)}$, ($r^2 = 0.9998$), in which the y -variable is the CSD velocity of propagation, and the x -variable is astaxanthin dose in µg/kg/day.⁴⁸ The average CSD velocities for the soybean oil and 10 µg/kg/day astaxanthin + soybean oil groups (not shown in the figure) were not statistically different from the water-treated control group. We conclude that the effectiveness of astaxanthin in antagonizing the CSD effects of ethanol supports our suggestion that the similar effect in the rats previously treated with the carotenoid extract is probably due to the high proportion of astaxanthin present in that extract.⁴⁸

Interaction antioxidant/nutrition on CSD features

When occurring in the initial phase of mammal's life, a deficient nutrition can alter negatively, and sometimes permanently, the anatomical, biochemical, and physiological organization of the brain. This initial period is the phase in which proliferation, growth, migration, and myelination of the brain cells are occurring with the highest rate.^{11,18} In the rat, this period corresponds to the first 3 weeks of post-natal life, i.e. the suckling period.⁴⁹

It had been demonstrated that early malnutrition enhances CSD propagation,^{25,50} but no information was available regarding a possible nutrition/antioxidants interaction on CSD. Recently,⁵¹ we addressed this issue by studying the CSD features in the cerebral cortex of well-nourished and malnourished developing

rats treated chronically (21 days) with another antioxidant, AA. This molecule (also denominated vitamin C) is present in the brain and can exert biphasic modulating effects (i.e. it can exert antioxidant or prooxidant action) in distinct models of excitability-related brain disorders.^{52,53} We addressed the following two questions in the brain of weaned young rats, subjected to malnutrition during lactation followed by nutritional recovery: (i) How does daily enteral administration of AA during the brain development affect CSD propagation, and (ii) if so, how this effect would be influenced by the previous brain nutritional condition. Wistar suckling rats were malnourished during the entire lactation period by feeding their lactating dams a deficient diet (with only 8% of protein), and were compared to well-nourished controls (maternal diet with 23% protein). From post-natal days 7–28, part of each nutritional group was treated with 60 mg/kg/day of L-AA. CSD propagation was analyzed when the pups were 30–40 days old. In line with previous findings (see¹⁸ for an overview), malnutrition was associated with higher ($P < 0.05$) CSD velocities of propagation and DC-amplitudes, as compared to the well-nourished controls. AA treatment resulted in an increased CSD amplitudes and propagation velocities ($P < 0.05$), as compared to non-treated ('naïve'; Nv) and saline-treated (Sal) controls, in both well-nourished and malnourished conditions. Data are presented in Fig. 7. We conclude that the chronic treatment of developing rats with AA at the dose of 60 mg/kg/day facilitated CSD




Figure 7 Body weight, and CSD velocity and amplitude of well-nourished and malnourished 30–40-day-old rats treated from the 7th to the 28th post-natal days with 60 mg/kg/day of ascorbic acid (AA group) or saline (Sal group) or no treatment (naïve – NV group). Asterisks indicate significant difference ($P < 0.05$) between well-nourished and the corresponding malnourished groups. The symbol # shows significant difference between the AA group and the indicated controls (ANOVA plus Tukey's test). Modified from a figure of our previous publication.⁵¹

propagation, and this effect is not significantly modulated by malnutrition. Considering that other antioxidants have antagonized CSD,^{42,48} and considering also that AA can eventually have prooxidant action, and thus can cause neurotoxicity,^{3,52,54} we suggest that AA at the dose of 60 mg/kg/day acts as prooxidant on the CSD model, as indicated by the larger amplitudes of the CSD DC-shifts and the faster CSD propagation, observed in the AA-treated rats.⁵¹ In fact, this AA dose of 60 mg/kg/day has been previously reported by others as being prooxidant in the rat.⁵² All the evidence notwithstanding, we think that future experiments for measuring blood and brain ROS levels, as well as studying developing rats treated with lower AA doses, or studying developed animals treated at adulthood, shall confirm this hypothesis.

Relations to neurological disorders, hypotheses, and concluding remarks

The involvement of neuronal and glial oxidative damage in several neurological disorders has been postulated by various authors based on a number of clinical and experimental pieces of evidence. For example, oxidative stress in the mitochondria has been implicated in the neuronal injury induced by seizures, possibly contributing to the pathogenesis of temporal lobe epilepsy,¹⁶ and hippocampal oxidative stress has been postulated as causally involved in age-related impairment in learning and memory.⁵⁵ In addition, deficient redox regulation during development has been speculated to play a role in schizophrenia.¹² The same is true concerning the role of ROS in Alzheimer's disease.⁵⁶ On the other hand, dietary treatment with antioxidants, and environmental enrichment have been shown to additively protect and even enhance cognitive function in aged humans,⁵⁷ and this has been also demonstrated in animal models.⁵⁸ A variety of foods usually present in the human diet, like nuts, vegetables, fruits, cereals, tea, wine, as well as some fishes and crustaceans, are natural sources of antioxidant compounds. As previously stressed in the Introduction, a diet that is rich in such foods may aid in protecting the organism against neurodegenerative diseases that depends on increased oxidative damage; also, it may decrease pro-inflammatory cytokines in the brain by reducing oxidative damage.⁵⁹ This implies that the systematic and long-lasting consumption of adequate amounts of the antioxidant-rich foods should be recommended as an effective way to prevent, or at least minimize, those neurological diseases related to increased oxidative stress during the aging process. At an epidemiological level however, it is doubtful whether many human beings would long lastingly adhere to this nutritional

intervention that sometimes would represent a radical change in their alimentary style.⁶

The analysis of CSD features under conditions of dietary antioxidant deficiency as well as under increased redox imbalance constitutes a promising experimental approach for the electrophysiological investigation of the brain effects of nutritional and non-nutritional conditions of great neuropathological relevance that can increase the energy demands in the brain, and are associated to important human diseases, such as brain ischemia, epilepsy, and migraine, which are also influenced by disorders of the brain redox homeostasis. Regarding the involvement of CSD in the migraine, it is important mentioning data from others⁶⁰ that suggest a beneficial effect of antioxidants on the frequency or severity of migraine. Recently, an increase in the activity of the enzyme superoxide dismutase has been reported in the rat cortex 1 hour after CSD.⁶¹ Such pieces of evidence highlight the clinical importance of the present data, as CSD has been postulated as being involved in the pathophysiology of brain stroke, epilepsy, and migraine. A number of possible mechanisms for the reported effects has been proposed, including the induction of neuroprotective genes,⁶¹ and the involvement of nitric oxide.⁶²

Certainly, the appropriate data extrapolation between species (e.g. from rat to humans) is not a simple task, requiring great caution and presenting some limitations. Notwithstanding such limitations, from the converging body of evidence here presented it turns out that the development of experimental models devoted to investigating this theme is highly desirable, and this is particularly true in the case of the electrophysiological models. The comprehension of the mechanisms by which such conditions affect CSD propagation may be helpful in the development of more effective strategies for treating those diseases.

Acknowledgements

The authors thank the Agencies CAPES (Procad/2007), CNPq (INCT de Neurociência Translacional – No. 573604/2008-8), MS/SCTIE/DECIT (No. 17/2006), Facepe (APQ0975-4.05/08), IBN-Net/Finep (No. 4191), FINEP-RECARCINE, PETROBRAS, and CNPq, SEAP/PR, for financial support. RCAG and RSB are Research Fellows from CNPq (No. 301190/2010-0).

References

- Seifried HE, Anderson DE, Fisher EI, Milner JA. A review of the interaction among dietary antioxidants and reactive oxygen species. *J Nutr Biochem* 2007;18:567–79.
- Chen K, Zhang X, Wei X-P, Qu P, Liu Y-X, Li T-Y. Antioxidant vitamin status during pregnancy in relation to cognitive development in the first two years of life. *Early Hum Dev* 2009;85:421–7.
- Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, *et al.* Ascorbate in pharmacologic concentrations selectively

- generates ascorbate radical and hydrogen peroxide in extracellular fluid *in vivo*. *Proc Natl Acad Sci USA* 2007;104:8749–54.
- 4 Codoñer-Franch P, López-Jaén AB, De La Mano-Hernández A, Sentandreu E, Simó-Jordá R, Valls-Bellés V. Oxidative markers in children with severe obesity following low-calorie diets supplemented with mandarin juice. *Acta Paediatr* 2010;99:1841–46.
 - 5 Ramesh BN, Sathyanarayana-Rao TS, Prakasam A, Sambamurti K, Jagannatha-Rao KS. Neuronutrition and Alzheimer's Disease. *J Alzheimers Dis* 2010;19:1123–39.
 - 6 Gemma C, Vila J, Bachstetter A, Bickford PC. Oxidative stress and the aging brain: from theory to prevention. In: Riddle DR (ed.) *Brain aging: models, methods, and mechanisms*. Boca Raton: CRC Press; 2007. p. 1–15.
 - 7 Loureiro SO, Heimfarth L, Reis K, Wild L, Andrade C, Guma FT, et al. Acute ethanol exposure disrupts actin cytoskeleton and generates reactive oxygen species in c6 cells. *Toxicol In Vitro* 2011;25:28–36.
 - 8 Axelsen PH, Komatsu H, Murray IV. Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease. *Physiology* 2011;26:54–69.
 - 9 Grosso S, Longini M, Rodriguez A, Proietti F, Piccini B, Balestri P, et al. Oxidative stress in children affected by epileptic encephalopathies. *J Neurol Sci* 2011;300:103–6.
 - 10 Grantham-McGregor S. A review of studies of the effect of severe malnutrition on mental development. *J Nutr* 1995;125: p2233S–8S.
 - 11 Morgane PJ, Austin-La France R, Bronzino J, Tonkiss J, Diaz-Cintra S, Cintra L, et al. Prenatal malnutrition and development of the brain. *Neurosci Biobehav Rev* 1993;17:91–128.
 - 12 Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. *Curr Opin Neurobiol* 2009;19:220–30.
 - 13 Guedes RCA. Electrophysiological methods: application in nutritional neuroscience. In: Liebermann H, Kanarek R, Prasad C (eds.) *Nutritional neurosciences: overview of an emerging field*. New York: CRC Press; 2005. p. 39–54.
 - 14 Kara I, Nurten A, Aydin M, Özkök E, Özen I, Özerman B, et al. Ischemia/reperfusion in rat: antioxidative effects of enoant on EEG, oxidative stress and inflammation. *Brain Inj* 2011;25: 113–26.
 - 15 Ayyildiz M, Coskun S, Yildirim M, Agar E. The effects of ascorbic acid on penicillin-induced epileptiform activity in rats. *Epilepsia* 2007;48:1388–95.
 - 16 Waldbaum S, Patel M. Mitochondria, oxidative stress, and temporal lobe epilepsy. *Epilepsy Res* 2010;88:23–45.
 - 17 Sun AY, Wang Q, Simonyi A, Sun GY. Resveratrol as a therapeutic agent for neurodegenerative diseases. *Mol Neurobiol* 2010;41:375–83.
 - 18 Guedes RCA. Cortical spreading depression: a model for studying brain consequences of malnutrition. In: Preedy VR, Watson RR, Martin CR (eds.) *Handbook of behavior, food and nutrition*. Berlin: Springer; 2011. p. 2343–55.
 - 19 Leão AAP. Spreading depression of activity in the cerebral cortex. *J Neurophysiol* 1944a;7:359–90.
 - 20 Dreier JP. The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. *Nat Med* 2011;17:439–47.
 - 21 Leão AAP. Pial circulation and spreading depression of activity in cerebral cortex. *J Neurophysiol* 1944b;7:391–6.
 - 22 Leão AAP. Further observations of the spreading depression of activity in the cerebral cortex. *J Neurophysiol* 1947;10:409–14.
 - 23 Martins-Ferreira H, De Oliveira Castro G, Stuchiner CJ, Rodrigues PS. Liberation of chemical factors during spreading depression in isolated retina. *J Neurophysiol* 1974; 37:785–91.
 - 24 Merkler D, Klinker F, Jürgens T, Glaser R, Paulus W, Brinkmann BG, et al. Propagation of spreading depression inversely correlates with cortical myelin content. *Ann Neurol* 2009;66: 355–65.
 - 25 Rocha-de-Melo AP, Cavalcanti JB, Barros AS, Guedes RCA. Manipulation of rat litter size during suckling influences cortical spreading depression after weaning and at adulthood. *Nutr Neurosci* 2006;9:155–60.
 - 26 Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, Strong AJ. Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. *J Cereb Blood Flow Metab* 2011;31:17–35.
 - 27 Amâncio-dos-Santos A, Pinheiro PCF, Lima DSC, Ozias MG, Oliveira MB, Guimarães NX, et al. Fluoxetine inhibits cortical spreading depression in weaned and adult rats suckled under favorable and unfavorable lactation conditions. *Exp Neurol* 2006;200:275–82.
 - 28 Amaral APB, Barbosa MSS, Souza VC, Ramos ILT, Guedes RCA. Drug/nutrition interaction in the developing brain: dipyrone enhances spreading depression in rats. *Exp Neurol* 2009;219: 492–8.
 - 29 Costa-Cruz RRG, Amâncio-dos-Santos A, Guedes RCA. Characterization of cortical spreading depression in adult well-nourished and malnourished rats submitted to the association of pilocarpine-induced epilepsy plus streptozotocin-induced hyperglycemia. *Neurosci Lett* 2006;401:271–5.
 - 30 Fregni F, Liebetanz D, Monte-Silva KK, Oliveira MB, Amâncio-dos-Santos A, Nitsche MA, et al. Effects of transcranial direct current stimulation coupled with repetitive electrical stimulation on cortical spreading depression. *Exp Neurol* 2007; 204:462–6.
 - 31 Tenorio AS, Oliveira IDVA, Guedes RCA. Early vibrissae removal facilitates cortical spreading depression propagation in the brain of well-nourished and malnourished developing rats. *Int J Dev Neurosci* 2009;27:431–7.
 - 32 Lima DSC, Maia LMSS, Barboza EA, Duarte RA, Souza LS, Guedes RCA. L-glutamine supplementation during the lactation period facilitates cortical spreading depression in well-nourished and early-malnourished rats. *Life Sci* 2009;85:241–7.
 - 33 Poon HF, Calabrese V, Scapagnini G, Butterfield DA. Free radicals and brain aging. *Clin Geriatr Med* 2004;20:329–59.
 - 34 Lynch MA. Analysis of the mechanisms underlying the age-related impairment in long-term potentiation in the rat. *Rev Neurosci* 1998;9:169–201.
 - 35 Guedes RCA, Amorim LF, Teodósio NR. Effect of aging on cortical spreading depression. *Braz J Med Biol Res* 1996;29: 1407–12.
 - 36 Bondy SC. Reactive oxygen species: relation to aging and neurotoxic damage. *Neurotoxicol* 1992;13:87–100.
 - 37 Svensson L, Wu C, Hulthe P, Johannessen K, Engel JA. Effect of ageing on extracellular ascorbate concentration in rat brain. *Brain Res* 1993;609:36–40.
 - 38 Mazel T, Richter F, Vargová L, Syková E. Changes in extracellular space volume and geometry induced by cortical spreading depression in immature and adult rats. *Physiol Res* 2002; 51(Suppl 1):S85–93.
 - 39 Netto M, Martins-Ferreira H. Elicitation of spreading depression by rose bengal photodynamic action. *Photochem Photobiol* 1989;50:229–34.
 - 40 Houba-Herlin N, Galberg-Bacq CM, Piette J, Van de Vorst A. Mechanism for dye-mediated photodynamic action: singlet oxygen production, deoxyguanosine oxidation and phage inactivating efficiencies. *Photochem Photobiol* 1982;36:297–306.
 - 41 Beyer WF, Fridovich I. Assaying for superoxide dismutase activity: some large consequences of minor changes in conditions. *Anal Biochem* 1987;161:559–66.
 - 42 El-Bachá RS, Lima-Filho JL, Guedes RCA. Dietary antioxidant deficiency facilitates cortical spreading depression induced by photo-activated riboflavin. *Nutr Neurosci* 1998;1:205–12.
 - 43 Kuo HC, Lee TC, Chichester CO, Simpson KL. The carotenoids in the deep sea red crab, *Geryon quinque-dens*. *Comp Biochem Physiol B* 1976;54:387–90.
 - 44 Guedes RCA, Frade SF. Effect of ethanol on cortical spreading depression. *Braz J Med Biol Res* 1993;26:1241–4.
 - 45 Bezerra RS, Abadie-Guedes R, Melo FRM, Paiva AMA, Amâncio-dos-Santos A, Guedes RCA. Shrimp carotenoids protect the developing rat cerebral cortex against the effects of ethanol on cortical spreading depression. *Neurosci Lett* 2005; 391:51–5.
 - 46 Bonthius DJ, Pantazis NJ, Karacay B, Bonthius NE, Taggard DA, Lothman EW. Alcohol exposure during the brain growth spurt promotes hippocampal seizures, rapid kindling, and spreading depression. *Alcohol Clin Exp Res* 2001;25:734–45.
 - 47 Nash CM, Ibram F, Dringenber HC, Reynolds JN, Brien JF. Effects of maternal administration of vitamins C and E on ethanol neurobehavioral teratogenicity in the guinea pig. *Alcohol* 2007;41:577–86.
 - 48 Abadie-Guedes R, Santos SD, Cahú TB, Guedes RCA, Bezerra RS. Dose-dependent effects of astaxanthin on cortical spreading depression in chronically ethanol-treated adult rats. *Alcohol Clin Exp Res* 2008;32:1417–21.
 - 49 Dobbins J. Vulnerable periods in developing brain. In: Davison AN, Dobbins J (eds.) *Applied neurochemistry*. Oxford: Blackwell; 1968. p. 287–316.

- 50 Rocha-de-Melo AP, Guedes RCA. Spreading depression is facilitated in adult rats previously submitted to short episodes of malnutrition within the lactation period. *Braz J Med Biol Res* 1997; 30:663–70.
- 51 Monte-Guedes CKR, Alves EVS, Viana-da-Silva E, Guedes RCA. Chronic treatment with ascorbic acid enhances cortical spreading depression in developing well-nourished and malnourished rats. *Neurosci Lett* 2011;496:191–4.
- 52 Aydoğan M, Korkmaz A, Barlas N, Kolankaya D. The effect of vitamin C on bisphenol A, nonylphenol and octylphenol induced brain damages of male rats. *Toxicology* 2008;249:35–9.
- 53 Oliveira MS, Furian AF, Royes LFF, Figuera MR, De Carvalho J, Fiorenza NG. Ascorbate modulates pentylentetrazol-induced convulsions biphasically. *Neuroscience* 2004;128:721–8.
- 54 Song JH, Shin SH, Ross GM. Oxidative stress induced by ascorbate causes neuronal damage in an *in vitro* system. *Brain Res* 2001;895:66–72.
- 55 Serrano F, Klann E. Reactive oxygen species and synaptic plasticity in the aging hippocampus. *Ageing Res Rev* 2004;3:431–43.
- 56 Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? *Nat Med* 2004;(Suppl 10)56(10):S18–25.
- 57 Willis SL, Tennstedt SL, Marsiske M, Ball K, Elias J, Koepke KM, *et al.* Long-term effects of cognitive training on everyday functional outcomes in older adults. *J Am Med Assoc* 2006; 296:2805–14.
- 58 Pop V, Head E, Hill M-A, Gillen D, Berchtold NC, Muggenburg BA, *et al.* Synergistic effects of long-term antioxidant diet and behavioral enrichment on β -amyloid load and non-amyloidogenic processing in aged canines. *J Neurosci* 2010; 30:9831–9.
- 59 Gemma C. Neuroimmunomodulation and aging. *Aging Dis* 2010;1:169–72.
- 60 Chayasirisobhon S. Use of a pine bark extract and antioxidant vitamin combination product as therapy for migraine in patients refractory to pharmacologic medication. *Headache* 2006;46:788–93.
- 61 Viggiano A, Viggiano E, Valentino I, Monda M, Viggiano A, De Luca B. Cortical spreading depression affects reactive oxygen species production. *Brain Res* 2011;1368:11–8.
- 62 Petzold GC, Haack S, von Bohlen Und Halbach O, Priller J, Lehmann TN, Heinemann U, *et al.* Nitric oxide modulates spreading depolarization threshold in the human and rodent cortex. *Stroke* 2008;39:1292–9.

CAPÍTULO III

Title: Antagonizing effect of α -tocopherol on the ethanol action in spreading depression in the rat cortex

Authors: Ricardo Abadie-Guedes¹, Ranilson de Souza Bezerra¹ and Rubem Carlos Araujo Guedes^{2, CA}

Afiliation: ¹Departamento de Bioquímica, CCB, Universidade Federal de Pernambuco, CEP 50670901, Recife, PE, Brazil.

²Departamento de Nutrição, CCS, Universidade Federal de Pernambuco, CEP 50670901, Recife, PE, Brazil.

CA=Corresponding Author; address as #2, above. (e-mail: rguedes@ufpe.br)

Abstract

Background: We have previously demonstrated in rats that acute and chronic treatment with ethanol respectively decelerated and accelerated the propagation of cortical spreading depression (CSD), and the antioxidant carotenoid astaxanthin antagonized such effects (Abadie-Guedes et al, 2008; 2012). However, it remained to clarify whether other non-carotenoid antioxidants would have the same effect. Here we investigated this possibility by testing the alpha-tocopherol.

Methods: Male Wistar adult rats of two age-groups (juvenile [J]; 60-80 days, and adult [A]; 150-170 days; n=8-10 for each group) received per gavage acute (1 day) or chronic treatment (21 days) with 3g/kg/d ethanol combined with 300 ug/kg (acute treatment), or 85ug/kg/d (chronic treatment) of tocopherol, or only vehicle (olive oil for tocopherol and water for ethanol). Under urethane+chloralose anesthesia, the CSD was recorded in two points of the cortical surface during 4h and the CSD velocity of propagation was calculated, based on the time spent for CSD to pass the interelectrode distance.

Results: In both age-groups, acute and chronic ethanol respectively decelerated and accelerated CSD, as compared to the corresponding control (vehicle) groups. Addition of tocopherol to the ethanol treatments antagonized the CSD effects of ethanol, bringing back the CSD velocities to the levels of the vehicle groups ($P < 0.05$; ANOVA plus Tukey test).

Conclusion: Data reinforce the antagonistic role of antioxidants on brain processes involved in CSD, and also suggest that the action of antioxidants on CSD is not a particular property of carotenoids, but rather a general feature of antioxidant molecules.

Introduction

In young and adult humans, the consumption of ethanol (EtOH) is a current worldwide health problem with serious social and physiological implications. This drug is generally of easy access to a large contingent of persons. Also, its amphipathic features enables a prompt action on several organs, like liver, kidney, heart, pancreas, and brain (Lieber, 1995). The production of reactive oxygen species (ROS) by EtOH metabolism results in toxic effects on the brain, mainly because the fact that this drug can easily permeate the brain tissue (Tapiero et al., 2004). Therefore, the investigation of such effects in neurophysiological models can shed light on the mechanisms underlying the brain EtOH actions.

In previous studies, the phenomenon of cortical spreading depression (CSD) has been used in order to investigate the neural protective action of the carotenoids, a particular class of antioxidant molecules, against chronic and acute EtOH effects (Bezerra et al, 2005; Abadie-Guedes et al, 2008; 2012). Initially, this protective effect was observed in the developing brain of rats treated with a shrimp carotenoid extract (Bezerra et al, 2005). As the most abundant carotenoid in shrimps is astaxanthin, we tested whether the protective effect of the shrimp carotenoid extract would be due to astaxanthin. The results confirmed that astaxanthin similarly antagonized the facilitation of CSD induced by *chronic* treatment with ethanol, and this astaxanthin effect was dose-dependent (Abadie-Guedes et al, 2008). We have further investigated the effects of astaxanthin on the *acute* action of ethanol on CSD. In contrast to the chronic treatment, acute ethanol (single dose) decelerated CSD propagation, and this effect was also antagonized by astaxanthin (Abadie-Guedes et al, 2012).

In fact, several studies have reported the antagonizing ethanol effect of different antioxidants (Hancock and Miller, 2006; Tiwari and Chopra, 2011; Ibraim et al, 2012),

and this includes tocopherols (Heaton et al, 2011; Tiwari et al, 2009; Kozan et al, 2007). This molecule plays an important role in modifying the ethanol-induced oxidative stress, acting as proton donator to scavenging reactive oxygen species.

In this study, we investigated the hypothesis that non-carotenoid antioxidant molecules could also antagonize the ethanol effect on CSD, by testing the α -tocopherol, reinforcing the role of antioxidants on brain processes involved in CSD.

Methods

The animals (male Wistar rats) were handled in accordance with the norms of the Ethics Committee for Animal Research of the Universidade Federal de Pernambuco, Brazil, which complies with the “Principles of Laboratory Animal Care”(National Institutes of Health, Bethesda, MD). They were reared in polypropylene cages (51 x 35.5 x 18.5 cm) in a room maintained at $21 \pm 1^\circ\text{C}$ with a 12 hour light/12 hour dark cycle (lights on at 7:00 AM).

Five groups of Wistar young (60 to 80 days of age) and 5 groups of adult rats (150 to 170 days old) received the treatment by gavage (a method consisting of administering substances directly into the stomach through a cannula inserted in the mouth). Two of the five groups (here named groups 1 and 2) received acute treatments (one-day gavage) and the other three groups (named groups 3, 4 and 5) were submitted to chronic treatment (one daily gavage during 21 days). In the moment of the treatment, tocopherol (purchased from Sigma, St. Louis, MO) was dissolved in olive oil, or in ethanol, respectively for the experiments with acute and chronic ethanol treatment. All manipulation of tocopherol was done in absence of light. The young and adult rats of the acute treatment groups received two gavages separated by a 1-hour interval. In gavage I, they received tocopherol (300 mg/kg). One hour later, they received in gavage

II 3 g/kg EtOH (group 1) or water (group 2). In the acute groups, we performed the CSD recordings immediately after the treatment.

The animals of the three groups on chronic treatment (groups 3, 4 and 5) received, during 21 days, a single daily gavage containing ethanol plus tocopherol (groups 3 and 4), or only ethanol (group 5). The reason of treating the chronic groups with only one gavage is to avoid excessive, long-lasting stress represented by two gavages per day during 21 days. In this case, tocopherol was dissolved directly in ethanol (groups 3 and 4). The difference between groups 3 and 4 consisted in the time point when CSD was recorded: group 3 was recorded immediately after the treatment, while group 4 was recorded 5-10 days thereafter (to simulate an “ethanol abstinence period”). In order to avoid excessive accumulation of tocopherol in the tissues, in the chronic groups the dose of tocopherol was reduced from 300mg/kg to 85 mg/kg/day. Finally, in group 5, only ethanol was administered, and CSD was recorded after a 5-10 days abstinence period. The dose of ethanol used in these experiments (3 g/kg) is within the range usually employed in experiments with rodents (Bonthius et al., 2001; Nash et al., 2007) and has been shown to produce blood alcohol levels effective in experimentally altering the nervous system (Nash et al., 2007).

All groups had free access to water and a commercial laboratory chow diet (containing 23 g protein per 100 g diet; Purina do Brazil Ltd, Paulínia, SP, Brazil).

The CSD recording session was carried out, as previously described (Bezerra et al., 2005). Briefly, under anesthesia with a mixture of 1 g/kg urethane plus 40 mg/kg chloralose (Sigma; injected intraperitoneally), a tracheal cannula was inserted and 3 trephine holes were made on the right side of the skull, aligned along the anteroposterior direction and parallel to the midline. One hole was positioned on the frontal bone (2 mm in diameter) and was used to apply the stimulus to elicit CSD. The other 2 holes were

drilled on the parietal bone (3 to 4 mm in diameter) and were used to record the propagating CSD wave. The distance between the centers of contiguous holes was about 3 to 5 mm. Rectal temperature was continuously monitored and maintained at $37\pm 1^{\circ}\text{C}$ by means of a heating blanket. At 20-minute intervals, CSD was elicited by application, for 1 minute, of a cotton ball (1 to 2 mm in diameter) soaked with 2% KCl solution (approximately 270 mM) placed on the frontal cortical surface through the hole drilled on that region. On the 2 parietal holes, both the slow DC-potential change and the reduction in the spontaneous cortical electrical activity accompanying CSD were continuously recorded for 4 hours using a pair of Ag–AgCl agar-Ringer electrodes (1 in each hole), as previously described (Abadie-Guedes et al., 2008). A common reference electrode, of the same type, was placed on the nasal bones (see insert of Fig. 1). The DC-potential changes were recorded by connecting the electrodes to GRASS DC-amplifiers (Astro-Med Industrial Park, West Warwick, RI), and the ECoG was recorded with AC-amplification (band pass filters set at 1 to 35 Hz range). Both DC-recording and ECoG were performed in a model 7-D GRASS chart recorder (Astro-Med Industrial Park). In some experiments, DC-recording was also computer-digitalized and recorded. The CSD velocity of propagation was calculated from the time required for a CSD wave to cover the distance between the 2 cortical electrodes. In the measurement of CSD velocities, we used as a reference the initial point of each DC negative rising phase. Body weight intragroup differences between before and after chronic treatment was analyzed by paired t-test. A repeated measure analysis of variance (ANOVA) followed by a post hoc (Tukey–Kramer) test was used to compare CSD propagation rates between groups. Differences between groups were accepted as significant when $p<0.05$. All values are presented as means \pm S.D.

Results

Body weights

After the 21 days of gavage, the young rats treated chronically displayed a significant weight gain of 12.7%, 22.0% and 21.3% body weights in groups 3, 4 and 5, respectively, as compared to the pre-gavage weight (247.6 ± 21.5 g; $P < 0.05$; paired t-test). In the chronic adult rats, no significant weight gain was observed. Rather, the group 3 (without the “abstinence period”) displayed a 3.8% weight reduction after the 21 days gavage treatment ($P < 0.05$), as compared with the pre-gavage weight (394.6 ± 30.6 g). The groups 4 and 5 presented no weight change.

Cortical Spreading Depression Propagation

Fig. 1 shows the electrophysiological recordings of the slow DC-potential changes during CSD. The CSD eliciting stimulus (application of 2% m/v KCl solution for 1 min on a cortical point in the frontal region) was effective in triggering a single CSD-wave, which propagated and was recorded by the two recording electrodes on the parietal region of the same hemisphere.

Confirming our previous results, the CSD propagation velocities were altered in the groups treated only with ethanol, with acute treatment decelerating, whereas chronic treatment accelerating CSD. In both cases, addition of tocopherol antagonized the ethanol CSD effects, and these findings were observed both in young and adult animals (Figure 2).

In the young groups, the mean \pm s.d. CSD velocities of propagation (in mm/min) were 3.05 ± 0.06 and 4.37 ± 0.31 for the acute and chronic ethanol treated groups; in the

acute tocopherol treatment, with or without ethanol, the CSD velocities were 3.35 ± 0.09 and 3.42 ± 0.16 , respectively; in the chronic tocopherol treatment, the CSD velocity was 3.46 ± 0.12 and 3.25 ± 0.08 , respectively for the groups in which the CSD recordings were taken with or without 5-10 days abstinence from ethanol.

In the adult groups, the CSD velocities were 2.66 ± 0.24 and 3.88 ± 0.31 for the acute and chronic ethanol treatment, respectively; in the acute condition, tocopherol, restored the CSD velocity to 3.21 ± 0.08 and 3.13 ± 0.09 for the groups with or without ethanol, respectively, comparable to the value previously reported for control rats ($P < 0.05$); this effect of tocopherol was also observed in the chronic condition, where the mean velocities were 3.23 ± 0.08 and 3.26 ± 0.08 for the groups in which the CSD recordings were taken with or without 5-10 days abstinence from ethanol.

Discussion

It has been largely accepted that the mechanisms of ethanol action on the brain involve the increase of reactive oxygen species in the tissue [Tapiero et al, 2004]. In this context, the scavenging of reactive oxygen species would be a useful mechanism whereby antioxidant molecules would help in antagonizing the ethanol effects on the brain. In line with this possibility, the present study strongly suggested that α -tocopherol antagonizes the CSD effects of ethanol, in the acute as well as in the chronic condition, in both young and adult rats.

The brain protective effects of antioxidant molecules have been largely discussed in the literature. The clinical and experimental results collectively demonstrate a positive action of antioxidants in counteracting reactive oxygen species occurring in several neurological diseases. Among them, the disturbances provoked by the abusive

consumption of ethanol are of great impact on the human health (Rehm et al, 2010). Several models on laboratory animals have been used to study this problem. Concerning the neurophysiological approach, several authors have demonstrated that the phenomenon of cortical spreading depression can provide useful information on the brain effects of ethanol (Sonn and Mayevsky, 2001; Guedes and Frade, 1993), and these effects are antagonized by the antioxidant carotenoid astaxanthin (Bezerra et al, 2005; Abadie-Guedes et al, 2008; 2012), probably by its scavenging action against reactive oxygen species. In this context, it is interesting to comment that reactive oxygen species produced in the nervous tissue can elicit CSD [Netto and Martins-Ferreira, 1989; El-Bachá et al, 1998).

In the present study, we found that the antagonizing action of α -tocopherol against the ethanol effects on CSD occurred in a way similar to that observed for astaxanthin. These findings support the hypothesis that the previously demonstrated effect of astaxanthin on the ethanol action on CSD is rather a general effect of antioxidant molecules and not a particular property of carotenoids. In fact, other antioxidant molecules, like taurine, have been shown to attenuate the effects of ethanol concerning the oxidative stress (Pushpakiran et al, 2004). Moreover, the comparison of young and adult groups demonstrated that tocopherol effect did not depend on the animal's age. The comparison between CSD velocities of young and adult groups has also confirmed previous evidence in favor of an inverse relationship between CSD velocity and the ages of the animals (Guedes et al, 1996; Batista-de-Oliveira et al, 2012).

The usual ethanol consumption by humans begins with single episodes of intake of alcoholic drinks. As time passes, alcohol ingestion events may become frequent, characterizing the passage from the acute to a chronic consumption. The sudden interruption of long-term frequent ethanol use generates a syndrome known as

abstinence, or withdrawal. The clinical features of abstinence include psychological symptoms like depression and anxiety, and also signs like hyperactivity and tremors. In some cases, rigidity and convulsion may be present and in extreme situations, coma and death may occur. Ethanol abstinence may also increase the production of reactive oxygen species (Jung and Metzger, 2010). When we have compared the group with 5-10 days of abstinence from ethanol (present results) with the group without abstinence (our previous study; Abadie-Guedes et al, 2008), we concluded that, under our experimental conditions, the abstinence did not influence the ethanol effect on CSD propagation.

The contrasting CSD effects produced by acute (Abadie-Guedes et al, 2012) as compared to chronic EtOH treatment (present study) deserve comment. While chronic ethanol accelerates CSD (Guedes and Frade, 1993; Bezerra et al, 2005; Abadie-Guedes et al, 2008), acute ethanol decelerates it (Sonn and Mayevsky, 2001; Abadie-Guedes et al, 2012), suggesting the participation of different mechanisms acting in the two conditions.

In conclusion, our findings confirms the hypothesis of an antagonistic role of antioxidants on brain processes involved in CSD. Since another class of antioxidant (carotenoids; Bezerra et al, 2005; Abadie-Guedes et al, 2008; 2012) had also antagonizing the ethanol effects on CSD, we would postulate that the action of antioxidants on CSD is a general feature of antioxidant molecules.

Acknowledgements

This work was financially supported by FINEP/RECARCINA (1650/10), PETROBRAS, CNPq (558258/2009-3, 475787/2009-9), CAPES (Procad/2007 and Ciencias do Mar/2009), CNPq (INCT de Neurociencia Translacional–No.573604/2008-8), Facepe (APQ0975-4.05/08), and IBN-Net/Finep (No. 4191). RCAG and RSB are Research Fellows from CNPq (No. 301190/2010-0 and 303570/2009-1, respectively).

References

- Abadie-Guedes R, Santos SD, Cahú TB, Guedes RCA, Bezerra RS (2008) Dose-dependent effects of astaxanthin on cortical spreading depression in chronically ethanol-treated adult rats. *Alcohol Clin Exp Res* 32:1417-1421.
- Abadie-Guedes R, Guedes RCA, Bezerra RS (2012) The impairing effect of acute ethanol on spreading depression is antagonized by astaxanthin in rats of two young-adult ages. *Alcohol Clin Exp Res* 36:1563–1567.
- Batista-de-Oliveira M, Lopes AAC, Mendes-da-Silva RF, Guedes RCA (2012) Aging-dependent brain electrophysiological effects in rats after distinct lactation conditions, and treadmill exercise: A spreading depression analysis. *Exp Gerontol* 47:452-457.
- Bezerra RS, Abadie-Guedes R, Melo FRM, Paiva AMA, Amâncio-dos-Santos A, Guedes RCA (2005) Shrimp carotenoids protect the developing rat cerebral cortex against the effects of ethanol on cortical spreading depression. *Neurosci Lett*, 391:51-55.
- Bonthius DJ, Pantazis N, Karacay B, Bonthius NE, Taggard DA, Lothman EW (2001) Alcohol exposure during the brain growth spurt promotes hippocampal seizures, kindling and spreading depression. *Alcohol Clin Exp Res* 25:734–745.
- El-Bachá RS, Lima-Filho JL, Guedes RCA (1998) Dietary antioxidant deficiency

facilitates cortical spreading depression induced by photoactivated riboflavin.
Nutr Neurosci 1:205–212.

Guedes RCA, Amorim LF, Teodósio NR (1996) Effect of aging on cortical spreading depression. Braz J Med Biol Res 29:1407–1412.

Guedes RCA, Frade SF (1993) Effect of ethanol on cortical spreading depression. Braz J Med Biol Res 26:1241–1244.

Hancock ML, Miller RR (2006) Resveratrol can only partially attenuate ethanol-induced oxidative stress in embryonic chick brains. Nutr Neurosci 9:121–129.

Heaton MB, Paiva M, Siler-Marsiglio K (2011) Ethanol influences on Bax translocation, mitochondrial membrane potential, and reactive oxygen species generation are modulated by vitamin E and brain-derived neurotrophic factor. Alcohol Clin Exp Res 35:1122-133.

Ibrahim M, Hassan W, Meinerz DF, Leite GO, Nogueira CW, Rocha JB (2012) Ethanol-induced oxidative stress: the role of binaphthyl diselenide as a potent antioxidant. Biol Trace Elem Res 147:309-314.

Kozan R, Ayyildiz M, Yildirim M, Agar E (2007) The influence of ethanol intake and its withdrawal on the anticonvulsant effect of alpha-tocopherol in the penicillin-induced epileptiform activity in rats. Neurotoxicol 28:463-470.

Lieber CS (1995) Medical disorders of alcoholism. *New Engl J Med* 333:1058–1065.

Jung ME, Metzger DB (2010) Alcohol Withdrawal and Brain Injuries: Beyond Classical Mechanisms. *Molecules* 15:4984-5011.

Nash CM, Ibram F, Dringenber HC, Reynolds JN, Brien JF (2007) Effects of maternal administration of vitamins C and E on ethanol neurobehavioral teratogenicity in the guinea pig. *Alcohol* 41:577–586.

Netto M, Martins-Ferreira H (1989) Elicitation of spreading depression by rose bengal photodynamic action. *Photochem Photobiol* 50:229–234.

Pushpakiran G, Mahalakshmi K, Anuradha CV (2004) Taurine restores ethanol-induced depletion of antioxidants and attenuates oxidative stress in rat tissues. *Amino Acids* 27:91–96.

Rehm J, Baliunas D, Borges GLG, Graham K, Irving H, Kehoe T, Parry CD, Patra J, Popova S, Poznyak V, Roerecke M, Room R, Samokhvalov AV, Taylor B (2010) The relation between different dimensions of alcohol consumption and burden of disease: an overview. *Addiction* 105:817–843.

Sonn J, Mayevsky A (2001) The effect of ethanol on metabolic, hemodynamic and electrical responses to cortical spreading depression. *Brain Res* 908:174–186.

Tapiero H, Townsend DM, Tew KD (2004) The role of carotenoids in the prevention of human pathologies. *Biomed Pharmacother* 58:100–110.

Tiwari V, Kuhad A, Chopra K (2009) Suppression of neuro-inflammatory signaling cascade by tocotrienol can prevent chronic alcohol-induced cognitive dysfunction in rats. *Behav Brain Res* 203:296-303.

Tiwari V, Chopra K (2011) Resveratrol prevents alcohol-induced cognitive deficits and brain damage by blocking inflammatory signaling and cell death cascade in neonatal rat brain. *J Neurochem* 117:678–690.

Figure legends

Fig. 1. Examples of recordings of the slow potential changes (P) occurring during cortical spreading depression (CSD) in two young rats (60-80 days of life; upper panels) and two adult animals (150-170 days; lower panels). The 2 animals of the right panels were chronically treated with ethanol (3 g/kg/day, per gavage, for 21 days). The two rats in the left panels received ethanol plus tocopherol (85 µg/kg/day, for the same period). In each panel, the black horizontal bar indicates the time (1 minute) of application of a cotton ball (1 to 2 mm diameter) of 2% KCl, which usually elicited a single episode of CSD. The central inset shows the recording positions 1 and 2 (on the parietal cortex) and the position of the reference electrode (R), on the nasal bones, as well as the place of KCl stimulus (on the frontal cortex). Traces marked with P1 and P2 are CSD recordings obtained in the cortical points 1 and 2, respectively. Vertical calibration bars equal 10 mV for the P-recordings (negative upward). The vertical interrupted lines delimit the latency for a CSD wave to propagate from cortical point 1 to point 2. Note that in the tocopherol-treated rats the latencies are longer as compared to the corresponding animals treated only with ethanol.

Fig. 2. Effect of α -tocopherol on the acute and chronic ethanol actions in the propagation velocity of cortical spreading depression (CSD) of young and adult rats. In each age group, treatments with ethanol and tocopherol, administered isolated or combined, were compared with controls treated with the vehicles (see convention in the upper part of the figure). T = tocopherol; E = ethanol; W = water. Data are expressed as

mean \pm S.D. Asterisks indicate that the groups chronically treated with ethanol have higher CSD velocities as compared with the corresponding tocopherol controls. The symbol # indicates that the groups acutely treated with ethanol (data from our previous study; Abadie-Guedes et al, 2012) display lower CSD velocities than the tocopherol controls ($P < 0.05$; ANOVA plus Tukey test).




Figura 1




Figura 2

5. CONCLUSÕES

Os resultados deste trabalho demonstraram efeitos opostos do álcool sobre a atividade elétrica do córtex cerebral, a depender da duração do consumo (agudo ou crônico). Foi verificado também que tanto os antioxidantes astaxantina quanto o α -tocoferol antagonizaram a ação do álcool sobre o sistema nervoso, o que sugere um efeito protetor contra espécies químicas reativas formadas, no modelo de estresse oxidativo (consumo de etanol) utilizado neste trabalho. A idade foi um fator que não influenciou na interação do álcool e das moléculas antioxidantes utilizadas no experimento. Na etapa em que foi avaliado se outro antioxidante, não carotenoide (tocoferol), promoveria efeito similar à astaxantina (verificado em estudos anteriores, BEZERRA et al., 2005). Os resultados comprovaram essa hipótese, indicando que a ação antagonista sobre o efeito do etanol na DAC não seria uma propriedade particular da astaxantina, mas provavelmente uma característica geral de moléculas antioxidantes.

Os resultados referentes ao primeiro objetivo acima originaram um artigo que foi publicado na revista ***Alcoholism: Clinical and Experimental Research*** (ABADIE-GUEDES et al, 2012). Os resultados referentes aos outros objetivos originaram outro artigo (anexo a esta tese), a ser submetido para publicação, também na revista acima.

Adicionalmente, o doutorando participou como co-autor de um trabalho de revisão sobre o uso da depressão alastrante cortical para o estudo da ação de antioxidantes no cérebro. Este trabalho foi recentemente publicado na revista *Nutritional Neuroscience* (GUEDES et al, 2012).

ANEXO I

Normas da revista à qual o segundo artigo da tese será submetido



Alcoholism: Clinical and Experimental Research

© Research Society on Alcoholism



Edited By: Ivan Diamond, Editor-in-Chief, and Harriet de Wit, Deputy Editor

Impact Factor: 3.343

ISI Journal Citation Reports © Ranking: 2011: 4/14 (Substance Abuse)

Online ISSN: 1530-0277

Author Guidelines

NIH Public Access Mandate

For those interested in the Wiley-Blackwell policy on the NIH Public Access Mandate, please visit our [policy statement](#). Frequently asked questions are answered [here](#).

Author Guidelines

Alcoholism: Clinical and Experimental Research is the official publication of the Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism. It is a peer-reviewed, multidisciplinary journal that

publishes papers based on original research that make substantial contributions to the understanding of the etiology, treatment, and prevention of alcohol-related disorders. Two kinds of papers may be submitted, full-length papers and critical reviews. Papers that the editors consider to have cross-disciplinary interest and significance may be highlighted as Feature Articles. The journal will also publish invited mini reviews and editorial commentaries.

Ethical/Legal Considerations

Note to NIH Grantees: Pursuant to NIH mandate, Wiley-Blackwell will post the accepted version of contributions authored by NIH grant-holders to PubMed Central upon acceptance. This accepted version will be made publicly available 12 months after publication. For further information, see www.wiley.com/go/nihmandate.

A submitted manuscript must be an original contribution not previously published (except as an abstract or a preliminary report), must not be under consideration for publication elsewhere, and, if accepted, must not be published elsewhere in similar form, in any language, without the consent of Wiley-Blackwell. Each person listed as an author is expected to have participated in the study to a significant extent. Although the editors and referees make every effort to ensure the validity of published manuscripts, the final responsibility rests with the authors, not with the Journal, its editors, or the publisher. **All manuscripts must be submitted on-line through the journal's Web site at <http://mc.manuscriptcentral.com/acer>. See submission instructions under 'On-line manuscript submission.'**

Patient anonymity and informed consent: It is the author's responsibility to ensure that a patient's anonymity be carefully protected and to verify that any experimental investigation with human subjects reported in the manuscript was performed with informed consent and following all the guidelines for experimental investigation with human subjects required by the institution(s) with which all the authors are affiliated. Authors should mask patients' eyes and remove patients' names from figures unless they obtain written consent from the patients and submit written consent with the manuscript.

Research ethics. You will be asked during online submission to confirm that your study has been approved by relevant bodies (e.g. institutional review boards, research ethics committees) and that appropriate consent was obtained for studies involving human or animal participants.

Permissions: Authors must submit written permission from the copyright owner (usually the publisher) to use direct quotations, tables, or illustrations that have appeared in copyrighted form elsewhere, along with complete details about the source. Any permissions fees that might be required by the copyright owner are the responsibility of the authors requesting use of the borrowed material, not the responsibility of Wiley-Blackwell.

Manuscript Submission

On-line manuscript submission: All manuscripts must be submitted on-line through the journal's Web site at <http://mc.manuscriptcentral.com/acer>. First-time users: Please click the Register button from the menu and enter the requested information. On successful registration, you will be sent an e-mail indicating your user name and password. Print a copy of this information for future reference. Note: If you have received an e-mail from us with an assigned user ID and password, or if you are a repeat user, do not register again; just log in. Once you have an assigned ID and password, you do not need to re-register, even if your status changes (that is, author, reviewer, or editor). Authors: Please click the log-in button from the menu at the top of the page and log into the system as an Author. Submit your manuscript according to the author instructions. You will be able to track the progress of your manuscript through the system. If you experience any problems, please contact Mary Newcomb, Acerjournal@earthlink.net, or by calling (317) 375-0819. You may also contact Lisa Daitch, Associate Managing Editor, LDaitchACER@gmail.com, or by calling (925) 915-0271. Requests for help and other questions will be addressed in the order received.

Authors who submit a manuscript do so with the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Research Society on Alcoholism.

Articles, editorials, letters to the editor, and other text material in the journal *Alcoholism: Clinical and Experimental Research* represent the opinions of the authors and do not reflect the opinions of the Research Society on Alcoholism, the International Society for Biomedical Research on Alcoholism, the publisher, or the institution with which the author is affiliated, unless the contrary is clearly specified. All papers are subject to peer review by a Review Editor (member of the Board of Review Editors, the Editor, and the Associate Editors) and one or two referees. Authors may suggest up to four, and disqualify two, potential referees.

A cover letter signed by all authors must accompany the manuscript. The letter should state that: a) the submitted manuscript has been read and approved by all signatories, b) all authors acknowledge that they have exercised due care in ensuring the integrity of the work, and c) none of the original material contained in the manuscript has been submitted for consideration nor will any of it be published elsewhere except in abstract form in connection with scientific meetings.

Requirements for authorship are: (1) substantial contribution to conception, design, gathering, analysis and/or interpretation of data and (2) contribution to the writing and intellectual content of the article.

Page Charges

Manuscripts accepted for publication in *Alcoholism: Clinical and Experimental Research* will be assessed a page charge of \$60.00 (U.S.) per printed page to cover, in part, the cost of publication. Color pages will be assessed a page

charge of \$650. Editorial consideration of a manuscript is in no way related to the author's ability to assume the page charge, but it is expected that this charge will be paid by the author's research funds that supported the research. Requests for waiver of page charges will be considered at the time of acceptance, if rationale can be provided.

OnlineOpen

OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, see: http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms.

Any authors wishing to send their paper OnlineOpen will be required to complete the payment form available from our website [here](#).

Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.

If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.

For authors signing the copyright transfer agreement

If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:

CTA Terms and Conditions

http://authorservices.wiley.com/bauthor/faqs_copyright.asp

For authors choosing OnlineOpen

If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):

Creative Commons Attribution Non-Commercial License OAA

Creative Commons Attribution Non-Commercial -NoDerivs License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services

http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit <http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html>.

If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal's compliant self-archiving policy please visit: <http://www.wiley.com/go/funderstatement>.

For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this license:

Creative Commons Attribution License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services

http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit <http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html>.

Types of Papers

The following types of articles may be submitted for publication in the journal.

Manuscripts exceeding the word and reference limitations will be returned without review.

- Critical Review articles **are not to** exceed 4500 words (excluding title page, abstract, references, figure legends, tables, and figures.) **References are not to exceed 50.**

- Original Research **are not to** exceed 4500 words (excluding title page, abstract, references, figure legends, tables, and figures.) **References are not to exceed 50.** It should be noted that Alcoholism: Clinical & Experimental Research does not impose a minimum length on original research articles.

-Commentaries **are not to exceed** 2500 words (excluding title page, abstract, references, figure legends, tables and figures) and 20 references.

Preparation of Manuscript

Please ensure that all text (including abstract, body of manuscript, figure legends, and references) is submitted as double-spaced type. **We also require all text be line-numbered.** Manuscripts that do not adhere to the following instructions will be returned to the corresponding author for technical revision before undergoing peer review.

Title page:

The title page should include:

- The complete manuscript title
- The full names of all authors, their highest academic degrees, and affiliations
- Name and address for correspondence, including fax number, telephone number, and e-mail address
- All sources of support, including pharmaceutical and industry support, that require acknowledgement

Manuscripts that do not adhere to the following instructions will be returned to the corresponding author for technical revision before undergoing peer review.

Structured abstract and key words: The article should be briefly summarized or abstracted in a short paragraph (approximately 300 words) at the beginning of the text on a separate page. It should contain 4 elements labeled: Background, Methods, Results, and Conclusions. At the end of the paragraph, provide no more than 5 key words or phrases.

Text: Organize the manuscript into four main headings: Introduction, Materials and Methods, Results, and Discussion. Define abbreviations at first mention in text and in each table and figure. If a brand name is cited, supply the manufacturer's name and address (city and state/country).

Abbreviations: For a list of standard abbreviations, consult the Council of Biology Editors Style Guide (available from the Council of Science Editors, 9650 Rockville Pike, Bethesda, MD 20814) or other standard sources. Write out the full term for each abbreviation at its first use unless it is a standard unit of measure.

References: The authors are responsible for the accuracy and completeness of information contained in the references. The journal uses **Harvard Style for Referencing**.

-Citation

Cite references in the text by name and year in parentheses. Several publications by the same author or group should be listed in chronological order; those that appeared in the same year should be distinguished by a,b,c, etc. Where there are two authors, both should be named, but with three or more only the first author's name plus "et al." should be given.

-Reference List

The list of references should only include works that are cited in the text and have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes

or endnotes as a substitute for a reference list. Reference list entries should be alphabetized by the last names of the first author of each work. References should be compiled (**double-spaced**) at the end of the article in alphabetical order. Identify multiple authors published in the same year with an a,b,c, etc. after the year. In-text citations should be listed by author name(s) and year of publication in parentheses.

Journal article, list all authors

1. Aragon CMG, Spivak K, Amit Z (1991a) Effect of 3-amino-1,2,4-triazole on ethanol-induced narcosis, lethality and hypothermia in rats. *Pharmacol Biochem Behav* 39:55-59.

Aragon CMG, Stotland LM, Amit Z (1991b) Studies on ethanol-brain catalase interaction: evidence for central ethanol oxidation. *Alcohol Clin Exp Res* 15:165-169.

Book chapter

2. Holtzman SG (1990) Discriminative stimulus effects of drugs: relationship to potential for abuse, in *Modern Methods in Pharmacology*, Vol. 6, Testing and Evaluation of Drugs of Abuse (Adler M, Cowan A eds), pp 193-210. Wiley-Liss, New York.

Entire book

3. Julien RM (1985) *A Primer of Drug Action*. 4th ed. WH Freeman, New York.

Software

4. Epi Info [computer program]. Version 6. Atlanta, GA: Centers for Disease Control and Prevention; 1994.

Online journals

5. Friedman SA. Preeclampsia: a review of the role of prostaglandins. *Obstet Gynecol* [serial online]. January 1988;71:22-37. Available from: BRS Information Technologies, McLean, VA. Accessed December 15, 1990.

Database

6. CANCERNET-PDQ [database online]. Bethesda, MD: National Cancer Institute; 1996. Updated March 29, 1996.

World Wide Web

7. Gostin LO. Drug use and HIV/AIDS [JAMA HIV/AIDS Web site]. June 1, 1996. Available at: <http://www.ama-assn.org/special/hiv/ethics>. Accessed June 26, 1997.

Figures: There are three preferred formats for digital artwork submission: Encapsulated PostScript (EPS), Portable Document Format (PDF), and Tagged Image Format (TIFF). We suggest that line art be saved as EPS files. Alternately, these may be saved as PDF files at 600 dots per inch (dpi) or better at final size. Tone art, or photographic images, should be saved as TIFF files with a resolution of 300 dpi at final size. For combination figures, or artwork that contains both photographs and labeling, we recommend saving figures as EPS files, or as PDF files with a resolution of 600 dpi or better at final size. More

detailed information on the submission of electronic artwork can be found at <http://authorservices.wiley.com/bauthor/illustration.asp>

Each figure should be submitted individually - one file per figure.

Figure legends: Include legends for all figures. They should be brief and specific, and they should appear on a separate manuscript page after the references. Use scale markers in the image for electron micrographs, and indicate the type of stain used.

Color figures: The journal accepts for publication color figures that will enhance an article. Authors who submit color figures will be assessed a charge of \$650 per color page to cover the cost for color reproduction. If they decide not to pay for color reproduction, they can request that the figures be converted to black and white at no charge.

Tables: Create tables using the table creating and editing feature of your word processing software (eg, Word, WordPerfect). Do not use Excel or comparable spreadsheet programs. Each table should include the table title, appropriate column heads, and explanatory legends (including definitions of any abbreviations used). Tables should be self-explanatory and should supplement, rather than duplicate, the material in the text. Cite tables consecutively in the text, and number them in that order. Tables may be submitted at the end of the manuscript text file. Table legends should appear on a separate page, labeled 'Table Legends'.

Supplementary material: If you have supplementary information that you would like to link to your submission, please read the following instructions: <http://authorservices.wiley.com/bauthor/supinfo.asp>

Style: Pattern manuscript style after the *American Medical Association Manual of Style* (10th edition). *Stedman's Medical Dictionary* (28th edition) and *Merriam Webster's Collegiate Dictionary* (11th edition) should be used as standard references. Refer to drugs and therapeutic agents by their accepted generic or chemical names, and do not abbreviate them. Use code numbers only when a generic name is not yet available. In that case, supply the chemical name and a figure giving the chemical structure of the drug. Capitalize the trade names of drugs and place them in parentheses after the generic names. To comply with trademark law, include the name and location (city and state in USA; city and country outside USA) of the manufacturer of any drug, supply, or equipment mentioned in the manuscript. Use the metric system to express units of measure and degrees Celsius to express temperatures. Please submit all text (including abstract, figures, legends, and references) as double-spaced.

Manuscript Revisions

All manuscript revisions should be submitted online within three months following the editor's decision. If this is not enough time in which to make your revisions, please contact the Editorial Office for an extension. If you do not request an extension and your revisions are not submitted within six months,

your manuscript will be withdrawn by the editorial office. At that point, any further work by you will be considered as a new submission.

After Acceptance

Author Services: Author Services enables authors to track their article – once it has been accepted – through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The author will receive an e-mail with a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript. Visit <http://authorservices.wiley.com/bauthor/> for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.

Page proofs and corrections: Corresponding authors will receive electronic page proofs to check the copyedited and typeset article before publication. Portable document format (PDF) files of the typeset pages and support documents (eg, reprint order form) will be sent to the corresponding author by e-mail. Complete instructions will be provided with the e-mail for downloading and printing the files and for faxing the corrected page proofs to the publisher. It is the author's responsibility to ensure that there are no errors in the proofs. Changes that have been made to conform to journal style will stand if they do not alter the authors' meaning. Only the most critical changes to the accuracy of the content will be made. Changes that are stylistic or are a reworking of previously accepted material will be disallowed. The publisher reserves the right to deny any changes that do not affect the accuracy of the content. Authors may be charged for alterations to the proofs beyond those required to correct errors or to answer queries. Proofs must be checked carefully and corrections faxed within 24 to 48 hours of receipt, as requested in the cover letter accompanying the page proofs.

Offprints: Free access to the final PDF offprint of your article will be available via Wiley-Blackwell's Author Services. Please register to access your article PDF offprint and enjoy the many other benefits the service offers. Visit <http://authorservices.wiley.com/bauthor/> to register.

If you wish to order reprints from this journal please click on the following link: <https://caesar.sheridan.com/reprints/redirect.php?pub=10089&acro=ACER>

NEW: Pre-acceptance English-language editing

Authors for whom English is a second language may choose to have their manuscript professionally edited before submission or during the review process. Authors wishing to pursue a professional English-language editing service should make contact and arrange payment with the editing service of their choice. For more details regarding the recommended services, please refer to http://www.blackwellpublishing.com/bauthor/english_language.asp.

ANEXO II

Shrimp carotenoids protect the developing rat cerebral cortex against the effects of ethanol on cortical spreading depression

Ranilson de Souza Bezerra^{a,c}, Ricardo Abadie-Guedes^a, Flávio Roberto Mendonça Melo^a,
Ana Maria de Albuquerque Paiva^b, Ângela Amâncio-dos-Santos^b,
Rubem Carlos Araújo Guedes^{b,c,*}

^a Departamento de Bioquímica, CCB, Universidade Federal de Pernambuco, 50670-901 Recife, PE, Brazil

^b Departamento de Nutrição, CCS, Universidade Federal de Pernambuco, 50670-901 Recife, PE, Brazil

^c Laboratório de Imunopatologia Keizo Asami, Universidade Federal de Pernambuco, 50670-901 Recife, PE, Brazil

Received 22 June 2005; received in revised form 17 August 2005; accepted 17 August 2005

Abstract

Cortical spreading depression is a neural phenomenon present in several animal species. Spreading depression features, like velocity of propagation, depends on several chemical and metabolic factors, as for example, anti-oxidants. Here we studied spreading depression-velocity changes in weaned rat-pups born from dams treated on a daily basis, either during gestation or lactation, with a carotenoid ethanolic extract (30 µg/kg/day) prepared from shrimp waste (heads). These pups were compared with age-mated ones, whose mothers were treated either with the vehicle (ethanol) or with distilled water. Compared to the distilled water-group (mean values, in mm/min, per hour of recording ranging from 3.02 ± 0.26 to 3.15 ± 0.27 [treatment during gestation; $n = 7$], and from 3.03 ± 0.25 to 3.22 ± 0.30 [lactation; $n = 11$]), ethanol-treated rats displayed higher spreading depression-velocities (from 3.74 ± 0.06 to 3.82 ± 0.08 [gestation; $n = 7$], and from 4.26 ± 0.32 to 4.33 ± 0.34 [lactation; $n = 11$]; $p < 0.05$). Compared to the ethanol-group, carotenoid-treatment lead to lower spreading depression-velocities ($p < 0.05$), ranging from 3.38 ± 0.09 to 3.42 ± 0.12 , $n = 7$ (gestation) and 3.58 ± 0.13 to 3.62 ± 0.17 , $n = 12$ (lactation). Carotenoid-treatment during lactation was shown to be significantly more effective than that during gestation ($p < 0.05$), in lowering spreading depression-velocity. The results suggest a protective action of shrimp carotenoids against the ethanol effects on spreading depression. This protective effect could be related to the carotenoid antioxidant properties, as previously indicated by evidence showing spreading depression-effects of other antioxidants.

© 2005 Elsevier Ireland Ltd. All rights reserved.

Keywords: Spreading depression; Shrimp carotenoids; Ethanol; Brain development; Antioxidants; Free radical injury

Spreading depression of brain electrical activity is a phenomenon first described in the rabbit cerebral cortex by Leão [21] as a propagating “wave” of suppression of the spontaneous electrical activity in response to stimulation of one point on the cortical surface. Concomitantly with the electrocorticographic depression, a slow negative potential change [22], as well as other spreading depression typical features, like transmembrane water- and ion flow [18], have been shown to occur.

The exact nature of the processes underlying spreading depression continues to be an object of much investigation. Roles have been suggested for some ions, like potassium [9], chloride

[15], and calcium [34], as well as for excitatory amino acids [12,38] and other neurotransmitters [3,10,13,14,33]. Evidence is also available suggesting a possible role for reactive oxygen species in spreading depression [6,7,26]. The deleterious reactive oxygen species action on the nervous tissue can be counteracted, under physiological conditions, by antioxidant substances like carotenoids [17,30]. These molecules are lipophilic and tend to accumulate in lipophilic compartments, like membranes or lipoproteins. In those places, they exert their scavenging effects, protecting against reactive oxygen species produced in certain pathological states, like alcoholism [37]. Animals are not biochemically capable of biosynthesizing carotenoids, but they can accumulate and/or convert precursors, which they obtain from the diet. In crustaceans, they are present as a carotenoprotein in some associations in the carapace, legs parts, blood, eyes, eggs, hepatopancreas and ovary [20].

* Corresponding author. Tel.: +55 81 21268936; fax: +55 21 2126 8473.
E-mail address: rc.guedes@terra.com.br (R.C.A. Guedes).

The main purpose of the present study is to analyze the occurrence of spreading depression-changes in weaned rat-pups born from dams treated either during gestation or lactation, with a shrimp-carotenoid ethanolic extract. An abstract containing part of the present results has appeared [1].

The shrimp (*Litopenaeus vannamei*) processing waste (heads) was provided by EMPAF Ltd. The waste was packed in plastic bags and stored at -20°C before use. The protease used was Alcalase (2.41 FG) provided by Novozyme Brazil S.A. All others reagents used were of analytical grade, provided by Sigma or Merck.

In a reaction vessel (100 mL), shrimp heads (30 g) were minced and mixed with 30 mL of 0.5% Alcalase solution. The proteolytic hydrolysis was carried out for 2 h at 40°C . Afterwards, the protease was inactivated by heating (100°C for 10 min), and the supernatant and carotenoprotein (sediment) were separated by centrifugation at $10,000 \times g$ for 10 min [8]. Then, the carotenoids were extracted using 90% (v/v) ethanol. Carotenoid concentration and pigment amounts were calculated according to Davies [4] following the formula: $Q = (\text{OD} \times V)/E$, where Q denotes carotenoids amounts (μg); OD stands for optical density (470 nm); V is the volume (mL); and $E = 2500$ (astaxanthin specific extinction coefficient). Ethanolic extraction was carried out in absence of light and in a N_2 atmosphere.

The rats utilized in this study were handled in accordance with the “Principles of Laboratory Animal Care” (National Institutes of Health, USA) and with the norms of the Ethics Committee for Animal Research of the Universidade Federal de Pernambuco. They were reared in polyethylene cages ($51 \text{ cm} \times 35.5 \text{ cm} \times 18.5 \text{ cm}$) in a room maintained at $21 \pm 1^{\circ}\text{C}$ with a 12 h light/12 h dark cycle (lights on at 7:00 a.m.). Female Wistar rats received, either during gestation days 7–21 or during lactation days 7–25, per gavage, $30 \mu\text{g/kg/day}$ of carotenoids extracted from shrimps and diluted in ethanol (3.8 mL/kg). Their pups were compared to pups, born from dams which had been treated in the same way either with the vehicle (ethanol-group) or with distilled water. After weaning (25th postnatal day), pups were fed the same lab chow diet, previously given to their mothers (Purina do Brasil Ltd. containing 23 g protein/100 g diet), until the day of the electrophysiological recording (36–40 days). For that purpose, the animal was intraperitoneally anesthetized with a mixture of 1 g/kg urethane plus 40 mg/kg chloralose. A tracheal cannula was inserted and three trephine holes were made on the right side of the skull. These holes were aligned in the anteroposterior direction and parallel to the midline. One hole was positioned on the frontal bone (2 mm in diameter) and was used to apply the stimulus to elicit spreading depression. The other two holes were drilled on the parietal bone (3–4 mm in diameter) and were used to record the propagating spreading depression wave. Rectal temperature was continuously monitored and maintained at $37 \pm 1^{\circ}\text{C}$ by means of a heating blanket.

Cortical spreading depression was elicited at 20 min intervals by 1 min application of a cotton ball (1–2 mm in diameter) soaked in 2% KCl solution, applied to the anterior hole, drilled at the frontal region. Both the slow potential change and the spontaneous cortical electrical activity accompanying spreading depression were continuously recorded for 4 h, by using a pair

of Ag–AgCl agar-Ringer electrodes (one in each hole). These electrodes consisted of 5 cm-long plastic conic pipettes (0.5 mm tip inner diameter), filled with Ringer solution, solidified with the addition of 0.5% agar, into which a chlorided silver wire was inserted. The pipettes were fixed together with cyanoacrylate glue, so that the interelectrode distance was kept constant. Each pair of electrodes was connected to a lever, which could be vertically moved by turning around a screw, so that the electrode tips could be gently placed on the intact dura-mater, under low-power microscope control, without any excessive pressure on the cortical surface. A common reference electrode, of the same type, was placed on the nasal bones (see inset of Fig. 1).




Fig. 1. Recordings of spontaneous cortical electrical activity (ECoG; two upper traces in each panel) and slow potential change (P; two lower traces) during spreading depression in rats whose mothers had been treated, either during gestation or during the lactation period, with ethanolic extract of shrimp carotenoids ($30 \mu\text{g/kg/day}$; groups E + C), or equivalent volumes (3.8 mL/kg/day) of vehicle (ethanol; group E). Spreading depression was elicited by applying a cotton ball (1–2 mm diameter) soaked in 2% KCl solution for 1 min, on the frontal cortex. Upwards and downwards arrows indicate respectively the beginning and the end of KCl stimulation. The right hemisphere inset shows the recording positions 1 and 2 (on the parietal cortex) and the position of the reference electrode (R), on the nasal bones, as well as the place of KCl stimulus (on the frontal cortex). The distance between the cortical electrodes was 4.0 mm in all examples in this figure. Note the slower spreading rates in the carotenoid-treated animals, as compared to the respective vehicle-treated controls. Vertical calibration bars equal 1 mV for the ECoG- and 10 mV for the P-recordings.




Fig. 2. Reduction of spreading depression-velocity in just-weaned rat pups (36–40 days of life) whose mothers had been treated with an ethanolic extract of shrimp carotenoids (30 μ g/kg/day), either during the gestation or during the lactation period, as compared to corresponding vehicle- (ethanol; 3.8 mL/kg) and distilled water-treated controls. Data are expressed as mean \pm standard deviation, per hour of recording. All groups were shown to be statistically different from each other (ANOVA plus Tukey test; $p < 0.05$). Insets show body weights. Values marked with distinct letters are significantly different (ANOVA plus Tukey-test; $p < 0.05$). E, E + C and DW refers to ethanol-, ethanol plus carotenoid- and distilled water-treatment, respectively.

The spreading depression velocity of propagation was calculated from the time required for a spreading depression wave to pass the distance between the two cortical electrodes (time between the two slow potential initial rising phases).

Body weights and spreading depression propagation rates were compared between groups by ANOVA, followed by a post-hoc (Tukey–Kramer) test, when indicated. Differences between groups were accepted as significant at the 95% confidence level ($p < 0.05$). All values are presented as means \pm standard deviations.

Application of KCl for 1 min on a cortical point in the frontal region was very effective in eliciting a single spreading depression-wave, which propagated without interruption and was recorded on the parietal region of the same hemisphere, as documented by the electrophysiological recordings (electrocorticogram and slow potential changes) shown in Fig. 1. Since KCl-elicited spreading depression episodes were obtained at 20 min intervals, three measurements of spreading depression-velocity could be obtained in each hour of recording, and the mean velocity per hour could be calculated. The two distilled water-groups, born from mothers treated with distilled water during gestation ($n = 7$) and during lactation ($n = 11$) displayed mean spreading depression velocities (in mm/min) ranging respectively from 3.02 ± 0.26 to 3.15 ± 0.27 (distilled water during gestation), and from 3.03 ± 0.25 to 3.22 ± 0.30 (lactation). Compared to the distilled water-controls, ethanol treatment, both during gestation ($n = 7$) and lactation ($n = 11$), increased significantly ($p < 0.01$) the spreading depression-velocities. The mean values ranged respectively from 3.74 ± 0.06 to 3.82 ± 0.08 (ethanol-treatment during gestation), and from 4.26 ± 0.32 to 4.33 ± 0.34 (lactation). The carotenoid-treated groups displayed intermediate spreading depression velocities, significantly lower than those of the respective ethanol-groups, but higher than those of the distilled water-animals ($p < 0.05$). The carotenoid-rat velocities ranged from 3.38 ± 0.09 to 3.42 ± 0.12 , (maternal

carotenoid ethanolic extract-treatment during gestation; $n = 7$), and from 3.58 ± 0.13 to 3.62 ± 0.17 , (lactation; $n = 12$). These data are presented at Fig. 2.

On the day of spreading depression-recording, both ethanol- and carotenoid-groups treated during gestation presented body weights lower ($p < 0.05$) than the distilled water controls (respectively 75.7 ± 2.3 , 73.4 ± 6.6 , and 102.2 ± 15.1 g). In contrast, ethanol- and carotenoid-treatment during lactation lead to mean weights higher than the corresponding distilled water-control, but the differences did not attain statistical significance (respectively 124.2 ± 16.3 , 128.7 ± 30.7 and 112.1 ± 10.5 g). Body weight data are presented as inset in Fig. 2.

Ethanol is the most frequent abused drug, mostly among young adults and adolescents. Its ingestion produces a wide variety of pathological disturbance affecting a number of organs. Due to the fact of being a small molecule, soluble in both lipids and water, it permeates all tissues of the body and affects most vital functions of virtually all organs, including liver, kidney, heart, pancreas and brain, [23]. In line with this view, we found a decrease in pup body weights, in the groups treated with ethanol during gestation, as compared to the distilled water-control group. Treatment during lactation resulted in a tendency to higher body weights in comparison to the distilled water-group, but the difference was not significant. It is interesting to note that an improvement of lactation outcome, associated with ethanol treatment, has been recently described in malnourished rats [36].

Concerning the spreading depression effects, it has previously been demonstrated that adult rats treated with ethanol for 7 days became more susceptible to spreading depression, in comparison with distilled water-treated controls, as judged by the higher spreading depression velocities [16]. The present data showed similar spreading depression-effects (increase in velocity) in the weaned rat pups, whose mothers had been treated with ethanol both during gestation and suckling, as compared to the distilled water-controls. The ethanol-treatment during

the suckling period was more effective in facilitating spreading depression propagation than the treatment during gestation. Data also indicated a higher effectiveness, in the lactation group, of the shrimp carotenoid protective action against the ethanol effect on spreading depression. These results are in agreement with the well-established fact that the suckling period is more relevant to spreading depression-effects, as well as to a number of other biochemical and physiological alterations, than the gestation phase [5,25,32].

Excessive alcohol intake characterizes a situation, which can lead to a toxic degeneration in several organs. Under this condition, lipid peroxidation increases, as a consequence of increased oxidative stress produced by ethanol intake and its subsequent oxidation [31]. Increases in the rate of lipid peroxidation can enhance reactive oxygen species formation, which is potentially injurious to the brain tissue [2]. The reactive oxygen species effects are usually counteracted by homeostatic mechanisms, under physiological conditions. These homeostatic mechanisms involve the participation of antioxidant substances, like ascorbic acid, α -tocopherol and carotenoids [19]. Carotenoids include an array of substances that address different biological properties, such as enhancement of immune functions, cell protection from DNA damage, stimulation of gap junction intercellular communication, induction of detoxifying enzymes and cell proliferation inhibition [19,28,35].

Reactive oxygen species scavenging would be a possible mechanism whereby shrimp carotenoids could antagonize the ethanol effects on spreading depression. The proof of this mechanism would require blood- and brain reactive oxygen species levels to be measured, which has not been done presently. Despite that, it is very tempting to think first about this hypothesis, for the two following reasons: first, reactive oxygen species production in the nervous tissue has been shown to elicit spreading depression in the isolated chicken retina [26] and in the rat cortex [7]; second, treating rats with diets deficient in the antioxidant vitamins C and E increased cortical spreading depression-susceptibility, both in young adult [7] and old rats [11]. Interestingly, brain structural effects of ethanol in laboratory animals have been recently reported to be counteracted by α -tocopherol ([24], in rats) and ascorbic acid ([27], in frogs). Antioxidant properties have also been shown to be important in protecting the brain against the deleterious effects of free radicals, particularly in neurodegenerative diseases. However, little is known about the impact of dietary antioxidants upon the development and progression of these diseases [17].

Other antioxidant molecules, like taurine, have been shown to attenuate the effects of ethanol concerning the oxidative stress [29]. These authors found an increased lipid peroxidation, as well as a decrease of superoxide dismutase, catalase and glutathione-peroxidase activities in the hemolysate and tissues of ethanol-fed rats, as compared to the controls. They also reported a diminution of the contents of reduced glutathione, α -tocopherol and ascorbic acid. All these changes were shown to be attenuated by the administration of taurine simultaneously with ethanol.

In conclusion, the present study describes, for the first time, the antagonizing action of shrimp carotenoids on the

brain spreading depression-susceptibility changes promoted by ethanol in the rat cerebral cortex. The data support previous evidence [7,11], on the spreading depression phenomenon, in favor of the hypothesis of a reactive oxygen species neutralizing action of antioxidant substances. The definitive proof of this hypothesis will require reactive oxygen species measurements in future experiments.

Acknowledgements

The authors gratefully acknowledge the financial support from the Brazilian agencies SEAP/CNPq, RECARCINE/FINEP, UFPE/FACEPE and from the Japanese agency JICA. R.C.A. Guedes is Research Fellow from CNPq (no. 30.7846/2004-0).

References

- [1] R.S. Bezerra, R. Abadie-Guedes, F.R.M. Melo, R.C.A. Guedes, Shrimp carotenoids protect the cerebral cortex against the effects of ethanol on spreading depression, XX Fesbe Meeting, Aguas de Lindoia, Brazil, (2005) Abstract 05.098.
- [2] S.C. Bondy, Reactive oxygen species: relation to aging and neurotoxic damage, *Neurotoxicol.* 13 (1992) 87–100.
- [3] J.E. Cabral-Filho, E.M. Trindade-Filho, R.C.A. Guedes, Effect of d-fenfluramine on cortical spreading depression in rats, *Braz. J. Med. Biol. Res.* 28 (1995) 347–350.
- [4] B.H. Davies, Carotenoids, in: T.W. Goodwin (Ed.), *Chemistry and Biochemistry of Plant Pigments*, Academic Press, New York, 1976, pp. 38–155.
- [5] J. Dobbing, J. Sands, Vulnerability of developing brain. IX. The effect of nutritional growth retardation on the timing of the brain growth-spurt, *Biol. Neonate* 19 (1971) 363–378.
- [6] R.J. Do Carmo, H. Martins-Ferreira, Recent studies on retinal spreading depression, in: R.J. do Carmo (Ed.), *Spreading Depression*, Exp. Brain Res. Ser., vol. 23, Springer, Berlin, 1992, pp. 49–62.
- [7] R.S. El-Bachá, J.L. Lima-Filho, R.C.A. Guedes, Dietary antioxidant deficiency facilitates cortical spreading depression induced by photo-activated riboflavin, *Nutr. Neurosci.* 1 (1998) 205–212.
- [8] A. Gildberg, E. Stenberg, A new process for advanced utilisation of shrimp waste, *Process Biochem.* 36 (2001) 809–812.
- [9] B. Grafstein, Mechanism of spreading cortical depression, *J. Neurophysiol.* 19 (1956) 154–171.
- [10] R.C.A. Guedes, A. Amâncio-dos-Santos, R. Manhães-de-Castro, R.R.G. Costa-Cruz, Citalopram has an antagonistic action on cortical spreading depression in well-nourished and early-malnourished adult rats, *Nutr. Neurosci.* 5 (2002) 115–123.
- [11] R.C.A. Guedes, L.F. Amorim, N.R. Teodósio, Effect of aging on cortical spreading depression, *Braz. J. Med. Biol. Res.* 29 (1996) 1407–1412.
- [12] R.C.A. Guedes, A.F.D. Andrade, E.A. Cavaleiro, Excitatory amino acids and cortical spreading depression, in: E.A. Cavaleiro, J. Lehman, L. Turski (Eds.), *Frontiers in Excitatory Amino Acid Research*, Alan R. Liss, New York, 1988, pp. 667–670.
- [13] R.C.A. Guedes, J.E. Cabral-Filho, N.R. Teodósio, GABAergic mechanisms involved in cortical spreading depression in normal and early malnourished rats, in: R.J. do Carmo (Ed.), *Spreading Depression*, Exp. Brain Res. Series, vol. 23, Springer, Berlin, 1992, pp. 17–26.
- [14] R.C.A. Guedes, F.A.M. de Azeredo, T.P. Hicks, R.J. Clarke, T. Tashiro, Opioid mechanisms involved in the slow potential change and neuronal refractoriness during cortical spreading depression, *Exp. Brain Res.* 69 (1987) 113–118.
- [15] R.C.A. Guedes, R.J. do Carmo, Influence of ionic disturbances produced by gastric washing on cortical spreading depression, *Exp. Brain Res.* 39 (1980) 341–349.
- [16] R.C.A. Guedes, S.F. Frade, Effect of ethanol on cortical spreading depression, *Braz. J. Med. Biol. Res.* 26 (1993) 1241–1244.

- [17] B. Halliwell, Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment, *Drugs Aging*. 18 (2001) 685–716.
- [18] R.P. Kraig, C. Nicholson, Extracellular ionic variation during spreading depression, *Neuroscience* 3 (1978) 1045–1059.
- [19] N.I. Krinsky, Mechanism of action of biological antioxidants, *Proc. Soc. Exp. Biol. Med.* 200 (1992) 248–254.
- [20] H.C. Kuo, T.C. Lee, C.O. Chichester, K.L. Simpson, The carotenoids in the deep sea red crab, *Geryon quinquedens*, *Comp. Biochem. Physiol.* B 54 (1976) 387–390.
- [21] A.A.P. Leão, Spreading depression of activity in the cerebral cortex, *J. Neurophysiol.* 7 (1944) 359–390.
- [22] A.A.P. Leão, Further observations on the spreading depression of activity in the cerebral cortex, *J. Neurophysiol.* 10 (1947) 409–414.
- [23] C.S. Lieber, Medical disorders of alcoholism, *N. Engl. J. Med.* 333 (1995) 1058–1065.
- [24] M.D. Marino, M.Y. Aksenov, S.J. Kelly, Vitamin E protects against alcohol-induced cell loss and oxidative stress in the neonatal rat hippocampus, *Int. J. Dev. Neurosci.* 22 (2004) 363–377.
- [25] P.J. Morgane, M. Miller, T. Kemper, W. Stern, W. Forbes, R. Hall, J. Bronzino, J. Kissane, E. Hawrylewicz, O. Resnick, The effects of protein malnutrition on the developing central nervous system in the rat, *Neurosci. Biobehav. Rev.* 2 (1978) 137–230.
- [26] M. Netto, H. Martins-Ferreira, Elicitation of spreading depression by rose bengal photodynamic action, *Photochem. Photobiol.* 50 (1989) 229–234.
- [27] Y. Peng, K.H.H. Kwok, P.-H. Yang, S.S.M. Ng, J. Liu, O.G. Wong, M.-L. He, H.-F. Kung, M.C.M. Lin, Ascorbic acid inhibits ROS production, NF- κ B activation and prevents ethanol-induced growth retardation and microencephaly, *Neuropharmacology* 48 (2005) 426–434.
- [28] M. Porrini, P. Riso, A. Brusamolino, C. Berti, S. Guarnieri, F. Visioli, Daily intake of a formulated tomato drink affects carotenoid plasma and lymphocyte concentrations and improves cellular antioxidant protection, *Br. J. Nutr.* 93 (2005) 93–99.
- [29] G. Pushpakiran, K. Mahalakshmi, C.V. Anuradha, Taurine restores ethanol-induced depletion of antioxidants and attenuates oxidative stress in rat tissues, *Amino Acids* 27 (2004) 91–96.
- [30] A.V. Rao, B. Balachandran, Role of oxidative stress and antioxidants in neurodegenerative diseases, *Nutr. Neurosci.* 5 (2002) 291–309.
- [31] J. Rashba-Step, N.J. Turro, A.I. Cederbaum, Increased NADPH- and NADH-dependent production of superoxide and hydroxyl radical by microsomes after chronic ethanol treatment, *Arch. Biochem. Biophys.* 300 (1993) 401–408.
- [32] A.P. Rocha-de-Melo, R.C.A. Guedes, Spreading depression is facilitated in adult rats previously submitted to short episodes of malnutrition within the lactation period, *Braz. J. Med. Biol. Res.* 30 (1997) 663–670.
- [33] P.S. Rodrigues, A.P.O. Guimarães, F.A.M. De Azeredo, H. Martins-Ferreira, Involvement of GABA and Ach in retinal spreading depression: effects of “low calcium-high magnesium” solutions, *Exp. Brain Res.* 73 (1988) 659–664.
- [34] B.K. Siesjö, F. Bengtsson, Calcium fluxes, calcium antagonists and calcium-related pathology in brain ischemia, hypoglycaemia and spreading depression: a unifying hypothesis, *J. Cereb. Blood Flow Metab.* 9 (1989) 127–140.
- [35] Y. Sharoni, M. Danilenko, N. Dubi, A. Ben-Dor, J. Levy, Carotenoids and transcription, *Arch. Biochem. Biophys.* 430 (2004) 89–96.
- [36] V.A. Silva, J.B. Silva, R.A.O.C. Gismondi, G.P. Rebello, Ethanol improves lactation outcome in malnourished rats, *Nutr. Neurosci.* 3 (2000) 277–282.
- [37] H. Tapiero, D.M. Townsend, K.D. Tew, The role of carotenoids in the prevention of human pathologies, *Biomed. Pharmacother.* 58 (2004) 100–110.
- [38] A. Van Harreveld, E. Fiková, Glutamate Release from the Retina during Spreading Depression, *J. Neurobiol.* 2 (1970) 13–29.

ANEXO III

Dose-Dependent Effects of Astaxanthin on Cortical Spreading Depression in Chronically Ethanol-Treated Adult Rats

Ricardo Abadie-Guedes, Suzan Diniz Santos, Thiago Barbosa Cahú, Rubem Carlos Araújo Guedes, and Ranilson de Souza Bezerra

Background: The consumption of alcoholic drinks is a frequent drug-abuse situation, which is associated to a wide variety of pathological disturbances affecting several organs, including the brain. We have previously shown in the developing rat brain that ethanol intake facilitates the propagation of cortical spreading depression (CSD), an excitability-related neural phenomenon present in several animal species. This electrophysiological effect was attenuated by a shrimp (*Litopenaeus vannamei*) carotenoids extract. Here we investigated the effects of pure astaxanthin, the main carotenoid found in shrimp, on CSD.

Methods: Adult Wistar rats were treated per gavage, during 18 days, with 2.5, 10 or 90 $\mu\text{g/kg/d}$ astaxanthin dissolved in ethanol (3 g/kg) and CSD was recorded on the cortical surface 1 to 3 days thereafter. Four groups, treated respectively with ethanol, distilled water and soybean oil with- and without astaxanthin were also studied for comparison with the ethanol + astaxanthin groups.

Results: Ethanol-treated rats displayed higher CSD-velocities (mean values, in mm/min, per hour of recording ranging from 4.08 ± 0.09 to 4.12 ± 0.16), compared to the distilled water-group (from 3.19 ± 0.13 to 3.27 ± 0.06). Addition of astaxanthin to ethanol lead to lower CSD-velocities in a dose-dependent manner, ranging from 3.68 ± 0.09 to 3.97 ± 0.22 for the 2.5 $\mu\text{g/kg/d}$ -dose, from 3.29 ± 0.09 to 3.32 ± 0.07 for the 10 $\mu\text{g/kg/d}$ -dose, and from 2.89 ± 0.13 to 2.92 ± 0.11 for the 90 $\mu\text{g/kg/d}$ -dose. The velocities of the soybean oil groups (with and without astaxanthin) were not statistically different from the 10 $\mu\text{g/kg/d}$ astaxanthin + ethanol and distilled water groups.

Conclusion: The results demonstrate the antagonistic effect of astaxanthin against the ethanol-induced facilitation of CSD propagation. Probably carotenoid antioxidant properties are involved in such effects.

Key Words: Ethanol, Cortical Spreading Depression, Antioxidants, Carotenoids, Astaxanthin.

CAROTENOIDS ARE MOLECULES that, in the mammal organism, tend to accumulate in lipophilic compartments, like membranes or lipoproteins. In those compartments, they exert their scavenging effects, protecting against reactive oxygen species produced in certain pathological states, like alcoholism (Kim et al., 2005; Mitchell et al., 1999; Tapiero et al., 2004). Although not biochemically capable of biosynthesizing carotenoids, mammals can accumulate and/or convert precursors obtained from the diet.

Astaxanthin, one of the dominant carotenoid in marine animals, is a powerful biological antioxidant. This molecule exhibits strong free radical scavenging activity and protects against lipid peroxidation and oxidative damage of LDL-cholesterol, cell membranes, cells, and tissues (Miki, 1991). In fact, it was previously observed (Bezerra et al., 2005) that a shrimp carotenoid ethanolic extract exert a protective action against the ethanol effects on the cortical spreading depression (CSD), an interesting excitability-related neural phenomenon. CSD has been first described as a cortical response consequent to electrical, mechanical or chemical stimulation of the tissue surface (Leão, 1944). This response consists of a reversible and slowly propagating “wave” of reduction of the spontaneous and evoked cortical electrical activity, with a simultaneous DC slow potential change of the tissue (Leão, 1947). CSD has been studied in vivo in several animal species (Gorgi, 2001), having also been recorded in the human brain (Mayevsky et al., 1996).

During CSD, while the spontaneous activity is depressed, “epileptiform waves”, similar to those found in the epileptic EEG, usually appear and propagate (Leão, 1944). This led to

From the Departamento de Bioquímica (RAG, SDS, TBC, RSB), CCB; Departamento de Nutrição (RAG, RCAG), CCS; and Laboratório de Imunopatologia Keizo Asami (SDS, TBC, RCAG), Universidade Federal de Pernambuco, 50670-901, Recife, PE, Brazil.

Received for publication September 22, 2007; accepted April 9, 2008.

Reprint requests: Ranilson S. Bezerra, Laboratório de Enzimologia – LABENZ, Departamento de Bioquímica, Universidade Federal de Pernambuco, Cidade Universitária, Recife-PE, Brazil, CEP 50670-901; Fax: + 55-81-21268576; E-mail: ransoube@uol.com.br

Copyright © 2008 by the Research Society on Alcoholism.

DOI: 10.1111/j.1530-0277.2008.00710.x

the idea that perhaps CSD- and epilepsy mechanisms would share some common features (Leão, 1944, 1972). The same logic led some authors to postulate an important role for CSD in the physiopathology of migraine (Hadjikhani et al., 2001; Lehmenkühler et al., 1993) and brain ischemia (Takano et al., 1996). In all cases, current discussions often mention the possible involvement of either certain ions (Guedes and Do Carmo, 1980; Siesjö and Bengtsson, 1989), neurotransmitter activity (Gorelova et al., 1987; Guedes et al., 1987, 1992), or free radicals produced in the nervous tissue (El-Bachá et al., 1998; Guedes et al., 1996).

Experimental evidence indicates that the neural tissue naturally offers a certain degree of resistance to CSD propagation (Guedes and Do Carmo, 1980). When this resistance decreases (by some kind of experimental treatment), CSD propagates at higher velocities, as compared to normal conditions, and vice-versa. So, experimental procedures that either weaken or strengthen the brain ability to counteract CSD may provide valuable clues to the understanding of the phenomenon and of the pathologies related to them. The brain CSD susceptibility has been further characterized by several authors in rats submitted to environmental, pharmacological, and nutritional manipulations (Amâncio-dos-Santos et al., 2006; Costa-Cruz et al., 2006; De Luca et al., 1977; Fregni et al., 2007). One of the conditions studied was ethanol ingestion (Guedes and Frade, 1993; Sonn and Mayevsky, 2001).

Chronic ethanol ingestion, mostly in young adults, constitutes a frequent drug-abuse situation, which is associated to a wide variety of pathological disturbance affecting a number of organs, including liver, kidney, heart, pancreas, and brain (Lieber, 1995). The main purpose of the present study was to analyze the effects of different astaxanthin doses on changes in CSD propagation in the cerebral cortex of adult rat chronically treated with ethanol. It was hypothesized that treatment with pure astaxanthin would mimic the CSD-effects of the shrimp carotenoids ethanolic extract, in the adult rat cortex, as previously demonstrated (Bezerra et al., 2005).

MATERIALS AND METHODS

Astaxanthin (purchased from Sigma, St. Louis, MO) was dissolved in pure ethanol, resulting in final concentrations of 2.5, 10, and 90 $\mu\text{g}/\text{ml}$. All others reagents used were of analytical grade, provided by Merck.

Astaxanthin concentration was calculated according to Davies (1976) following the formula: $Q = (\text{OD} \times V)/E$, where Q denotes carotenoids amounts (μg); OD stands for optical density (470 nm); V is the volume (ml); and $E = 2500$ (astaxanthin specific extinction coefficient). After prepared, the astaxanthin solutions were maintained in absence of light and in a N_2 atmosphere. The rats utilized in this study were handled in accordance with the "Principles of Laboratory Animal Care" (National Institutes of Health, Bethesda, MD) and with the norms of the Ethics Committee for Animal Research of the Universidade Federal de Pernambuco, Brazil. They were reared in polyethylene cages ($51 \times 35.5 \times 18.5$ cm) in a room maintained at $21 \pm 1^\circ\text{C}$ with a 12 h light/12 h dark cycle (lights on at 7:00 AM).

Male Wistar young adult rats (60 to 70 days of life) received for 18 days, per gavage, astaxanthin in doses of 2.5, 10 or 90 $\mu\text{g}/\text{kg}/\text{d}$, diluted in 95% ethanol (corresponding to a dose of 3 g/kg/d). This

ethanol daily dose (3 g/kg/d) is within the range usually employed in rodents (Bonthius et al., 2001; Nash et al., 2007), and has been shown to produce blood alcohol levels effective in experimentally altering the nervous system (Nash et al., 2007).

These animals were compared to control rats that had been treated in the same way either with the vehicle (ethanol-group), or with distilled water, or with soybean oil (used as alternative vehicle to dissolve astaxanthin, which is not hydrosoluble). The influence of astaxanthin without ethanol was evaluated in another group treated with 10 $\mu\text{g}/\text{kg}/\text{d}$ astaxanthin dissolved in soybean oil instead of ethanol. All groups had free access to water and a commercial lab chow diet (Purina do Brasil Ltd. containing 23 g protein/100 g diet), until the day of the electrophysiological recording (79 to 89 days), which corresponded to 1 to 3 days after terminating the ethanol treatment. During this 1 to 3 days post ethanol period, daily examination of the animals revealed a certain degree of increased locomotor activity and aggressivity in response to manipulation.

The surgical and CSD-recording procedures were performed as previously described (Bezerra et al., 2005). Briefly, the animal was intraperitoneally anesthetized with a mixture of 1 g/kg urethane plus 40 mg/kg chloralose. A tracheal cannula was inserted and three trephine holes were made on the right side of the skull. These holes were aligned in the anteroposterior direction and parallel to the midline. One hole was positioned on the frontal bone (2 mm in diameter) and was used to apply the stimulus to elicit CSD. The other two holes were drilled on the parietal bone (3 to 4 mm in diameter) and were used to record the propagating CSD wave. The distance between the centers of contiguous holes was about 3 to 5 mm. Rectal temperature was continuously monitored and maintained at $37 \pm 1^\circ\text{C}$ by means of a heating blanket. CSD was elicited at 20-minute intervals by 1 minute application of a cotton ball (1 to 2 mm in diameter) soaked in 2% KCl solution, applied to the anterior hole, drilled at the frontal region. Both the slow DC-potential change and the spontaneous cortical electrical activity accompanying CSD were continuously recorded for 4 hours, by using a pair of Ag-AgCl agar-Ringer electrodes (one in each hole). These electrodes consisted of 5 cm-long plastic conic pipettes (0.5 mm tip inner diameter), filled with Ringer solution, solidified with the addition of 0.5% agar, into which a chlorided silver wire was inserted. The pipettes were fixed together with cyanoacrylate glue, so that the interelectrode distance was kept constant. Each pair of electrodes was connected to a lever, which could be vertically moved by turning around a screw, so that the electrode tips could be gently placed on the intact dura-mater, under low-power microscope control, without any excessive pressure on the cortical surface. A common reference electrode, of the same type, was placed on the nasal bones (see inset of Fig. 1). The DC-potential changes were recorded by connecting the electrodes to GRASS DC-amplifiers, and the ECoG was recorded with AC-amplification (band pass filters set at 1 to 35 Hz range). Both DC-recording and ECoG were performed in a model 7-D GRASS chart recorder.

The CSD velocity of propagation was calculated from the time required for a CSD-wave to pass the distance between the two cortical electrodes. In the measurement of CSD velocities, the initial point of each DC negative rising phase was used. Body weights and CSD propagation rates were compared between groups by a repeated measures ANOVA, followed by a post-hoc (Tukey-Kramer) test, when indicated. Differences between groups were accepted as significant at the 95% confidence level ($p < 0.05$). All values are presented as means \pm standard deviations.

RESULTS

Body Weights

On the day of CSD recording, rats treated with distilled water, ethanol and astaxanthin ethanolic solutions during




Fig. 1. Recordings of spontaneous cortical electrical activity (E; two upper traces in each panel) and slow potential change (P; two lower traces) during cortical spreading depression in adult rats (90 days of life) treated per gavage with astaxanthin at doses of 2.5, 10, and 90 $\mu\text{g/kg/d}$ (respectively $A \times 2.5$, $A \times 10$, and $A \times 90$), as well as in rats treated with vehicle- (ethanol; 3 g/kg; group Etoh) and distilled water-treated (DW) controls. Spreading depression was elicited by applying a cotton ball (1 to 2 mm diameter) soaked with 2% KCl solution for 1 minute on the frontal cortex. Horizontal bars under P1 indicate the time (1 min) of KCl stimulation. The right hemisphere inset shows the recording positions 1 and 2 (on the parietal cortex) and the position of the reference electrode (R), on the nasal bones, as well as the place of KCl stimulus (on the frontal cortex). The distance between the cortical electrodes was 4.0 mm in all examples in this figure. Note the slower spreading rates in the carotenoid-treated animals compared to the respective vehicle-treated controls. Vertical calibration bars equal 1 mV for the electrocorticogram and 10 mV for the P-recordings.

18 days were weighed. The mean body weights were: 355.7 ± 9.9 g ($n = 8$); 300.4 ± 14.3 g ($n = 7$); 274.9 ± 7.8 g ($n = 5$); 316.7 ± 11.3 g ($n = 6$); 293.6 ± 11.5 g ($n = 8$) for the rats treated with distilled water, ethanol, and 2.5 $\mu\text{g/kg}$, 10 $\mu\text{g/kg}$ or 90 $\mu\text{g/kg}$ astaxanthin ethanolic solutions, respectively. When compared with the initial mean weight (282.4 ± 5.2 g; $n = 36$), it was observed that the distilled water group showed a positive weight gain. In contrast, all ethanol-treated groups failed in increasing body weight. Moreover, it was also found that astaxanthin treatment did not change the negative ethanol effect on the weight gain. The body weights of the soybean oil groups treated with and without astaxanthin (respectively 332.7 ± 14.2 g; $n = 4$ and 327.8 ± 46.3 g; $n = 7$) were not statistically different from the DW-treated group.

Cortical Spreading Depression Propagation

The electrophysiological recordings (electrocorticogram and slow DC-potential changes) during CSD are documented in Fig. 1. As a rule, application of KCl for 1 minute on a cortical point in the frontal region very effectively elicited a single CSD-wave, which propagated without interruption between the two recording electrodes and was recorded on the parietal region of the same hemisphere. Three measurements of




Fig. 2. Reduction of cortical spreading depression-velocity in young adult rats (90 days of life) treated per gavage with astaxanthin at doses of 2.5, 10, and 90 $\mu\text{g/kg/d}$ (respectively $A \times 2.5$, $A \times 10$, and $A \times 90$) compared to rats treated with vehicle- (ethanol; 3 g/kg; group Etoh) and controls treated with distilled water (DW). Data are expressed as means \pm standard deviation, calculated in each hour of recording. (A) All groups significantly differed from the Etoh-group, except for the third and fourth hour values of group $A \times 2.5$. (B) Furthermore, with the exception of group $A \times 10$, all groups were shown to be statistically different from the DW controls (ANOVA plus Tukey-Kramer test; $p < 0.05$).

CSD-velocity could be obtained in each hour of recording, since KCl-elicited CSD episodes were obtained at 20-minute intervals. The CSD-velocities are presented as mean \pm SD velocity per hour, in all groups (Fig. 2).

Dose-Response Effect of Astaxanthin on Ethanol-Induced CSD Facilitation

As can be seen in Fig. 2, the distilled water-group displayed mean CSD propagation velocities, (in mm/min, measured at each hour of recording) ranging from 3.19 ± 0.13 to 3.27 ± 0.06 ($n = 7$). The ethanol-treated rats presented higher CSD-velocities (from 4.08 ± 0.09 to 4.12 ± 0.16 ; $n = 7$; $p < 0.05$). Astaxanthin-treatment dose dependently leads to lower CSD-velocities, in comparison to the ethanol group. The mean CSD-velocities, per hour of recording, in the astaxanthin groups ranged as follows, respectively in the groups treated with 2.5, 10, and 90 $\mu\text{g/kg/d}$: from 3.68 ± 0.09 to 3.97 ± 0.22 ($n = 5$), from 3.29 ± 0.09 to 3.32 ± 0.07 ($n = 5$) and from 2.89 ± 0.13 to 2.92 ± 0.11 ($n = 5$). ANOVA showed that all astaxanthin-treated groups presented significantly lower CSD velocities, except for the third and fourth hour in the 2.5 $\mu\text{g/kg/d}$ treatment. No significant differences were seen between the treatments with the 10 $\mu\text{g/kg/d}$ astaxanthin dose and distilled water groups. The group treated with the highest astaxanthin dose (90 $\mu\text{g/kg/d}$) displayed the lowest CSD velocities (Fig. 2).

Figure 3 represents the average CSD velocities calculated for the whole 4-hour period. These velocities changed as a




Fig. 3. Dose–response effects of astaxanthin dissolved in ethanol on cortical spreading depression velocity in the rat cortex (open circles). The curve resulted from plotting the mean CSD velocities (during the entire 4-h recording period) as a function of the astaxanthin doses. Each point represents the average CSD velocity for the respective group. Note that the values for the soybean oil groups (with and without astaxanthin; open triangles) are not different from that of the distilled water control group (black dot).

function of astaxanthin dose, following an exponential decay model ($r^2 = 0.9998$; $y = 2.9048 + 1.1988e^{(-x/9.0217)}$, where the x -variable is astaxanthin dose in $\mu\text{g/kg/d}$). The average CSD velocities for the DW-, as well as for the soybean oil- and $10 \mu\text{g/kg/d}$ astaxanthin + soybean oil groups are also presented in this figure for comparisons. These velocities were not statistically different from the $10 \mu\text{g/kg/d}$ astaxanthin + ethanol group.

DISCUSSION

It is well established that alcoholism represents a condition in which reactive oxygen species (ROS) are produced (Tapiero et al., 2004). Under such a condition, antioxidant molecules like carotenoids have been shown to protect tissues, as for example gastric mucosa (Kim et al., 2005) and brain (Mitchell et al., 1999), from ethanol-induced injuries. Antioxidant properties have also been shown to be important in protecting the brain against the deleterious effects of free radicals, particularly in neurodegenerative diseases (Tapiero et al., 2004). Our data are consistent with the reported protective effects of carotenoids on brain tissue.

One possible mechanism whereby astaxanthin could antagonize the ethanol effects on CSD would be based on the reactive oxygen species scavenging action of astaxanthin. It is very tempting to think first about this hypothesis for the two following reasons: first, it has been already shown that reactive oxygen species production in the nervous tissue can elicit CSD in the isolated chicken retina (Netto and Martins-Ferreira, 1989) and in the rat cortex (El-Bachá et al., 1998); second, dietary deficiency of the antioxidant vitamins C and E resulted in increased CSD-susceptibility, both in young adult (El-Bachá et al., 1998) and old rats (Guedes et al., 1996). Furthermore, in this respect it has recently been demonstrated

that α -tocopherol associated to ethanol has a higher protecting effect against penicillin-induced epileptic activity, as compared with the actions of either drug alone (Kozan et al., 2007). However, to confirm this hypothesis, blood- and brain reactive oxygen species levels have to be measured in future experiments.

On the other hand, the ethanol action on the brain has generally been believed to occur through the γ -aminobutyric acid (GABA) system (Kozan et al., 2007; Kumar et al., 2003; Sonn and Mayevsky, 2001). In this context, it is interesting to note that GABA-mediated mechanisms participate in the phenomenon of cortical spreading depression. Guedes et al. (1992) found an increase in cortical spreading depression propagation velocity in the cerebral cortex of rats treated with the GABA-agonist diazepam. Moreover, studies have reported that rats chronically treated with ethanol present enhancement of the cortical spreading depression-phenomenon (Bonthuis et al., 2001; Guedes and Frade, 1993). By treating developing rats with ethanol, we previously described a protective action of a shrimp carotenoids extract against the ethanol-effects on cortical spreading depression in the developing brain. It was also found that weaned rat pups born from dams treated during gestation or lactation with an ethanolic extract of shrimp carotenoids presented lower cortical spreading depression velocities, as compared with a group treated with ethanol (Bezerra et al., 2005).

The daily ethanol treatment per gavage during 18 days has presently been considered as chronic treatment. Sonn and Mayevsky (2001) used acute treatment, by intravenously infusing ethanol during the CSD recording session and found an impairing effect on CSD propagation, which is opposite to the results of Guedes and Frade (1993), Bezerra et al. (2005) and this work. Methodological differences, namely ethanol administration methods and durations, are likely to have contributed for the here commented different results. Furthermore, it is difficult to determine whether the present facilitating ethanol effect on CSD propagation has been due to the chronic ethanol treatment or correspond to an acute withdrawal effect. The first possibility seemed more plausible to us, in view of the findings of Guedes and Frade (1993), who observed the CSD propagation enhancement 1 hour after the last ethanol dose. However, we agree that additional experiments are necessary to further clarify this point.

Besides the problem of maternal drug consumption affecting their offspring, ethanol effects on the adult brain also deserves considerable attention, since chronic alcohol intake by young adults represents a worldwide public health problem nowadays. Such concern has been addressed in the present work, regarding the carotenoids protective role. Furthermore, as astaxanthin is the main carotenoid present in shrimp, it would be judged interesting to test astaxanthin action against the ethanol effects on CSD in young adult rats. The present results showed that astaxanthin administration per gavage during 18 days exerted a protective effect in a dose-dependent manner, with the CSD velocity varying according to a mathematic model presenting an exponential decay (with an $r^2 = 0.9998$).

Due to the lipophilic nature of astaxanthin, we had to use soybean oil as vehicle in the group receiving only astaxanthin (without ethanol). At the dose of 10 $\mu\text{g/kg/d}$, no statistical differences were seen, when compared with the DW-, or with the soybean oil groups, suggesting that if astaxanthin has effects on CSD that are independent of ethanol effects, it might occur at higher doses.

In conclusion, our data have demonstrated, for the first time, that astaxanthin antagonizes the ethanol effect on cortical spreading depression in the young adult rat brain. The present results are consistent with our previous data (Bezerra et al., 2005), suggesting that astaxanthin, the main shrimp carotenoid, could be, at least in part, the responsible for the previously observed cortical spreading depression-effects. Despite being clear that the mechanisms of ethanol action on the brain are mostly based on the GABAergic activity and on the ROS-production, and that both mechanisms influence cortical spreading depression propagation, the astaxanthin protective action on cortical spreading depression remains to be further clarified. Probably carotenoid antioxidant properties are involved in such effects.

ACKNOWLEDGMENTS

This work was financially supported by FINEP/RECARCINE, PETROBRAS, CNPq, SEAP/PR, FINEP/IBN-Net (No. 4191), and FACEPE. R.C.A. Guedes is a Research Fellow from CNPq (No. 307846/2004).

REFERENCES

- Amâncio-dos-Santos A, Pinheiro PCF, Lima DSC, Ozias MG, Oliveira MB, Guimarães NX, Guedes RCA (2006) Fluoxetine inhibits cortical spreading depression in weaned and adult rats suckled under favorable and unfavorable lactation conditions. *Exp Neurol* 200:275–282.
- Bezerra RS, Abadie-Guedes R, Melo FRM, Paiva AMA, Santos AA, Guedes RCA (2005) Shrimp carotenoids protect the developing rat cerebral cortex against the effects on cortical spreading depression. *Neurosci Lett* 391:51–55.
- Bonthius DJ, Pantazis NJ, Karacay B, Bonthius NE, Taggard DA, Lothman EW (2001) Alcohol exposure during the brain growth spurt promotes hippocampal seizures, rapid kindling, and spreading depression. *Alcohol Clin Exp Res* 25:734–745.
- Costa-Cruz RRG, Amâncio-dos-Santos A, Guedes RCA (2006) Characterization of cortical spreading depression in adult well-nourished and malnourished rats submitted to the association of pilocarpine-induced epilepsy plus streptozotocin-induced hyperglycemia. *Neurosci Lett* 401:271–275.
- Davies BH (1976) Carotenoids, in *Chemistry and Biochemistry of Plant Pigments* (Goodwin TW ed.), pp 38–155. Academic Press, New York.
- De Luca B, Cioffi LA, Bures J (1977) Cortical and caudate spreading depression as an indicator of neural changes induced by early malnutrition in rats. *Acta Nerv Super* 19:130–131.
- El-Bachá RS, Lima-Filho JL, Guedes RCA (1998) Dietary antioxidant deficiency facilitates cortical spreading depression induced by photoactivated riboflavin. *Nutr Neurosci* 1:205–212.
- Fregni F, Liebetanz D, Monte-Silva KK, Batista-de-Oliveira M, Amâncio-dos-Santos A, Nitsche MA, Pascual-Leone A, Guedes RCA (2007) Effects of transcranial direct current stimulation coupled with repetitive electrical stimulation on cortical spreading depression. *Exp Neurol* 204:462–466.
- Gorelova NA, Koroleva VI, Amemori T, Pavlik V, Burš J (1987) Ketamine blockade of cortical spreading depression in rats. *Electroencephalogr Clin Neurophysiol* 66:440–447.
- Gorgi A (2001) Spreading depression: a review of the clinical relevance. *Brain Res Rev* 38:33–60.
- Guedes RCA, Amorim LF, Teodósio NR (1996) Effect of aging on cortical spreading depression. *Braz J Med Biol Res* 29:1407–1412.
- Guedes RCA, Cabral-Filho JE, Teodósio NR (1992) GABAergic mechanisms involved in cortical spreading depression in normal and malnourished rats, in *Spreading Depression* (Do Carmo RJ ed.), pp 17–26. Springer, Berlin.
- Guedes RCA, de Azeredo FAM, Hicks TP, Clarke RJ, Tashiro T (1987) Opioid mechanisms involved in the slow potential change and neuronal refractoriness during cortical spreading depression. *Exp Brain Res* 69:113–118.
- Guedes RCA, Do Carmo RJ (1980) Influence of ionic alterations produced by gastric washing on cortical spreading depression. *Exp Brain Res* 39:341–349.
- Guedes RCA, Frade SF (1993) Effect of ethanol on cortical spreading depression. *Braz J Med Biol Res* 26:1241–1244.
- Hadjikhani N, Sanchez del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, Kwong KK, Cutrer FM, Rosen BR, Tootell RBH, Sorensen AG, Moskowitz MA (2001) Mechanisms of migraine aura revealed by functional MRI in human visual cortex. *Proc Natl Acad Sci U S A* 98:4687–4692.
- Kim JH, Choi SK, Choi SY, Kim HK, Chang HI (2005) Suppressive effect of astaxanthin isolated from *Xanthophyllomyces dendrorhous* mutant on ethanol-induced gastric mucosal injury in rats. *Biosci Biotechnol Biochem* 69:1300–1305.
- Kozan R, Ayyildiz M, Yildirim M, Agar E (2007) The influence of ethanol intake and its withdrawal on the anticonvulsant effect of α -tocopherol in the penicillin-induced epileptiform activity in rats. *Neurotoxicology* 28:463–470.
- Kumar S, Kralic JE, O'Buckley TK, Grobin AC, Morrow AL (2003) Chronic ethanol consumption enhances internalization of $\alpha 1$ subunit-containing GABA_A receptors in cerebral cortex. *J Neurochem* 86:700–708.
- Leão AAP (1944) Spreading depression of activity in the cerebral cortex. *J Neurophysiol* 7:359–390.
- Leão AAP (1947) Further observations on the spreading depression of activity in the cerebral cortex. *J Neurophysiol* 10:409–414.
- Leão AAP (1972) Spreading depression, in *Experimental Models of Epilepsy* (Purpura DP, Penry K, Tower DB, Woodbury DM, Walter RD eds), pp 173–195. Raven Press, New York.
- Lehmenkühler A, Grottemeyer KH, Tegtmeier F (1993) *Migraine: Basic Mechanisms and Treatment*. Urban and Schwarzenberg, Munich.
- Lieber CS (1995) Medical disorders of alcoholism. *N Engl J Med* 333:1058–1065.
- Mayevsky A, Doron A, Manor T, Meilin S, Zarchin N, Ouaknine GE (1996) Cortical spreading depression recorded from the human brain using a multi-parametric monitoring system. *Brain Res* 740:268–274.
- Miki W (1991) Biological functions and activities of animal carotenoids. *Pure Appl Chem* 63:141–146.
- Mitchell JJ, Paiva M, Heaton MB (1999) Vitamin E and β -carotene protect against ethanol combined with ischemia in an embryonic rat hippocampal culture model of fetal alcohol syndrome. *Neurosci Lett* 263:189–192.
- Nash CM, Ibram F, Dringenber HC, Reynolds JN, Brien JF (2007) Effects of maternal administration of vitamins C and E on ethanol neurobehavioral teratogenicity in the guinea pig. *Alcohol* 41:577–586.
- Netto M, Martins-Ferreira H (1989) Elicitation of spreading depression by rose Bengal photodynamic action. *Photochem Photobiol* 50:229–234.
- Siesjö BK, Bengtsson F (1989) Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression: a unifying hypothesis. *J Cereb Blood Flow Metab* 9:127–140.
- Sonn J, Mayevsky A (2001) The effect of ethanol on metabolic, hemodynamic and electrical responses to cortical spreading depression. *Brain Res* 908:174–186.
- Takano K, Latour LL, Formato JE, Carano RAD, Helmer KG, Hasegawa Y, Sotak CH, Fisher M (1996) The role of spreading depression in focal ischemia evaluated by diffusion mapping. *Ann Neurol* 39:308–318.
- Tapiero H, Townsend DM, Tew KD (2004) The role of carotenoids in the prevention of human pathologies. *Biomed Pharmacother* 58:100–110.